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Abstract 
 
Serum response factor (SRF) controls gene activation in response to 
changes in actin dynamics and mitogen-activated protein kinases. SRF has low 
intrinsic transcriptional activity and requires the recruitment of one of two families of 
co-activators: the MRTFs (myocardin-related transcription factors) and the TCFs 
(ternary complex factors). MRTFs are actin-binding proteins. Disruption of the 
actin-MRTF interaction is sufficient to induce MRTF nuclear accumulation and 
transcriptional activation. The TCF family are specifically activated by MAPK 
signalling. This thesis aims to elucidate how the SRF transcription network is 
controlled. The work presented encompasses two projects focused on each of the 
co-activator families. 
The regulation of MRTF shuttling from the cytoplasm to the nucleus is 
relatively well understood while its regulation once in the nucleus is still 
uncharacterized. The work demonstrates that nuclear MRTF activities are 
influenced by nuclear actin. Nuclear actin interferes with MRTF-DNA binding and 
target gene activation. In the presence of G-actin, nuclear MRTF can associate 
with target loci and recruit Pol II that, although traverses the gene body, does not 
generate stable mRNA. This inhibited state is accompanied by hypo-
phosphorylation of the Pol II CTD. Dissociation of MRTF-actin interaction is 
required to re-establish Pol II phosphorylation and mRNA accumulation. 
The Erk-TCF signalling pathway was used to investigate how chromatin 
signatures are established in response to cues. Fibroblasts lacking all three TCFs, 
or reconstituted with mutant derivatives of the Elk-1 TCF were generated. Following 
Erk activation, chromatin immunoprecipitation and RNA-sequencing techniques, 
were employed to study the role of the TCFs in chromatin changes and 
transcriptional activation. It was possible to show that signal-induced chromatin 
changes occur in absence of transcription, and the specific chromatin signature 
requires Elk-1 DNA binding and phosphorylation. In addition analysis of the 
H3K27me3 mark demonstrated that Elk-1 activation is required to maintain a 
permissive chromatin landscape. 
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Chapter 1. Introduction 
1.1 Signalling to Transcription 
Cells are capable of recognising and responding to particular stimuli outside 
or inside their cellular environment. This collection of complex signals is matched to 
sophisticated intracellular responses. The molecular co-evolution of signals and 
responses was the main route through which metazoan life evolved (Pires-daSilva 
& Sommer 2003).The connection between signal transduction and control of gene 
expression is the backbone of modern developmental genetics and cellular 
biochemistry. 
Signal-dependent gene regulation operates throughout the life of cells, 
tissues, organs and organisms. All these processes require the production of 
messenger RNA from protein coding genes, which is carried out by the RNA 
polymerase II (Pol II). In synthesis, the elaboration of the recorded signals leads to 
the assembly of the initiation complex and Pol II recruitment that gives rise to the 
primary transcript that ultimately becomes mRNA (see Chapter 1.3).  
Members of a large family of proteins, the Transcription Factors (TFs, see 
below in this chapter), coordinate signal-dependent gene activation. TFs, between 
1000 and 2000 in humans and mice (H. M. Zhang et al. 2012b), display two 
characteristic domains: a DNA binding domain and a regulatory domain. TFs are 
site-specific factors able to recruit co-regulators and the transcriptional machinery 
producing a specific transcriptional program. 
With the transcriptome currently estimated to include over 20000 protein 
coding genes and about 7000 non coding genes in mammals (Pruitt et al. 2013), 
what gives a unique spatial and temporal expression to each gene is the 
combinatorial use of transcription factors and co-regulators (Carninci et al. 2005). 
1.2 Regulatory transcription factors 
Research on organismal evolution, from unicellular organisms to complex 
systems, has shown that the degree of complexity does not directly correlate with 
the number of genes but to the complexity of the transcriptional programming 
(Gregory 2005). 
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Higher systems, such as eukaryotes, have evolved a more complex way of 
controlling their gene expression than prokaryotes (Levine & Tjian 2003). The 
arrangement of encoded DNA information, the way the DNA is packed into 
chromatin and the combination of different TFs is what allows complex organisms 
to alter their cell types and growth patterns in different ways (Gregory 2005; 
Carninci et al. 2005; Levine & Tjian 2003). 
Transcription factors are modular proteins consisting of two major domains: 
(I) a sequence-specific DNA-binding domain (DBD), that allows TFs to bind cis-
regulatory DNA sequences either at enhancers or at promoters; and (II) a 
regulatory domain that allows TFs to receive and respond to signals, interact with 
the transcriptional machinery and influence the outcome of the transcriptional 
process. These domains are most of the time separable within the TF protein. 
However the DNA-binding and regulatory domain can also be embedded within the 
same amino-acid sequence, for example in the serum response factor (SRF) in 
metazoan or GAL4 in yeast (Ling et al. 1998; Mizutani & Tanaka 2003).  
TFs can activate or repress transcription and they do so using diverse 
mechanisms such as: Pol II holo-enzyme direct recruitment, block or stabilisation; 
modification of the chromatin template via recruitment of re-modellers and 
modifiers; and recruitment of co-regulators. 
1.2.1 Transcription co-regulators 
TFs are often found in association with other factors called co-regulators. 
Co-regulators, including chromatin modifiers and re-modellers, while also playing 
crucial roles in controlling genes activation, lack DNA-binding domains and 
therefore are not classified as transcription factors (Schaefer et al. 2011). Co-
regulators are specifically recruited by TFs, thus providing additional regulatory 
domains and functions. Examples are the CREB binding protein (CBP), recruited 
by the cyclic AMP response element-binding protein (CREB) (Mayr et al. 2001), 
and the Myocardin-related transcription factors (MRTFs), co-regulators of the 
serum response factor (SRF) (D. Z. Wang et al. 2002). 
A recent classification of transcription co-factors comes from Schaefer and 
colleagues who considered proteins involved in transcription, interacting with TFs 
but not interacting with the DNA (Schaefer et al. 2011). The in-silico screen, based 
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on other databases and the web, led to the generation of the transcription co-
factors database (TcoFs-DB). The TcoF-DB includes 1365 TFs and 529 co-
regulators, of which 374 are hypothetical. This classification is just a starting point 
as most of the data is based on protein annotation, experiments and data 
submission that could be inaccurate and incomplete. Nevertheless up to a tenth of 
the human proteome is involved in transcription regulation and it is possible to 
appreciate that transcription co-regulator activities are diverse including, among 
others, signal transmission, control of TF-DNA binding and chromatin modification 
(Schaefer et al. 2011). 
1.2.2 DNA binding domains and the principle of DNA recognition 
The defining feature of a TF is its sequence-specific DNA binding domain. 
TFs are able to selectively distinguish DNA elements out of a vast number of 
sequences, and they do so through their DNA binding domain (Jolma et al. 2013). 
Each TF associates with its partially degenerated consensus sequence (about 6-16 
nucleotides long). As will be seen below, TF sequence specificity is essential but 
not sufficient to uniquely specify their genomic distribution. 
The focus of this introduction is about transcription related proteins but it is 
necessary to specify that there are other examples of sequence-specific DNA 
recognition among proteins that mediate recombination, DNA cleavage, and other 
processes. The general principle of DNA recognition is common between TFs and 
all these factors but the structural details differ. 
The nucleic acid substrate presented to DNA binding proteins is a relatively 
uniform polymer. Negative charged sugar-phosphates constitute the main 
backbone of the DNA and a core of paired bases expose their functional groups in 
the major and minor grooves (Garvie & Wolberger 2001). As each base is 
chemically different, every given DNA sequence has its own “signature” determined 
by the pattern of functional groups exposed into the DNA grooves (Garvie & 
Wolberger 2001; Rohs et al. 2010). It is through a series of favourable electrostatic 
and van der Waals interactions that TFs are able to interact specifically with the 
DNA. Furthermore the DNA-binding domain of all TFs together with the DNA builds 
up a network of contacts that include salt bridges with positive side chains and 
hydrogen bonds with uncharged chains (Luscombe et al. 2001). In addition to 
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chemically driven interaction the DNA platform is distorted by TFs through α helices, 
β sheets and various secondary structure units that protrude into the DNA grooves 
forming specific contacts (Garvie & Wolberger 2001). DNA kinking and bending is 
not only a cause of lower free energy structures but in many cases affects TF 
activity (Rohs et al. 2010).  
TFs can be classified according to their DNA-binding domains. The TFClass 
database stratifies TFs into five levels: superclass, class, family, genus and 
molecular species (Wingender et al. 2013). In total it is possible to distinguish nine 
superclasses (see Table 1.1), whose definition is based on the overall topology of 
their DBDs and the way they interact with the target DNA. Each superclass is then 
divided into several classes. TFs in the same class share a similar structure of the 
DNA-binding motif. An examples is SRF that belong to the class of MADS box 
factors and to the α-helices exposed by β-structure superclass. Each class is then 
divided into families based on sequence and functional similarities. For example 
the MADS box class comprises two families of TFs: TFs that regulate differentiation 
and TFs that respond to signals. Ultimately different families are composed of 
different genus, representing the physical TF encoded by a given gene, and 
molecular species when one gene produces more than one isoform.  
How do TFs recognise their specific binding sites in vivo? How do 
structurally related DBD exert their unique function in vivo? How do different TFs 
influence each other? With modern genetics the assignment of TFs to their target 
genes becomes fundamental for a comprehensive understanding of all 
physiological, developmental and environmental conditions.  
Knowing exclusively the DNA binding activity of each TF and their diverse 
affinity to consensus sequences is not sufficient to answer all these questions. Not 
all occurrences of a TF consensus element are bound by a TF in a given cell, and 
the location of TF binding sites in orthologous genes exhibits rapid evolutionary 
divergence (Villar et al. 2014). Nevertheless the DNA sequence is the primary 
driver of different TF binding (Wilson et al. 2008). The addition of a human 
chromosome into mouse liver cells leads to identical TF binding profiles and gene 
expression of the human chromosome when compared to human hepatocytes 
(Wilson et al. 2008). Despite this clear evidence we cannot predict functional TF 
binding patterns based solely on the DNA sequence (Odom et al. 2007; Borneman 
et al. 2007). Deciphering the protein-DNA recognition mechanism is crucial to 
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understand and potentially predict the DNA-binding specificity of uncharacterised 
proteins (Chu et al. 2009).  
Classical genetics, chromatin immunoprecipitation followed by sequencing 
(ChIP-seq) and RNA silencing techniques (RNAi and shRNA), have being applied 
to dissect several transcriptional networks (Esnault et al. 2014; Rahl et al. 2010; X. 
Chen et al. 2008). Even in these cases, due to the large number of TFs, cell lines, 
environmental and developmental states the use of these methods is not sufficient 
to exhaustively understand transcriptional regulation. 
1.2.3 DNA accessibility 
As mentioned earlier most TF activities rely on their ability to recognise 
specific DNA sequences. DNA-binding affinity has been measured extensively for 
several TFs in vitro, and high-throughput methods have allowed the quantitation of 
TF binding preferences (Geertz & Maerkl 2010). In vivo analysis of TF genomic 
distributions using ChIP-seq approaches shows that most of the known TFs bind 
only a few per-cent of their potential consensuses in the genome (Carr & Biggin 
1999; Joseph et al. 2010; Kaplan et al. 2011). In vivo the binding-site affinity of any 
given TF needs to be considered in the context of the chromatin.  
Many TFs show little, if any affinity for their consensus when in the context 
of nucleosomes, therefore TFs seeking access to specific genomic loci need to 
compete directly with nucleosomes (Adams & Workman 1995). The 
thermodynamic model of this competition involves a straightforward reaction 
influenced by the TFs’ affinity for its consensus and the relative concentration of 
both the nucleosomes and the TF in question (Raveh-Sadka et al. 2009). Co-
occupancy of multiple TFs at the same loci also influences this model. Although the 
basis for this functional cooperation remains poorly understood, functional networks 
in which TFs co-localise together could be caused by specific or unspecific 
interactions between them at regulatory sequences (Ravasi et al. 2010; Voss et al. 
2011). Consistent with this hypothesis DNAseI hypersensitive sites could be a 
result of multiple independent TF binding events as originally showed for the β-
globin gene (Boyes & Felsenfeld 1996). Furthermore TFs clusters correlate with 
DNAseI hypersensitive sites across the genome (Thurman et al. 2012).  
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Nucleosome-TF competition has been invoked to explain why the majority of 
SRF binding sites become occupied only upon activation of the MRTF co-factors 
(Esnault et al. 2014). SRF DNA binding across the genome can be divided into 
constitutive and inducible sites. The former are embedded in broad regions of 
conserved motifs and nucleosome desert loci, consistent with the DNAseI 
hypersensitive maps (Thurman et al. 2012). The latter instead are associated with 
narrow regions of conservation occupied by nucleosomes under resting condition, 
suggesting that cooperative binding with other factors are less abundant and that it 
is the MRTF co-regulator recruitment that favours nucleosome displacement. 
Nucleosomes also show different affinities for different DNA sequences 
(Sekinger et al. 2005; J. D. Anderson & Widom 2001). Different DNA sequences 
have diverse abilities to bend sharply, influencing the capability of the histone 
octamer to assemble with the DNA. Genome-wide studies have shown that it is 
possible to partially predict the disposition of nucleosomes across the genome on 
the basis of the DNA sequence (Segal et al. 2006). The combination of the TF 
binding and their cellular concentration with the affinity of the nucleosome to DNA 
sequences across the genome would potentially provide a tool to predict which 
consensus binding motifs are occupied in a given cell (Raveh-Sadka et al. 2009). 
The access of TFs to highly condensed chromatin has been shown to 
require special features characteristic of a defined group of TFs called “pioneers” 
(Cirillo et al. 2002). Pioneer factors are chromatin binding factors able to recognise 
their target sequence in a nucleosomal context (for a review see Zaret & Carroll 
2011). Studies on hepatogenesis lead to the discovery of FoxA and GATA, the first 
factors able to bind the condensed chromatin of the albumin gene enhancer in liver 
precursor cells (Cirillo et al. 2002). Members of the forkhead box protein A (FoxA) 
and FOXO families contain a C-terminal histone-binding domain required to loosen 
the condensed chromatin in vivo and in vitro (Zaret & Carroll 2011). Importantly the 
nucleosome de-compaction activity of FoxA does not require ATP or ATP-
dependent chromatin remodellers (Cirillo et al. 2002). Furthermore the crystal 
structure of FoxA DBD showed a high similarity with the linker histone H1 and an 
avid nucleosome binding affinity (K. L. Clark et al. 1993). Although in vitro 
competition between FoxA and the histone H1 has not been demonstrated, in vitro 
biochemical studies extensively characterised the ability of FoxA to bind 
nucleosomes similarly, although less tightly, to histone H1 (Cirillo et al. 1998).  
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A different example comes from the glucocorticoid receptor (GR), which was 
found to bind its consensus specifically on nucleosomes (Perlmann & Wrange 
1988). Recently it has been shown that GR works as an “assistant” helping factors 
to bind via the recruitment of ATP-dependent remodelling complexes (Voss et al. 
2011).  
A further example of this interdependence between TFs was recently shown 
for the “master regulators” Oct4, Sox2, Klf4, and c-Myc (Soufi et al. 2012). Oct4, 
Sox2 and Klf4 could all be defined as pioneer factors as they are all able to bind 
condensed chromatin allowing c-Myc to associate with this DNaseI-resistant 
landscape.  
In conclusion each TF has its own strategy to reach its target sequence 
including: competition or specific affinity for nucleosomes, recruitment of chromatin-
remodelling complexes and co-operative binding between multiple TFs. 
1.2.4 Regulatory domains 
If TFs’ DNA-binding domains account for their correct positioning in the 
genome, TFs’ activation (AD) or repression domains are responsible for their 
capacity to sense signals and mediate most of TF-protein interactions (Uesugi et al. 
1997; Uesugi & Verdine 1999). It is through their activation domains that TFs are 
able to activate transcription, interacting with an elaborate set of general 
transcription factors (GTFs, see Chapter 1.3), co-regulators, chromatin remodellers, 
modifying enzymes and Pol II (see Chapter 1.3 and 1.4).  
It has always been a challenge to efficiently classify ADs due to their 
unstructured nature (J. Liu et al. 2006). As ADs’ activation properties cannot be 
easily recognised by sequence homology, several studies have tried to categorise 
them on the basis of polypeptide sequence (Mitchell & Tjian 1989): acidic activators 
like GAL4, GCN5 and VP16 (Sadowski et al. 1988), Glutamine-rich activators such 
as Sp1 (Courey & Tjian 1988) and proline-rich activators that include CTF and NF-
1 (Mermod et al. 1989). Furthermore different features have been described within 
activation domains including hydrophobic and hydrophilic patches (Regier et al. 
1993), amphipathic α-helices (Giniger & Ptashne 1987) and serine/threonine-rich 
patches (Cress & Triezenberg 1991; Drysdale et al. 1995). 
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Defining activation domains on the basis of their amino acid composition is 
somehow obsolete in the field as it is not clear if they truly reflect their activity. With 
advances in understanding transcription at the biochemical level, the classification 
of activation domains by structure, as opposed to sequence, has become more 
important. Interesting observations come from functional-structural studies of 
specific transactivation domains. In order to understand how TFs’ regulatory 
domains work, the detailed description of the cocrystal or NMR structures of the 
activation domain together with their target is necessary. One of the most 
representative examples has been the herpes virion protein 16 (VP16) that is 
recruited to cellular targets through its interaction with TFs (Triezenberg et al. 1988). 
The carboxy-terminal part of VP16 (410-490aa) comprises two potent 
transactivation domains able to target several components of the basal RNA 
polymerase II machinery including TFIIA, TFIIB, TFIID, subunits of TFIIH and the 
Mediator complex (Kobayashi et al. 1995; D. B. Hall & Struhl 2002; Xiao et al. 
1994; Uesugi et al. 1997; Mittler et al. 2003). Interaction between VP16’s activation 
domain and target proteins is mediated by several acidic residues complemented 
by positive charges on the target protein (Jonker et al. 2005). These long-range 
electrostatic forces are responsible for an unstable complex. In this respect, 
hydrophobic residues are the key to obtain a stable interaction as side chains of 
these residues make important hydrophobic contacts with the target (Walker et al. 
1993; Cress & Triezenberg 1991; Regier et al. 1993). Based on these observations, 
TADs are flexible domains in their free state able to form a structure upon 
interaction with their target proteins. Studies of the interaction between VP16 and 
Med25 have extended this view, proposing that VP16’s AD is able to adapt to 
unrelated target surfaces (Vojnic et al. 2011). Similar concepts arise from studies 
based on c-Myc transactivation domain and its interaction with TBP. c-Myc 
interacts with TBP in two steps so that the folding of its TAD is coupled to the 
interaction with the TBP’s surface (Hermann et al. 2001). Folding coupled to target 
binding could explain how TADs are able to interact with structurally different 
surfaces (Ferreira et al. 2005). 
Other activation domains have been described using NMR studies. Clear 
examples come from the nuclear receptor with SRC-1, NcoA-1/STAT6, and p53-
MDM2. A common feature of these interactions is a ΦXXΦΦ motif, where Φ is a 
hydrophobic residue within the transactivation domain. This motif can be the 
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archetypal LXXLL, common in nuclear receptors (Darimont et al. 1998), the 
FXXWL motif in p53 activation domain (Kussie et al. 1996) or domains within the 
Adenovirus early region 1A (E1a), able to interact with target proteins by forming 
amphipathic helices that plug into hydrophobic grooves (Pelka et al. 2008).  
Conformational changes in activation domains can also be induced by post-
translational modifications. In this case, the activation domain works as a switch 
able to record signals, adopting a permissive structure that can accommodate 
target surfaces. Section 1.5 will describe in detail the studies on the Elk-1 
transactivation domain and its interaction with subunits of the Mediator complex. 
1.2.5 Transcription factor regulation 
Cells employ diverse mechanisms to efficiently control the accurate 
expression of genes required for cellular processes. Development, stem cell 
maintenance, environmental adaptation, cell cycle control and pathogenesis are 
only a few examples where TFs are causal effectors. Control of TF activity is 
therefore fundamental for accurate gene expression. 
It is possible to distinguish mechanisms of regulation that directly affect the 
biochemical properties of TFs and mechanisms that affect TFs’ functional 
behaviours. The former refers to the mode by which TFs are regulated and could 
include TFs’ post-translational modifications (PTMs), synthesis and protein stability. 
The latter refers to general mechanisms employing a combination of mode of 
regulation that can affect, among others, TFs dimerization and oligomerisation, 
subcellular localisation and protein-protein interaction. 
It is challenging to precisely separate each mechanism due to their high 
interdependency. PTMs can potentially affects any TFs’ functional behaviour and 
many changes in behaviours, such as dimerization and protein-protein interaction, 
are prerequisite for bestowing determined functions.  
TF mode of regulation 
Regulation of TF synthesis is one of the most direct ways to control the 
expression of a defined set of genes in a restricted time and space. Tissue specific 
factors like the MyoD were shown to be essential and sufficient for embryonic-
muscle fibroblast differentiation into myoblasts (R. L. Davis et al. 1987). Like other 
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myogenic regulatory factors, MyoD is expressed and synthesised exclusively in 
skeletal muscle. A further example of synthesis-driven regulation of TFs’ activity 
comes from the homeobox transcription factor family (Hox genes). This family of 
transcription factors are used across several bilateral animals controlling 
developmentally regulated genes (Pearson et al. 2005). Mutation in Hox genes 
results in morphological defects restricted to certain segmental zones across the 
anterior-posterior axis. Hox genes are grouped in large collinear genetic clusters 
(Pearson et al. 2005) and their spatial organisation within the cluster reflects the 
order in which they are expressed (McGinnis & Krumlauf 1992). It is in fact the 
expression gradient of these genes that controls the precise expression of 
downstream “realisator genes”, which harbour at their promoters high affinity or low 
affinity consensus for the Hox protein (Small et al. 1992). 
TF concentration can also be controlled through degradation, as is the case 
with AP-1, HIF-1 and p53. The best example comes from the p53 transcription 
factor. p53 is essential in the control of cell cycle and apoptosis (Lane 1992). In 
normal cells p53 is kept ubuquitinated by the Mdm2 ubiquitin ligase (Haupt et al. 
1997) and its protein levels are kept low through proteosomal degradation (Maki et 
al. 1996). Challenging cells with different stresses such as DNA damage, hypoxia 
and heat shock, blocks MDM2 function, thereby increasing p53 levels. 
PTMs are a further key mode of regulation directly affecting TFs’ 
biochemical properties. PTMs are one of the most studied mechanisms in TF 
regulation as they directly or indirectly control most if not all TF functions (Filtz et al. 
2014). Surface-initiated signalling pathways induce an array of PTMs that decorate 
TFs. Signalling pathway crosstalk provides an integrated response to cues 
(Bardwell et al. 2007). Ligand - receptor - transducer is the typical path through 
which signal is delivered and amplified. Most studied PTMs affecting TFs include, 
among others, phosphorylation, sumoylation, ubiquitilation, acetylation and 
methylation (see Table 1.2).  
Among the PTMs listed above phosphorylation is the most studied and 
consists of the addition of a phosphate group on selected amino acid residues by 
active kinases. Phosphorylation and de-phosphorylation can affect TFs’ activity by 
altering their allosteric conformation and attractive/repulsive forces (Sprang et al. 
1991). This change could affect several TFs’ function. Protein stability of p53 and 
ATF-2 is increased upon phosphorylation (Fuchs et al. 2000; Appella & C. W. 
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Anderson 2000) while on the other hand TFs such as E2F-1 and MyoD are 
susceptible to degradation once they are phosphorylated (Song et al. 1998; Vandel 
& Kouzarides 1999). Negatively charged TFs, as mentioned in the description of 
the transactivation domain, constitute an effective interaction surface for several 
target proteins (see the VP16 TADs). The ability to induce an accumulation of 
negatively charged phosphate could constitute an effective mechanism to induce 
TADs activity.  
Dimerization 
Protein-protein interactions are employed by TFs in order to produce an 
enormous functional diversity (Klemm et al. 1998). TF dimerization provides an 
additional level where activator functions could be regulated. Dimerization relies on 
conserved motifs embedded into the TFs allowing them to form homotypic or 
heterotypic multimers (depending on whether proteins of the same or different 
family are interacting with each other). It is important to highlight that most if not all 
TFs are found as dimers or oligomers.  
Diverse heterodimers are responsible for controlling specific sets of genes 
combining a limited number of TFs (Amoutzias et al. 2008). Considering all the 
possible pairs within each TF family, it is conceivable that dimerization could 
account extensively for flexibility and complexity in gene regulation but the 
functional regulation still has to be addressed (van Nimwegen 2003; Kummerfeld & 
Teichmann 2006). TFs complexes obtained through dimerization potentially hold 
different DNA binding specificity than their constituents. The AP-1 transcription 
factor family is a clear example. Composed of Jun, Fos and ATF, which can homo-
or heterodimerize, the AP-1 family is able to generate different regulatory functions 
(reviewed in Karin et al. 1997 and Shaulian & Karin 2001). For example Jun-Jun or 
Jun-Fos dimers bind DNA elements containing TGACTCA sequence, whereas Jun-
ATF or ATF-ATF associate with the DNA sequences TGACGTCA. However, the 
significance of the variation in formation of AP1 complexes for target gene selection 
has not been investigated. 
Dimerization can also be induced upon signal transduction, in many cases 
controlling DNA binding affinity. In this circumstance dimerization plays a crucial 
role in acutely changing TFs’ functional behaviours. For example, the JAK-
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dependent phosphorylation of a single tyrosine residue at the C-terminus of STAT 
molecules induces their dimerization and accumulation into the nucleus (T. Meyer 
& Vinkemeier 2004). Similarly, Smad proteins undergo oligomerization upon TGF-β 
stimulation and concomitant nuclear retention (see within the following section).  
Subcellular localisation 
Cytoplasmic retention of TFs, away from their nuclear “playground”, is an 
additional way to regulate them. This mechanism is especially important for signal-
dependent transcription where effector proteins need to be maintained in an 
inactive state until a signal promotes their activation and relocation into the nucleus 
(Ziegler & S. Ghosh 2005).  
This mechanism could be achieved by masking nuclear-localisation signal 
(NLS) within TFs. This unidirectional model was proposed for several TFs and co-
regulators including, among others, NF-κB (whose NLS could be masked by IΚBα), 
the steroid receptor (SR) and components of the Wnt signalling pathway (Htun et 
al. 1996; Moon & Kimelman 1998). Most if not all TFs controlled via subcellular 
localisation are found to be constantly shuttling between the cytoplasm and the 
nucleus (Ziegler & S. Ghosh 2005). Nuclear accumulation can therefore reflect a 
sophisticated regulation of import/export through differential binding interactions in 
the nucleus and in the cytoplasm. TF shuttling may ensure that inducible activators 
are inactive in the absence of signals and readily induced in the presence of signal. 
This mechanism will be further discussed in section 1.7 as a key mechanism 
controlling MRTF co-factor localisation/activity in the SRF transcription network. 
One crucial finding has been the shuttling mechanism in NF-ΚB- IΚBα 
localisation (Tam et al. 2000; Malek et al. 2001). Inhibition of the exportin CRM1 
using Leptomycin B (LMB) induces NF-ΚB- IΚBα nuclear accumulation, providing 
compelling evidence for an active import-export activity under resting conditions. 
This mechanism was described in more detail in several research papers, 
suggesting an imbalance between the contribution of import and export signals on 
NF-κB and IκBα (Tam et al. 2000). 
Smad proteins represent another example of localisation-controlled 
transcriptional regulators. Smad transcription factors respond to transforming 
growth factor–β (TGF-β) ligands, including TGF-β and BMP (reviewed in Yigong 
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Shi & Massagué 2003). Smad proteins shuttle between the cytoplasm and the 
nucleus with discrete periods using NLS signals for import and CRM1-dependent or 
independent processes for their export (Pierreux et al. 2000; Xu et al. 2002). 
Following stimulation, phosphorylation-induced oligomerization of the Smad 
proteins promotes their retention in the nucleus allowing them to recruit co-
activators and induce transcription (Inman & Hill 2002). Changes in shuttling 
behaviours after nuclear accumulation suggest a possible active retention of Smad 
proteins in the cytoplasm (Dong et al. 2000; Inman & Hill 2002). 
TF shuttling is also a key mechanism in biological oscillations. Several 
biological processes could be described as rhythmic phenomena such as cell cycle 
progression, circadian clock and the activity of neuronal and cardiac cells (Belchetz 
et al. 1978; Shimojo et al. 2008; Gerber et al. 2013). It has recently been described 
in soil-living amoeba that nucleocytoplasmatic shuttling of TFs is essential to 
decode the number, rather than the level, of external stimuli ensuring 
developmental synchronisation of cells (H. Cai et al. 2014).  
Protein-protein interaction 
As described throughout the introduction, TFs can be regulated through 
protein-protein interactions. Co-regulator recruitment or multi-TF complex formation 
determines the function of most TFs allowing them to recruit, interact and regulate 
components of the transcriptional machinery. Beside direct recruitment of co-
regulators, protein-protein interaction could also directly influence TFs’ functional 
behaviours including nuclear localisation, DNA binding and avoid or favour other 
protein-protein interactions required for transcriptional activation. An example that 
will be described in more detail later is the regulation of MRTF co-factor nuclear 
localisation and activity (Miralles et al. 2003). In particular MRTF is able to interact 
with several actin molecules using specialized motifs at its N-terminus and these 
interactions have profound effects on MRTF behaviour and SRF-dependent gene 
activation (see section 1.7). Furthermore, as will be described in the results, MRTF-
DNA association could also be controlled by its interaction with monomeric actin 
within the nucleus.  
Recent works based on different organisms have tried to systematically 
dissect this intricate network of interactions. Recently Ravasi et al. generated an 
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atlas of combinatorial TFs, aimed at describing the way different combinations of 
TFs account for different modes of regulation (Ravasi et al. 2010). These studies 
highlight the importance of protein-protein interaction in TF regulation as key in 
determining cell fate. An interesting observation emerging from these TF networks 
is that interaction maps are evolutionarily conserved and can be traced between 
different organisms and species (Ravasi et al. 2010). 
1.3 The transcriptional machinery 
Pioneering work in 1959 led Samuel Weiss and Leonard Gladstone to 
discover the RNA polymerase as the primary enzyme responsible for DNA-
dependent RNA synthesis in rat liver (Weiss & Gladstone 1959). At that time, the 
isolation from rat liver nuclei of this enzyme was not trivial. Since bacterial extracts 
were easier to make and handle, in 1965 Jacob, Monod and Lwoff succeed in the 
isolation of the first prokaryotic RNA polymerase. This research was awarded with 
the Nobel prize (Stent 1965).  
Isolation from HeLa cell extracts (Roeder & Rutter 1970), rat liver (R. C. 
Conaway & J. W. Conaway 1990) and yeast (Lue & Kornberg 1987) showed a 
different scenario for eukaryotic cells. In contrast to bacteria, eukaryotic cells 
contain three different forms of RNA polymerase (I-III) (Roeder & Rutter 1970; 
Kedinger et al. 1970). As opposed to prokaryotes, eukaryote RNA polymerases are 
“blind” enzymes unable to initiate transcription given a dsDNA (Roeder & Rutter 
1969; Roeder & Rutter 1970). Enzymatic activities were observed for less purified 
polymerase samples (Weil et al. 1979) suggesting that for eukaryotic polymerases 
additional factors were required. Several studies over the years showed that 
additional factors required for transcription in vitro are required for sequence 
specific initiation on dsDNA (Matsui et al. 1980). These are the so-called General 
Transcription Factors (GTFs) as they are generally required for the expression of 
all genes (Chambon 1975). The five major GTFs (TFIIB, -D, -E, -F, and -H) that 
assist the RNA polymerase lead to the recognition of the transcriptional start site 
(TSS) of a gene, melting of the double stranded DNA, and copying one strand 
(coding or leading) into RNA using ribonucleoside triphosphate and lastly re-
winding the two strands of the DNA at its back while the polymerase translocates 
forward (see later in this chapter). This set of six proteins was still not sufficient to 
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explain how eukaryotic TFs were activating transcription. Studies aiming to 
recapitulate in vitro the mechanism of activated transcription lead to the 
identification of intermediary proteins, part of the Mediator complex (Y. J. Kim et al. 
1994). The Mediator is highly sophisticated and complex machinery recruited by 
TFs and required to specifically potentiate initiation (Thompson & Young 1995; 
Takagi & Kornberg 2006).  
The next sections summarise the key works that over the past decades 
shed more light on the complexity of the transcription process. 
1.3.1 The DNA template 
The correct positioning of the transcriptional machinery is crucial for 
accurate transcription of all genes. Each gene displays a so-called core promoter 
sequence composed of DNA elements. From textbooks we learnt that promoters 
are regions directing accurate transcriptional initiation by RNA polymerase II. It is 
possible to distinguish two kinds of promoters: the so-called “focused promoters”, 
showing a unique TSS and “broad promoters” where transcription initiation can 
occur at multiple sites (Juven-Gershon & Kadonaga 2010). As shown by Carninci 
et al., focused promoters account for a minority in vertebrates (Carninci et al. 2006). 
Most promoters could be defined as ‘broad’ promoters showing more than one TSS 
linked to CpG islands around constitutively expressed genes. Several types of cis-
elements contribute to core promoters’ activity (Juven-Gershon & Kadonaga 2010) 
and figure 1.1 shoes the consensus that has been catalogued through several 
studies based on single genes or hybridisation-based methods. 
 
Inr: The Inr element spans the TSS and is probably the most common 
feature in core promoters (FitzGerald et al. 2006; Gershenzon & Ioshikhes 2005). 
Inr consensus varies according to organism and analysis, at mammalian promoters 
it has the sequence YYANWYY (IUPAC annotation) (Juven-Gershon & Kadonaga 
2010). Conventionally the A nucleotide within the Inr motif is assigned to the +1 
position as it generally represents the first nucleotide of the RNA. 
 
TATA box and BRE: The TATA box was the first eukaryotic promoter 
element to be identified (Figure 1.1) (Lifton et al. 1978). As will be discussed later 
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the TATA element is recognised by the TBP subunit of the TFIID complex. This 
interaction is conserved from Archea to human (Reeve 2003). A perfect TATA 
consensus only exists in 10%-15% of core promoters (Carninci et al. 2006). A 
further conserved element is the TFIIB regulatory element or BRE (Lagrange et al. 
1998). BREs are found both upstream or downstream of the Inr referred to as 
BREu for upstream and BREd for downstream (Figure 1.1). 
 
DPE and MTE: The DPE, which is also contacted by the TFIID complex, is 
located downstream of the Inr (+28 to +33 from the A+1 of the Inr) and is 
conserved in Drosophila and human (Burke & Kadonaga 1997). Inr and DPE act 
cooperatively allowing TFIID to bind on certain promoters in a TATA-independent 
manner (Kutach & Kadonaga 2000). Upstream of the DPE an MTE element was 
found in Drosophila and human, and it can also cooperate with the Inr to locate the 
TFIID complex in a TATA-independent manner (Ohler et al. 2002; Lim et al. 2004). 
However MTE and DPE as well as MTE and TATA could act synergistically. 
 
Although most promoters fall into the ‘broad’ category the distribution of cis-
elements has shown to be conserved for most yeast and human genes (Rhee & 
Pugh 2012). Core promoter elements have very little or no tolerance for variable 
spacing, reflecting the structural constraints of the initiation complex (Kostrewa et 
al. 2009). Several maps of TSSs using cap analysis of gene expression (CAGE) 
still confirm the division in ‘sharp’ and ‘broad’ promoters as observed by Carninci in 
2006 (Carninci et al. 2006; Juven-Gershon et al. 2006; FANTOM Consortium 2014). 
Recent studies in zebrafish tried to address how TSSs are selected and used 
throughout early embryonic development (Haberle et al. 2014). Analysis of 
maternal TSSs suggested that broad promoters could be constituted by multiple 
individual sharp TSSs. In order to acquire a definitive picture of promoter usage 
and TSS selection, more work needs to be done combing TSS maps and genome-
wide transcriptional machinery footprints. 
Besides the elements constituting core promoters, further elements have 
been identified as being essential to modulate the transcriptional output of a given 
gene. Early studies of the HSV promoter led to the identification of DNA elements 
in addition to the conserved TATA sequence required for maximal promoter activity 
(McKnight et al. 1981). It was following the works of the Schaffner lab that the term 
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enhancer was first coined (Banerji et al. 1981). The key characteristic that uniquely 
describes enhancer elements is that they can act irrespectively of the distance or 
orientation to the target promoter (Shlyueva et al. 2014). In addition to enhancers, 
silencers, insulators and tethering elements also play a crucial role in gene 
activation and, like the enhancers, are all distal elements of the TSS (Petrykowska 
et al. 2008; Gaszner & Felsenfeld 2006; Calhoun et al. 2002). Among these 
elements, enhancers are crucial for transcriptional activation. Enhancer activity 
relies on the combined action of different TFs and similarly gene activation requires 
interplay between several enhancers (Spitz & Furlong 2012). Enhancers’ activity 
and their associated TFs are cell-type-specific (Bulger & Groudine 2011). These 
DNA elements are often devoid of nucleosome and correlate with a set of histone 
modifications such as histone H3 lysine 4 monomethylation (H3K4me1) and H3K27 
acetylation (H3K27ac) (see in Chapter 1.4). The number of enhancers in the 
mammal genome has been estimated between 400,000 and 1.4 milion (Dunham et 
al. 2012; Thurman et al. 2012) but only a few thousand are used in a cell-type 
specific manner (Dunham et al. 2012; Yip et al. 2012; Y. Shen et al. 2012). Being 
able to identify all the enhancers contributing to the activity of a given gene is 
crucial in order to understand how activated transcription works.  
1.3.2 Early transcriptional events 
Pol II is the key enzyme of the transcriptional machinery that catalyses the 
synthesis of pre-mRNA, snRNA and miRNA (Cramer et al. 2008). Its 12 subunits 
(RPB1-RPB12) are highly conserved in all eukaryotes (Cramer et al. 2008). The 
main core of the RNA polymerase II, RPB1, RPB2, RPB3 and RPB11, represents a 
conserved structure in Pol I, Pol III, bacterial RNA polymerase and archeal 
polymerase (for a review see Cramer et al. 2008). 
In higher eukaryotes, before heading to productive transcription, the 
transcriptional machinery has to overcome five major transitions (Figure 1.2) 
(Michel & Cramer 2013). Initially the assembly of the Pre-Initiation Complex (PIC), 
comprising Pol II and six GTFs (TFIID, TFIIA, TFIIB, TFIIE, TFIIF and TFIIH), 
occurs at dsDNA promoters. Before transcription can occur two further transitions 
are required (Figure 1.2). First the PIC isomerizes into an open complex where the 
promoter is partially melted. DNA melting consists of a so-called ‘bubble’, allowing 
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access of the initiating nucleotide to the template through the catalytic site. The 
next stage sees extension of the ‘bubble’ allowing RNA synthesis in a 
discontinuous fashion entailing for abortive transcript. Pol II escape from core 
promoters is achieved when a stable RNA-DNA hybrid is formed. 
In vitro studies carried-out by several labs lead to a stepwise assembly 
pathway of the PIC obtained using purified GTFs and pure Pol II (Figure 1.3).  
Everything starts with TFIID. TFIID is a key player in early transcription. 
Composed of the TATA-binding protein (TBP) and TBP associated factors (TAFs), 
TFIID is responsible for promoter recognition and Pol II positioning in an activator 
dependent way (Mencía et al. 2002). How TBP and TFIID recognise core 
promoters and how this complex recruits the Pol II machinery have been a matter 
of study for many years. The recognition of the TATA motif by TBP in vivo is not the 
only way TFIID is recruited. TBP was found also at ‘TATA-less’ promoters where 
evolutionarily conserved TFIID subunits such as TAF1 (Basehoar et al. 2004) and 
TAF4-12 (Gazit et al. 2009) contribute to promoter recognition. In addition TFIID 
can be also recruited to defined histone modifications. As will be presented in 
chapter 1.4, H3K4me3 is a hallmark of active promoters and TAF3, with its PHD 
finger domain can recognise this mark (van Ingen et al. 2008).  
TFIID action is diverse as each TAF can have promoter-specific function 
(Ohtsuki et al. 2010). For example knockdown of TAF10, a subunit known to 
disassemble the TFIID complex, blocks embryonic liver development but has little 
effect on gene expression in adult adipocytes (Tatarakis et al. 2008). 
TFIID-DNA interaction can be affected via several negative effectors such 
as Mot1 and NC2. In vitro and cell based studies have shown that TFIIA is 
essential to stabilise TFIID-DNA interaction and overcome these inhibitory effects, 
enhancing PIC assembly (Thomas & Chiang 2006). 
The next GTF to enter the PIC is TFIIB. TFIIB is essential for further 
stabilisation of the TFIID-DNA complex and for Pol II/TFIIF recruitment (Cramer et 
al. 2008). TFIIB forces Pol II to assume an ordered conformation and concomitant 
binding of a second Mg atom in the Pol II active site (Sainsbury et al. 2013). 
Furthermore TFIIB, interacting with both TBP-DNA and the Pol II, controls the DNA 
path in the Pol II cleft (H.-T. Chen & Hahn 2004). 
Pol II enters the PIC along with TFIIF, which may play an allosteric role in 
opening the Pol II clamp and ordering the DNA over the cleft (Y. He et al. 2013). 
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The positioning of the DNA is accompanied by its bending by ~18 degrees, a 
conformation that will be maintained in the complete PIC. These changes in 
conformation may facilitate TSS selection downstream of the BREd element (Y. He 
et al. 2013). 
Finally TFIIE gets recruited to the PIC. Its major role, together with TFIIH 
(see later in this section), is to induce the open complex transition prior to promoter 
escape (see Figure 1.2) (Fishburn & Hahn 2012). 
Composed of ten subunits, of which three have enzymatic activity, TFIIH is 
one of the most complex GTFs. The ATP-dependent enzymatic subunits are CDK7, 
XPD and XPB (Egly & Coin 2011). The helicase-like XPB promotes ATP-
dependent unwinding of the DNA, characterising the first step in the transition from 
the PIC to the Open Complex (OC) state (Tirode et al. 1999). The XPB enzyme 
works as an ATP-dependent DNA translocase moving 15 bp of dsDNA towards the 
Pol II active site, leading to DNA unwinding (T. K. Kim et al. 2000). Consistent with 
this, recent maps of TFIIE and TFIIH binding locate them downstream of the start 
site (Grünberg et al. 2012; Y. He et al. 2013) Holding of TFIID, TFIIB and Pol II 
onto the upstream part of the promoter while TFIIH and TFIIE pump DNA into the 
active site, provokes the melting of the DNA strand in the cleft (Y. He et al. 2013). 
Recently it has been shown that this step is regulated in eukaryotes (Kouzine et al. 
2013). Pol II is pre-loaded but DNA melting occurs only during activation, 
correlating with increases in TFIIH recruitment. 
The OC is accompanied by an initial synthesis of RNA involving ‘scrunching’ 
of the DNA as the DNA cannot flow freely through the PIC while downstream DNA 
is pulled into the active cleft (Kapanidis et al. 2006; Revyakin et al. 2006). This step 
involves cycle of abortive transcription where the polymerase maintains contacts 
with the promoter and the GTFs (Kireeva et al. 2000). This step in part correlates 
with TSSs selection where the B-reader domain of TFIIB, interacting with the 
upstream DNA, plays a crucial role (Y. He et al. 2013).  
The abortive phase is resolved once the Pol II synthesises a longer RNA 
chain leading to disassociation of TFIIB from Pol II (Y. He et al. 2013; Pal et al. 
2005). This final step marks the end of the early transcription phase. Dramatic 
changes characterised by bubble collapse transition, promoter clearance and 
escape, will lead the Pol II in productive transcription. 
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1.3.3 Transcription activation: the Mediator complex 
Since the discovery of the major components of the PIC it was clear that 
under suitable conditions this complex could suffice for basal transcription in vitro. 
Early models of activator function proposed that activation domains directly 
facilitated Pol II recruitment in order to stimulate transcription (Ptashne & Gann 
1997). Failures in recapitulating activated transcription in vitro suggested that 
possible intermediary proteins were necessary. A breakthrough came in 1994 with 
the purification of the Mediator complex and the reconstitution of activated 
transcription in vitro (Y. J. Kim et al. 1994). This discovery demonstrated that 
recruitment of co-activator proteins by specific TFs is a major step in activated 
transcription. 
Of all the co-activators identified over the past years, the 30-subunit 
Mediator complex is potentially the most crucial, allegedly having a widespread role 
across the transcriptome (Takagi & Kornberg 2006).  
The Mediator complex is composed of 30 or more subunits that can be 
divided into four main modules called ’head’, ‘middle’, ‘tail’ and ‘kinase’ (Figure 1.4) 
(G. Cai et al. 2009). The head, middle and tail modules form a stable ‘core’ while 
the kinase module associates reversibly with the Mediator complex (Malik & 
Roeder 2010). This transient association of the kinase module was suggested to 
correlate with inactive to active state transition (Malik & Roeder 2010). The overall 
structure of the Mediator complex is heterogeneous. Incorporation of paralogues 
subunits and tissue-specific subunits makes this complex highly diverse (Sato et al. 
2004). Although the modules and overall structure are conserved across 
eukaryotes, several subunits diverge significantly in mammals when compared to 
yeast (Bourbon 2008). Some conserved residues, located in structurally disordered 
domains, are potential interfaces acquiring structural features upon interaction with 
other proteins (Tsai et al. 2014). 
As mentioned earlier the Mediator complex could be considered a major end 
point for signalling pathways (Figure 1.4). Activated nuclear receptors, the MAPK-
regulated factor Elk1 and the regulator of lipid metabolism SREBP1α are a few 
examples of TFs interacting with different subunits of the Mediator complex (P. 
Jiang et al. 2010; G. Wang et al. 2005; F. Yang et al. 2006). Interactions between 
TFs and Mediator complex show extensive architectural rearrangement of the latter 
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(Bernecky & Taatjes 2012). These rearrangements were shown to be required for 
transcriptional activation as much as TFs recruitment and PIC formation (Meyer et 
al. 2010). 
Mediator’s function as a bridging complex becomes clear with works aimed 
at understanding the dynamic interaction between promoters and distal elements. 
Studies focused on MED1 and the nuclear receptor (NR) interaction have shown 
that knockdown of MED1 negatively regulates NR-dependent genes followed by a 
loss of looping between enhancers and promoters (Park et al. 2005). The Mediator 
complex was found to work cooperatively with cohesin to establish enhancer-
promoter loops (Kagey et al. 2010). Moreover the distribution of these loops, and 
the occupancy of Mediator and cohesin, changes with cell differentiation (Kagey et 
al. 2010). 
Each module of the Mediator domain exerts different functions. Most 
Mediator-TFs interactions were mapped within or in close proximity to the tail 
module (Malik & Roeder 2010) while most of the functional activities occur at the 
head module (Figure 1.4).  
As mentioned earlier the Mediator complex bridges TFs with the PIC. 
Indeed Mediator is able to interact with most of the Pol II subunits and in particular 
with the unstructured corboxy-terminal domain (CTD) (Robinson et al. 2012; 
Soutourina et al. 2011). Upon interaction the Mediator head module undergoes 
extensive structural shifts (Naar et al. 2002). Together with Mediator’s structural 
changes, Pol II undergoes conformational variations such as a possible movement 
of the clamp, as suggested from recent EM studies (G. Cai et al. 2009). 
Furthermore the Mediator complex is allegedly able to interact with all the GTFs 
composing the PIC. Works done by the Carey, Roeder and Conaway labs have 
shown that the Mediator can interact and specifically recruit TFIID to promoters (K. 
M. Johnson et al. 2002; Guermah et al. 1998; Takahashi et al. 2011). Additionally 
the Cramer and Werner labs demonstrated direct interaction between the Mediator 
subunit MED11 and TFIIH (Esnault et al. 2008; Seizl et al. 2011). This interaction 
enhances TFIIH kinase activity towards Pol II CTD (see later in this chapter).  
Beside its clear role in PIC formation, Mediator also plays a crucial role in 
post-recruitment steps both at Pol II pause-release and transition to active 
elongation. A full description of these functions will be presented in specific 
sections throughout the introduction.  
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1.3.4 Polymerase pausing during early elongation 
As described previously, PIC formation is a major step in controlling RNA 
transcription. A further regulatory block in the transition to productive transcription 
of metazoan genes is the promoter-proximal Pol II pausing (Adelman & Lis 2012) 
(Figure 1.3). Pol II pausing is an intermediate step between promoter escape and 
productive transcription, suggested to provide a possible input for transcriptional 
regulation. This transition occurs when Pol II is already stably engaged, detached 
from TFIIB and the chain of RNA is longer than 12 nts (Kwak & Lis 2013). Paused 
Pol II describes a stage in the transcription cycle different to Pol II arrest. During 
elongation Pol II is susceptible to arrest where Pol II is found in a backtracked 
position with the nascent RNA spanning the active site (Bengal et al. 1991). In this 
circumstance TFIIS recruitment is required to stimulate Pol II to cleave the 
protruded RNA, re-establishing a realigned RNA 3’ end with the Pol II active site 
(Bengal et al. 1991). TFIIS activity on arrested Pol II is key in promoting efficient 
Pol II elongation (see Chapter 1.3.5). 
Pol II pausing was first observed on chicken and human genes where Pol II 
levels at gene promoters were significantly higher than in the gene body (Gariglio 
et al. 1981; Gilmour & Lis 1986; Krumm et al. 1992). Nuclear run-on experiments 
showed that this Pol II was transcriptionally engaged (Giardina et al. 1992). Use of 
high salt or ionic detergent (sarkosyl) is essential for the paused Pol II to transcribe, 
indicating that removal of chromatin proteins is indispensable in these assays 
(Rougvie & Lis 1988). Paused Pol II was shown to be associated with the DRB 
(5,6- dichloro-1-β-D-ribofuranosylbenzimidazole) sensitivity-inducing factor (DSIF) 
and the negative elongation factor (NELF) (Wada et al. 1998; Yamaguchi et al. 
1999). DRB is a small molecule known to inhibit most transcriptional CDKs with a 
higher affinity for CDK9, the kinase part of the p-TEFb complex (see later within 
this chapter). Several hypotheses have tried to model how DSIF and NELF are 
able to induce pausing but definitive evidence is still missing. Genome wide 
analyses have shown that both NELF and DSIF associate with Pol II at promoter 
proximal regions while only DSIF is also distributed along the gene body where Pol 
II elongates (Rahl et al. 2010). In higher eukaryotes there is some evidence that 
RNA binding factors could determine pausing. Both NELF and DSIF were shown to 
interact with short RNA emerging from the elongating Pol II (Fujinaga et al. 2004; 
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Narita et al. 2003; Missra & Gilmour 2010). Other hypotheses are based on the 
‘barrier’ model. As described in a recent review by Kwak and Lis, the first 
nucleosome could provide an energy barrier that needs to be overcome in vitro 
(Kwak & Lis 2013). This model is supported by the observation that in Drosophila 
the first nucleosome interacts with Pol II (Mavrich et al. 2008). 
Paused Pol II was shown to provide a lapse of time for different checkpoint 
mechanisms to occur (Figure 1.3). The first checkpoint is provided by the 5’ 
Capping of the RNA. As will be discussed later, transcription is accompanied by 
other essential events that contribute to proper processing of the RNA (see chapter 
1.3.7). In metazoan a unique enzyme is able to catalyse two major modifications of 
the RNA 5’ end. Capping enzyme (CE) digests the 5’ triphosphate of RNA and is 
able to add a guanine base (Bentley 2014). When the Pol II is ready to head into 
elongation CDK7 Kinase phosphorylates the Pol II CTD on Serines 5 (see chapter 
1.3.6). This PTM recruits CE that, interacting with Pol II and DSIF, relives the action 
of NELF providing a platform for p-TEFb (Lenasi et al. 2011; Mandal et al. 2004). 
P-TEFb complex, a heterodimer of the kinase CDK9 and Cyclin T, is essential for 
productive transcription and can be recruited in several ways to the paused Pol II 
(D. H. Price 2000). In human cells p-TEFb is maintained in a repressive complex by 
the 7SK snRNP (small nuclear ribonucleoprotein) (Nguyen et al. 2001; Z. Yang et 
al. 2005). Upon activation p-TEFb is released and relocated to promoters. 
Recruitment of p-TEFb leads to phosphorylation of both NELF and DISF (Yamada 
et al. 2006). These modifications allow Pol II to detach from NELF and enter into 
elongation in association with DSIF. The CE-induced and the p-TEFb dependent 
mechanism of Pol II pause release might act either synergically or in a context 
specific manner. Further insights are required in order to gain a full picture of this 
mechanism. 
TFs such as c-MYC, NF-κb and the human immunodeficiency virus (HIV) 
TAT trans-activator were shown to directly interact with p-TEFb (Eberhardy & 
Farnham 2002; Barboric et al. 2001; D. H. Price 2000). Co-regulators can also 
recruit p-TEFb. BRD4 is a co-activator containing a bromodomain able to directly 
interact with p-TEFb (Z. Yang et al. 2005; Jang et al. 2005). By means of its 
bromaodomain BRD4 is able to recognise acetylated histones that mostly occur at 
gene promoters. As proposed by the Oliviero lab, BRD4 can be recruited as a 
result of a histone modifications cross-talk leading to H4K16 acetylation (see 
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chapter 1.4) (Zippo et al. 2009; Zippo et al. 2007). Although it is not yet clear how 
this histone cross talk is initiated and maintained at gene promoter, BRD4-
dependent CDK9 recruitment seems crucial for Fosl1 gene activation.  
Paused Pol II is suggested to bring two advantages for gene activation. It 
was shown in several systems that having paused Pol II at gene promoters allows 
prompt and synchronized responses to activating signals (Bentley & Groudine 
1986; Kao et al. 1987; Rougvie & Lis 1990; Gilmour & Lis 1986). Furthermore 
pausing factors such as NELF are suggested to play a positive role in maintaining a 
permissive landscape at defined promoters (Muse et al. 2007; Gilchrist et al. 2008). 
Reduction of pausing factors such as NELF, negatively affects transcription of 
several genes in mouse embryonic stem cells (mEsc) (Rahl et al. 2010; Gilchrist et 
al. 2008). 
1.3.5 Polymerase elongation and processivity 
The action of p-TEFb is restricted at promoter proximal Pol II as it is not 
required once productive elongation has started (Y. Jiang et al. 2004; Egyházi et al. 
1996). Several changes occur on the traveling polymerase starting with the loss of 
NELF and retention of DSIF after phosphorylation (Figure 1.3). One major 
observation is the change in traveling or elongation rate. Paused Pol II is moving 
less than 5 bases per minute, being essentially static (Peng et al. 1998) while 
elongating Pol II travels at ~3-4 kb/min, depending on the gene (Danko et al. 2013). 
The speed of the transcribing Pol II is not homogeneous along the template as 
several obstacles through its path can interrupt it. Promoter proximal pauses, 
termination, folding of nascent RNA, polyadenylation, splice site selection, the 
nucleosomes or even clashing with other polymerases are a few examples 
affecting the elongation rate. Several factors have been described as involved in 
facilitating Pol II processivity and elongation rate.  
TFIIS and TFIIF were the first two factors discovered with a role in Pol II 
elongation. As described earlier, TFIIS activity is crucial to liberate Pol II from 
arrested sites along the template both in vivo and in vitro. Genome-wide studies 
conducted in Drosophila showed that TFIIS function is exerted at early elongation 
complexes (Nechaev et al. 2010). Beside its role in initiation, TFIIF is also involved 
in Pol II elongation. TFIIF increases the elongation rate by reducing Pol II dwell-
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time (the time Pol II spends at each successive nucleotide) (D. H. Price et al. 1989; 
Flores et al. 1989). TFIIF does not remain associated with Pol II throughout 
elongation and its activity in vitro is concentration dependent, allowing a 20-fold 
increase in elongation rate.  
A further complex involved in pause release and enhancement of Pol II 
catalytic rate is the super elongation complex (SEC) (Lin et al. 2010). This complex 
was initially identified through studies of aberrant gene activation in mixed lineage 
leukaemia (MLL) (Luo et al. 2012). SEC can be described as an assembly of 
different factors exerting diverse functions, including AFF1 or AFF4 (AF4/FMR2 
family members), ENL (elevated-ninteen leukemia) or AF9 (ALL fused gene from 
chromosome 9), ELL1 or ELL2, and p-TEFb (Luo et al. 2012). Although SEC 
complex has a clear role in promoting elongation both in vitro and in vivo much 
work is needed to elucidate the biochemical mechanism entailing its activity. 
As mentioned earlier chromatin is a major obstacle to the travelling Pol II. 
Even after release of the Pol II from the PIC the transcribing machine requires 
factors helping in removing or weakening the nucleosome barrier. The FACT 
(facilitates chromatin transcription) complex was identified from HeLa nuclear 
extract as a crucial component allowing in vitro transcription from chromatinised 
templates (Orphanides et al. 1998). Made of SPT16 and SSRP1 subunits, FACT is 
able to evict H2A/H2B dimer from the nucleosomes allowing Pol II to go through 
the histone hexamer (Belotserkovskaya et al. 2003). As Pol II transcribes, FACT is 
able to replace back the H2A/H2B dimer (Xin et al. 2009). 
A further factor involved in promoting Pol II elongation rate is the histone 
chaperon SPT6 (Yoh et al. 2008). Due to its ability to interact with histone proteins 
it was proposed to facilitate elongation via nucleosome destabilisation (Bortvin & 
Winston 1996). Beside its possible role in modifying the chromatin structure, SPT6 
also affects Pol II elongation rate in vitro on naked DNA (Endoh et al. 2004). 
Furthermore in mammals SPT6 was reported to interact with Ser2 phosphorylated 
Pol II (see chapter 1.3.6). This interaction is required to recruit chromatin 
remodelling complexes and mRNA export factors (M. Sun et al. 2010; Yoh et al. 
2007). 
The PAF1 (polymerase associated factor 1) complex is a further factor 
having a role in Pol II elongation. PAF1 complex was first identified in yeast as a 
Pol II-associated factor (X Shi et al. 1996). PAF1 complex is composed of Ctr9, 
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CDC73, Rft1, Leo1, Ski8 and Paf1 (Jaehning 2010). PAF1 co-localises with Pol II 
from the promoter to the 3’ end of genes (M. Kim et al. 2004; Mayer et al. 2010). 
During the transcription cycle PAF1 mediates several events including co-
transcriptional histone modifications (Krogan et al. 2003), Pol II CTD 
phosphorylation and recruitment of termination factors (Nordick et al. 2008; 
Sheldon et al. 2005). Elegant biochemical studies have shown that PAF and DSIF 
are able, non-redundantly, to cooperate in stimulating Pol II elongation both in vivo 
and in vitro (Y. Chen et al. 2009). Furthermore recent studies from the Roeder lab 
have shown that PAF1 promotes transcriptional elongation through direct 
interaction with Pol II as well as TFIIS (J. Kim et al. 2010). Furthermore PAF1 was 
co-purified with components of the SEC complex leading to the hypothesis that 
PAF1 mediates the recruitment of the SEC complex to Pol II on chromatin (N. He et 
al. 2011). 
1.3.6 Pol II CTD as platform coordinating the transcription cycle 
RNA Pol II is unique among the three Polymerases in eukaryotes as it is 
equipped with an appendix – the Carboxy-teminal domain (CTD) within the Pol II 
large subunit. Pol II CTD is made of several heptad repeats showing the consensus 
sequence YSPTSPS (Eick & Geyer 2013). Pol II CTD coordinates the entire cycle 
of transcription from initiation to termination with a crucial function in pre-mRNA 
maturation. Beyond the production of RNA, Pol II CTD is involved in the epigenetic 
control of a cell contributing to “read”, “write” and “erase” epigenetic marks. 
The main feature of the CTD is the heptad repeat. This consensus is 
conserved in yeast and mammals. In yeast the CTD is composed of 26-29 heptad 
repeats while in mammals it reaches 52 repeats, with a greater degeneration of the 
consensus towards the N-terminal part (Eick & Geyer 2013). Deletion of a few 
repeats has little effect while removal of half or more of the CTD, in both mammals 
and yeast, is detrimental for cell viability (Thompson et al. 1993; Bartolomei et al. 
1988). Extensive analysis done by Stiller and Shuman dissected the functional unit 
of the CTD in S. cerevisea and S. pombe. This unit is composed of an entire 
heptad repeat plus the first four amino acids (YSPT) of the next repeat, giving a 
final unit of YSPTSPS-YSPT (P. Liu et al. 2008; Schwer et al. 2012). In addition the 
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positions of the three serine-proline motifs and the two tyrosine residues were 
found to be crucial for CTD functions (P. Liu et al. 2008).  
The Pol II CTD can be defined as one of the longest polypeptide chains 
without any charged residue. Serines, threonines and tyrosines with their hydroxyl-
groups constitute a hydrophilic surface (Eick & Geyer 2013). The five amino acids 
composing the heptad repeat could all be modified by phosphorylation. By 
including dynamic glycosylation of some residues, proline isomerisation and the 
several PTMs there are 432 possible configurations for a heptad repeat and 10,368 
for the functional unit (Eick & Geyer 2013). In the context of the full length CTD in 
vivo it is not clear how many combinations are possible. Many CTD modifications 
could affect each other accounting for a more convoluted system. Alongside the 
vast number of possible configurations, the CTD is a highly flexible and mostly 
unstructured domain with a length 5 to 6 times greater than the diameter of the 
RNA Pol II (Figure 1.5) (Cramer 2001). Electron micrographs of the Pol II in an un-
modified state revealed weak density attributed to the CTD with a dimension of 
about 100 Å (Meredith et al. 1996). Furthermore, as shown in one of the first 
structures of the Pol II, the Pol II crystal has only a limited space close to the linker 
(Cramer 2001). This observation lead to the hypothesis that hypo-phosphorylated 
CTD is in a compact conformation. Extensive phosphorylation is a major cause of 
decompaction of the CTD due to charge repulsion (J. Zhang & Corden 1991). 
Several kinases contribute to the modification of the Pol II CTD. Different 
complexes are responsible to deliver these kinases in a specific moment of the 
transcription cycle. CTD PTMs generate defined docking units characterised by a 
unique phospho-signature recognised by ‘readers’ of the Pol II CTD (Eick & Geyer 
2013). Table 1.3 presents a list of CTD interacting proteins divided in to ‘writers’ 
such as kinases, ‘readers’ and ‘erasers’ of the CTD marks. As described earlier 
complexes such as TFIIH and the Mediator are responsible of delivering certain 
kinases in defined moments of the transcription cycle. Complex-delivered kinase is 
not the only mechanism as the CTD itself could provide docking sites recognised 
by kinases. This mechanism allows an ordered pattern of phosphorylation detected 
across the transcription unit. Similar mechanisms could occur for phosphatases 
that also contribute to the shaping of the CTD code. 
In order to allow initiation Pol II has to be hypo-phosphorylated (R. C. 
Conaway et al. 1992). Phosphorylated CTD is unnecessary for PIC formation but is 
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indispensible to activate transcription (R. C. Conaway et al. 1992). Indeed 
phosphorylation of the Pol II CTD is essential to overcome negative effects caused 
by the interaction with the Mediator complex that avoids Pol II entering into 
elongation (Wong et al. 2014). The structure of Mediator and Pol II CTD has 
recently been described, elucidating the current model where the CTD acts at 
initiation to favour interaction with the PIC and Madiator but subsequently becomes 
detrimental (Wong et al. 2014; Robinson et al. 2012).  
One of the first kinase to enter into the transcription cycle is CDK7 with 
TFIIH. CDK7 was shown both in vitro and in vivo to phosphorylate the CTD heptad 
repeats at Ser5 and Ser7 (Shiekhattar et al. 1995). 
A second kinase, part of the Mediator complex, is CDK8. It was reported 
that CDK8 could phosphorylate Ser2 and Ser5 residues with negative effects in re-
initiation in vivo (for a recent review see Nemet et al. 2014). Works from the 
Reinberg lab have shown that CDK8 can negatively affect transcription. 
Recombinant CDK8 is able to phosphorylate the Cyclin H subunit of TFIIH such 
that TFIIH activity is impaired (Akoulitchev et al. 2000). Its role in phosphorylating 
the CTD is directly dependent on its association with the Mediator complex, as 
recombinant CDK8 shows no activity towards Pol II CTD in vitro (Nemet et al. 
2014). Recent works conducted by the Espinoza lab showed that CDK8 is also 
required for activation of several genes by targeting several TFs (Donner et al. 
2010). Thus CDK8 may act in a context specific manner. Further investigations 
regarding the CDK8-dependent control of gene activity and Pol II phosphorylation 
are needed. 
As mentioned earlier CDK9 is another kinase that is recruited at the 
promoters of active genes. CDK9 was thought to be involved in Serine 2 
phosphorylation of Pol II as DRB treatment was clearly impairing Pol II elongation 
(Rahl et al. 2010). Recent studies have shown that CDK9 preferentially 
phosphorylates Ser5 and partially Ser7 in vitro (Baumli et al. 2008; Czudnochowski 
et al. 2012). In these studies human p-TEFb activity appears to be enhanced on a 
Ser7 pre-phosphorylated peptide. This result was also confirmed in yeast where 
Ser7-P seems to prime CDK9 activity (St Amour et al. 2012). In vivo live imaging 
further elucidates the co-localisation between CDK9 and Ser5 but not Ser2 
(Ghamari et al. 2013). Although mammal CDK9 does not seem to contribute to 
Ser2 phosphorylation the co-regulator BRD4, found in complex with CDK9, seems 
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to phosphorylate Ser2 through a noncanonical N-teminal kinase domain (Devaiah 
et al. 2012). These results require confirmation and a more accurate biochemical 
analysis. 
The identification in higher eukaryotes of kinases involved in elongation has 
been a matter of debate. The recent discovery of CDK12/CDK13 seems to have 
solved a longstanding enigma (Bartkowiak et al. 2010). In S. pombe and S. 
cerevisea two kinases are involved in phosphorylation of Pol II at initiation and 
elongation. Bur1 in S. cerevisiae and CDK9 in S. pombe are involved in 
phosphorylating Pol II and DSIF (NELF is a metazoan specific factor) while Ctk1 in 
S. cerevisea and Lsk1 in S. pombe are contributing to Ser2 phosphorylation and 
therefore efficient elongation (Johnsen 2012). In metazoan CDK12 could be the 
main kinase contributing for Ser2 phosphorylation of Pol II CTD towards the end of 
the gene body. As described by Bosken and collaborators, CDK12 activity is 
enhanced when the Pol II CTD is phosphorylated at Ser7 (Bösken et al. 2014). 
Alongside the phosphorylation of Serine residues in the functional unit of the 
CTD, Tyrosine and Threonine could also be phosphorylated. Thr-4P seems to be 
recognised mainly by 3’ end processing factors on chicken histone genes (Hsin et 
al. 2011). In mammals Polo-like kinase 3 (Plk3) seems to be a specific Thr-4 kinase 
(Hintermair et al. 2012) Tyr1 seems to be phosphorylated by Abl1 and Abl2 in 
human cells (Baskaran et al. 1997). This modification in yeast plays a crucial role in 
termination (see chapter 1.3.8). 
The defined pattern of phosphorylation of the Pol II CTD is also determined 
by phosphatases. Phosphatases are not only crucial in determining the CTD 
phosphorylation status but also to prepare Pol II for re-initiation. Two major 
phosphatases are involved in this process, named Fcp1 and Ssu72. Fcp1, 
conserved both in human and yeast, exerts its action during elongation and is 
required for Pol II re-initiation (Chesnut et al. 1992; Archambault et al. 1997; H. Cho 
et al. 1999). Recent studies have shown that Fcp1 is mainly found at the 3’ end of 
active genes and its inactivation leads to Ser2-P accumulation (D. W. Zhang et al. 
2012a; Bataille et al. 2012). Ssu72 is a further conserved phosphatase that acts in 
de-phosphorylating both Ser5-P and Ser-7P (D. W. Zhang et al. 2012a; Bataille et 
al. 2012). Ssu72 was found as a component of the yeast cleavage and 
polyadenylation factor (CPF) and its activity is enhanced by interaction with 
components of the CPF (Dichtl et al. 2002; X. He et al. 2003; Nedea et al. 2003; 
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Ghazy et al. 2009). In HeLa cells Ssu72 phosphatase activity was found to be 
essential in 3’ end processing suggesting that Ser5-P dephosphorylation is 
essential at the end of the gene (Xiang et al. 2010).  
These and other phosphatases, such as the small CTD phosphatases 
(SCPs) in human, contribute to shape the Pol II CTD. Several genome-wide studies 
both in mammals and yeast contributed to describing the distribution of the CTD 
PTMs for an average gene (Figure 1.6). As described in Figure 1.6, signal for both 
Ser-5p and Ser7-P increases right at the TSS of active genes. While the signal for 
Ser7-P remains high throughout the transcription unit, Ser5-P signal slowly 
decreases towards the poly-A (pA) site. In contrast signals for Tyr1-P, Ser2-P and 
Thr4-P are low at the TSS but increase downstream in the gene body. At the 
crossing of the pA site the Pol II CTD presents a defined pattern that was shown 
recently to be crucial in yeast for certain termination events (Mayer et al. 2012). 
While Ser2-P reaches its maximum as it cross the pA site, Tyr1-P and Thr4-P 
drastically decrease as a result of phosphatase action. 
1.3.7 Co-transcriptional RNA processing 
Beside the regulation of the transcription process itself, CTD 
phosphorylation is allegedly fundamental in all RNA processing reactions. The CTD 
is the major platform required to couple transcription to RNA processing. Analysis 
of Pol II mutants in higher eukaryotes lead Bentley and colleagues to show for the 
first time that Pol II CTD is required for mRNA processing (McCracken et al. 1997). 
Pol II CTD is unnecessary for transcription per-se but is essential for 5’ capping, 
splicing, and 3’ end processing (McCracken et al. 1997). 
 
Capping: The first step in mRNA maturation involves capping of the nascent 
RNA. As mentioned earlier this step correlates with TFIIH recruitment and 
disassociation of the Pol II from the pausing site (Adelman & Lis 2012) (Figure 1.3). 
The capping process consists of three main enzymatic activities, including 
triphosphatase, guanylyltransferase and methyltransferase (Cowling & Cowling 
2009). Three enzymes in yeast are responsible for carrying out this reaction. On 
the other hand in mammals the triphosphatase and guanylyltransferase activities 
are performed by the bi-functional enzyme RNGTT while the addition of a methyl 
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group is performed by the methyltransferase RNMT (for review see Cowling & 
Cowling 2009) 
Recently it was possible to observe both in vitro and in vivo that the capping 
reaction does not always reach completion and the step between RNGTT and 
RNMT activity can be controlled (Jiao et al. 2010). In particular, in yeast the Rai1 
and Dxo1 enzymes are able to remove specifically 5’-end cap when unmethylated, 
and degrade the aberrant transcript providing a further quality-control mechanism 
in RNA processing (Jiao et al. 2010; Chang et al. 2012). This mechanism was 
recently shown to also apply in higher eukaryotes where Dom3Z is able to function 
on incompletely capped RNA (Jiao et al. 2013). Dom3Z as Dxo1 are both able to 
remove the cap structure, generating a 5’ end monophosphate, and degrade the 
entire RNA with a 5’-to-3’ exoribonuclease activity. As will be described later, de-
capping can prime premature transcription termination due to the action of XRN2 
5’-to-3’ exoribonuclease (Brannan et al. 2012). Furthermore, as mentioned earlier 
co-transcriptional capping coincides with promoter proximal paused Pol II. Beside 
differences in architecture and structure across different taxa, the interaction 
between the guanylyltransferase enzyme and Pol II requires an intact CTD 
phosphorylated on Ser5 and Tyr1 (C. K. Ho & Shuman 1999; A. Ghosh et al. 2011). 
Observations in S. pombe and mammals are suggesting a possible function 
of the capping in Pol II pause release. In S. pombe the completion of the cap is 
achieved with the recruitment of the methyltransferase Pcm1 that requires 
interaction with CDK9 in addition to the CTD (Viladevall et al. 2009; Pei et al. 2003). 
In higher eukaryotes it was also possible to determine a direct interaction between 
RNGTT and DSIF (Wen & Shatkin 1999). This interaction was reported to increase 
RNGTT activity. Furthermore data from the Reinberg lab brought these 
observations further as they reported that the capping enzyme is capable of 
reversing the negative effect of NELF on Pol II elongation, possibly by competing 
for Pol II interaction (Mandal et al. 2004). In addition cap-binding Protein Complex 
(CBC) was suggested to coordinate correct mRNA capping with p-TEFb activity 
(Lenasi et al. 2011). Furthermore, TFs such as Myc and the HIV TAT protein could 
induce RNGTT and RNMT recruitment, providing another possible layer of 
regulation (Chiu et al. 2002; Cowling & Cole 2010). 
 
Chapter 1 Introduction 
 50 
 Splicing: In 1978 Walter Gilbert described eukaryotic genes as shredded 
into pieces, where the coding bits are intercalated by non-coding sequences called 
introns (Gilbert 1978). Most animals and plants present multiple introns per gene, 
whereas in fungi and unicellular eukaryotes introns seem to have drifted away 
(Rogozin et al. 2012). Despite these differences in intron density across eukaryote 
genomes, the highly sophisticated machinery responsible for intron removal, 
named spliceosome, is conserved. The spliceosome is a large ribonucleoprotein 
composed of five snRNPs (U1, U2, U4, U5 and U6) and hundreds of accessory 
proteins (Jurica & M. J. Moore 2003). Splicing and transcription can occur 
separately, but evidence has shown that co-transcriptional splicing is fundamental 
in transcription (Jeronimo et al. 2013). Transcription coupled splicing seems 
primarily controlled via the Pol II CTD. Several studies have shown how different 
components of the spliceosome are specifically recruited through the Pol II CTD 
(Eick & Geyer 2013; Hsin & Manley 2012). In vitro experiments demonstrated that 
hyper-phosphorylated Pol II is able to initiate several steps of spliceosome 
assembly (Hirose et al. 1999).  
The assembly of the spliceosome is based on specific, consensus 
sequences on the growing RNA called splicing sites. Splicing sites are delimiting 
intron sequences both at the 5’ and the 3’ end. The first step in spliceosome 
assembly is the recognition of the 5’ splice site by the U1 snRNP that is responsible 
for cleaving the 5’ end of the intron (Jeronimo et al. 2013). The action of U1 snRNP 
allows the formation of a ‘lariat’ intermediate where the 5’-end of the cut intron 
attaches to a branch point through a pair of guanine and adenine forming a loop 
structure (for review see McManus & Graveley 2011). The next step consists of the 
recruitment of the U2AF snRNP to the polypirimidine tract of the 3’ splice site so 
that the U2 snRNP can be recruited to the branch point in order to form the pre-
spliceosome complex. Key subunits of U2AF were reported by the Manley and 
Bensaude groups to interact directly with the phosphorylated CTD (David & Manley 
2011; Gu et al. 2013). This network of interaction involving snRNPs, the CTD and 
the RNA lead Manley and colleagues to propose that the CTD function consists of 
tethering the 5’ splice site in proximity to the RNA exit channel of Pol II (David & 
Manley 2011). The newly transcribed 3’ splice site, loaded with U2AF in a Ser2-P 
dependent manner, is going to be in close proximity to the tethered 5’ splice site. 
This elegant model still needs experimental confirmation.  
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The transcriptional elongation rate and processivity influence the splicing 
efficacy due to a ‘kinetic coupling’ of the two processes (Eperon et al. 1988). 
Induction of a transcription pause can indeed favour the inclusion of exons 
(Roberts et al. 1998). The pause site in this circumstance allows more time to 
assemble the spliceosome leading to exon inclusion. As phosphorylation of the 
CTD has been reported to influence Pol II processivity, it is clear that CTD 
phosphorylation could indirectly influence splicing efficiency (Muñoz et al. 2009). 
1.3.8 3’ end processing and the transcription termination  
Processing of the RNA 3’ end is a key step in transcription. Due to the 
crucial role of the 3’ end in transcription termination the two processes are going to 
be introduced together. The characterisation of the 3’ untranslated region (UTR) 
started with the analysis of specific highly transcribed genes including the globin 
gene, the ovalbumin gene and the immunoglobin gene (for review see Proudfoot 
2011). These pioneer studies lead to the identification of a long poly(A) tail 
synthesized by a poly(A) polymerase (Takagaki et al. 1988). Sequencing of six 
mRNA 3’ ends led Proudfoot and colleagues to identify the common sequence 
AAUAAA 20-30 nt adjacent to the poly(A) tail (Proudfoot & Brownlee 1976). This 
sequence turned out to be indeed essential for 3’ end poly(A) tailing. In addition, 
further elements appeared to contribute to a functional polyadenylation site (PAS) 
including a GU-rich sequence (downstream of AAUAAA also called DSE), and an 
U-rich tract (upstream of AAUAAA). Recent genomic studies conducted by Ozsolak 
et al. confirmed the generality of the PAS sequence and organisation (Ozsolak et 
al. 2010).  
The 3’ end processing consists in cleavage and polyadenylation of the 
nascent RNA in the correct position and at the right time during transcription. 
Manley and Keller performed extensive biochemical studies using HeLa cell 
nuclear extract in order to purify factors associated with the 3’ UTR of a synthetic 
RNA substrate (Millevoi & Vagner 2010). Two protein complexes were purified: the 
cleavage and polyadenylation specific factor (CPSF) and the cleavage stimulatory 
factor (CstF). Both factors associate with the AAUAAA and the GU-rich DSEs 
promoting cleavage of the pre-mRNA. Furthermore the poly(A) polymerase was 
shown to be recruited to the 3’ end of the cleaved product. The complexes involved 
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in what looks like a simple enzymatic reaction, cleavage and polyadenylation, are 
composed of several subcomplexes comprising 50 or more polypeptides. 3’ end 
formation can be uncoupled to polymerase termination (C. L. Moore & Sharp 1985; 
Butler & Platt 1988). In addition cleavage and polyadenylation could be separated 
as two distinct reactions using ATP inhibitors or EDTA (Butler & Platt 1988; Zhao et 
al. 1999). 
The idea that each step in 3’ end formation is distinct and separable 
becomes clear with the study of 3’-end formation in replication-dependent histone 
mRNAs (Gick et al. 1986). Replication-dependent histone mRNAs do not have 
canonical PAS and these mRNA are formed through the recognition of the histone 
downstream element (HDE), a purine-rich sequence downstream of the conserved 
3’-terminal hairpin, by the snRNA U7 (Schaufele et al. 1986; Schümperli 1988). The 
U7 snRNA, associated with several proteins constituting the U7 snRNP, is recruited 
to the 3’ ends of histones mRNA by interacting with other factors recognising the 3’ 
terminal hairpin (Marzluff et al. 2008). These, together with additional components 
of the cleavage/poly(A) complex, such as CPSF-73, CPSF-100 and Symplekin 
specifically recognise and cleave the 3’ end mRNA.  
Although the 3’ end formation can occur both in vitro and in vivo 
independently of transcription termination, this latter mechanism requires 3’ end 
processing (Whitelaw & Proudfoot 1986). Transcription termination is indeed 
coupled to 3’ end processing as mutation of the PAS sequence allows Pol II to read 
through and bypass the normal termination site (Whitelaw & Proudfoot 1986; 
Connelly & Manley 1988). Recruitment of the cleavage/poly(A) complexes to the 
elongating Pol II requires an intact CTD (McCracken et al. 1997; Zhao et al. 1999). 
In particular phospho-CTD specifically interacts with both CPSF and CstF. A crucial 
example is the Pcf11 component of the CFII in mammals, and CF1A in yeast. 
Pcf11 is specifically recruited by Ser2-P and its distribution over the elongating Pol 
II is controlled by Tyr1-P that, at least in yeast, masks Ser2-P until the 
polyadenylation site appears (Mayer et al. 2012). Cleavage by the CFII complex in 
mammals, or the CF1A in yeast, exposes residual uncapped RNA attached to the 
elongating Pol II. Both in yeast and mammals this RNA is recognised and degraded 
by the 5’-3’ exonucleolytic RNAase (Rat1 in yeast and XRN2 in mammals) (M. Kim 
et al. 2004; West et al. 2004). This exonuclease can be directly recruited to the 
elongating Pol II via p54nrb/PSF that can interact with both CTD and XRN2 
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(Kaneko et al. 2007). It is thought that the exonuclease is in kinetic competition with 
the elongating Pol II such that, when RNA degradation reaches the elongating Pol 
II, termination will be induced by conformational changes in the Pol II active site 
(Connelly & Manley 1988; Proudfoot 1989). This mechanism is called the Torpedo 
model and likely occurs in coordination with the cleavage/poly(A) factors ensuring 
correct and efficient termination of the transcribing Pol II. In order for the Torpedo 
mechanism to occur, the polymerase has to either slow down in a certain position 
after the PAS element or additional and more efficient cleavage has to occur 
proximal to the RNA exit channel of the Pol II. These two scenarios were described 
in several works aimed at identifying additional sequences influencing Pol II 
termination. The first scenario seems to correlate to GC-rich sequences 
downstream at the PAS site where Pol II pause gives more time for the 
exonuclease to reach Pol II (Plant et al. 2005; Gromak et al. 2006). These 
elements are associated with RNA:DNA hybrids and their resolution by specific 
helicases (Sen1 in yeast and senataxin in mammals) is essential for termination to 
occur (Skourti-Stathaki et al. 2011). The second case is more elusive and has been 
recently described as valid for 78 gene loci after a genomic approach aimed at 
assessing the generality of this mechanism (Nojima et al. 2013). In this case an 
AT-rich sequence 1 to 2 kb downstream of the PAS site is prone to co-
transcriptional cleavage (Dye & Proudfoot 2001). This element is called co-
transcriptional cleavage (CoTC) element and might occur when PAS-proximal 
pause sites are absent. These AT-rich sequences are highly unstable and 
susceptible to degradation so that, as soon as they are synthesised, they are 
attacked by exonucleases allowing fast and efficient termination (West et al. 2008). 
CoTC cleavage drives the Torpedo mechanism then to occur further downstream 
the PAS site and the release of the Pol II precedes cleavage and 3’ end processing. 
1.4 The chromatin template 
Eukaryotic DNA is packed around a sophisticated complex of proteins called 
histones. Two copies of histones H2A, H2B, H3 and H4 combine in an octamer 
called a nucleosome (Kornberg 1977). The entire DNA is assembled around an 
array of nucleosomes that take contact with every 146 bp of DNA. The 
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DNA/nucleosome array is in turn folded into chromatin fibres compacting the long 
DNA into a few microns within a cell’s nuclei. 
Although chromatin is a major challenge to overcome for both TFs and Pol II, 
it provides opportunities for gene regulation. The packaging of the DNA indeed 
affects genes regulation and it seems to contribute to the setup and maintenance of 
cell identities (T. Chen & Dent 2014). 
Multiple mechanisms contribute to control chromatin assembly and 
compaction including DNA modifications (e.g. cytosine methylation and cytosine 
hydroxymethylation), histones PTMs, incorporation of histone variants (e.g. H2A.Z 
and H3.3) and ATP-dependent chromatin remodelling. A combination of these 
modifications could contribute to the regulation of DNA accessibility. Beside the 
regulation of the chromatin architecture and nucleosome density each histone PTM 
and each histone variant can constitute a possible docking site for regulatory 
machines (see below). 
More than half a century ago the word ‘epigenetics’ was coined by 
Waddington, defining the mechanisms that temporally and spatially control gene 
activity during development (Waddington 1959; Holliday 2007). Nowadays the word 
‘epigenetics’ is extensively used to group all the DNA sequence-independent 
mechanisms controlling gene expression, including DNA methylation states and 
histone modifications (Bernstein et al. 2007; Bonasio et al. 2010). It is important to 
point out that the instruction provided by the ‘epigenome’ is functional if considered 
in the context of the genetic information coded within the DNA.  
Dynamic and reversible changes occurring at the chromatin structure are of 
particular interest in gene activation while long-term modifications such as DNA 
methylation are mostly associated with genomic imprinting, X-chromosome 
inactivation, suppression of repetitive elements and long-term gene silencing. DNA 
methylation occurs in the context of CpG dinucleotide (Jones 2012). CpG regions 
are mostly present at active promoters and methylation of cytosines by DNMT 
enzymes causes stable gene repression. On the other hand histone modifications, 
exchange and repositioning are fast changes correlating with different ‘chromatin 
states’. Several works contributed to elucidating how these chromatin states or 
signatures are influencing the transcriptional outcome.  
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1.4.1 Histone post-translational modification 
Histone proteins have an amino-terminal tail protruding from the 
nucleosome core and can be subject to several PTMs (Tan et al. 2011; Tian et al. 
2012). Due to the number of combinations the total number of ‘chromatin states’ is 
likely inestimable (Cieślik & Bekiranov 2014). Several studies aimed at mapping 
PTMs described a certain correlation between specific combinations of PTMs and 
precise functions or genomic loci, reducing the number of possibilities. Histone 
PTMs include: acetylation, methylation and phosphorylation. Further modifications 
such as deamination, ADP ribosylation, ubiquitylation, sumoylation and proline 
isomerisation could also occur but are not going to be introduced here. For a recent 
review on histone PTMs see Bannister & Kouzarides 2011. 
 
Histone acetylation: The acetylation of lysine residues within histone N-
terminal tails is a highly dynamic process under the control of the opposing 
enzymes; histone acetyltransferases (HATs) and histone deacetylases (HDACs). 
The addition of an acetyl group to lysine causes neutralisation of the lysine’s 
positive charge, weakening the interaction between histones and DNA (Bannister & 
Kouzarides 2011). At the same time acetylated lysines can appear as functional 
docking sites for proteins harbouring specific domains (for a review see Patel & 
Zhanxin Wang 2013). HATs can be grouped depending on their catalytic domain 
(see Table 1.4). HATs reside in multi-protein complexes where the specific 
composition dictates the unique features of each HAT complex. Various chromatin-
binding domains can determine the location of HATs complexes docking onto 
modified histones. HATs are therefore taking advantage of specialised subunits 
that are able to determine their genomic localisation (Sterner & Berger 2000).  
HDACs have opposing actions, restoring the positive charge of the lysine, 
consistent with their function in transcription repression. In mammals it is possible 
to list 18 different HDACs divided into four classes, each showing different structure, 
enzymatic function, subcellular localisation and expression patterns (Haberland et 
al. 2009; de Ruijter et al. 2003). HDAC activity is controlled through the association 
with co-repressor and accessory proteins assembled into multi-subunit complexes 
(Adcock 2006). 
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Histone phosphorylation: Like acetylation, phosphorylation of histones on 
serines, threonines and tyrosine dramatically alters their overall charge. Histone 
phosphorylation has the most disparate functions spanning from regulation of 
chromatin compaction in meiosis and mitosis to DNA damage repair and 
transcription regulation (Rossetto et al. 2012). Chromatin compaction and DNA 
damage response involve extended phosphorylation over several kilobases. 
However phosphorylation of histones in association with transcriptional regulation 
resides in defined and restricted genomic loci (Barratt et al. 1994). The most 
studied phospho-modifications lie within the N-terminal tail of the histone H3, in 
particular H3S10 and H3S28 (Sawicka & Seiser 2012). Kinase dependent histone 
modifications were always seen as possible starting points required to induce 
defined activating signature at promoters. The identification of the kinases involved 
in transcriptional activation through histone phosphorylation has always been a 
challenge. Uncoupling the causal effect of activated kinases and the coinciding 
histone modification is difficult to rule out. Several indirect effects could be 
observed as in most cases the primary readout is the activation of target genes 
rather than the appearance of the modification. In vitro studies often try to validate 
the in vivo observations but are often subject to unspecific effects. Table 1.5 
presents the kinases that were shown to phosphorylate histone residues in vitro or 
through correlation studies in vivo. The best-described kinases are the Aurora 
family of kinases. Their role is best described in mitosis and meiosis but recent 
evidence described a possible function in controlling gene activity in quiescent 
lymphocytes directly associated with target promoters (Frangini et al. 2013).  
Beside the identification of the kinase responsible for histone modifications, 
the consequence of having a phosphate residue on the histone H3 tail is of central 
interest. Several studies tried to rule out the relation between phosphorylation and 
other PTMs at the histone tail. The identification of the 14-3-3 factors has been 
pivotal in understanding the function of signalling induced histone H3 
phosphorylation in transcription (Macdonald et al. 2005; Walter et al. 2008). 
Biochemical studies highlighted how 14-3-3 binding is enhanced when the H3S10 
phosphorylation (H3S10P) is accompanied by H3K9 and K14 acetylation 
(H3K9K14Ac) (Winter et al. 2008). As presented in several studies, 14-3-3 works 
as a reader of modified histones providing further docking sites for downstream 
effectors (Drobic et al. 2010; Zippo et al. 2009; K. D. Meyer et al. 2008). 
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It is going to be crucial to understand how histone phosphorylation is 
directed to specific loci and in particular to promoters of genes downstream of 
signalling pathways. Furthermore it is going to be important to identify and describe 
phosphatases that possibly regulate the dynamicity of these marks that, at the 
moment, remain understudied. 
 
Histone methylation: Methylation occurs on both lysine and arginine of 
histone side chains. Unlike acetylation and phosphorylation, histone methylation 
does not affect the charge of the targeted residue. Lysine can be mono- di- or tri-
methylated while arginine may be mono- and symmetrically or asymmetrically di-
methylated (for review see Shilatifard 2006). It is possible to distinguish six major 
classes of lysine methyltransferase (KMTs) (Table 1.6). KMTs act either as single 
entities or as part of complexes. All the KMTs posses a so-called SET domain 
(named after the Drosophila Su(var)3–9, Enhancer of zeste [E(z)], and trithorax 
[trx]) with the exception of Dot1 which presents an unique domain. Histone 
methylation has diverse roles in gene activation spanning from positive to negative 
functions. Several so-called readers are capable of interacting with methylated 
lysine through specific domains. Two key works employing extensive SILAC-based 
mass spectrometry, using peptides or reconstituted nucleosomes, described an 
intricate network made of methylated lysine at the histone tails (Vermeulen et al. 
2010; Bartke et al. 2010). These studies clearly demonstrate the correspondence 
between the known biological function of methyl marks and the biological function 
of the associated reader. For decades histone methylation was supposed to be a 
fairly stable modification but the identification of (K)-specific demethylase (KDM) 
showed how dynamic these marks are. The first demethylase, named lysine-
specific demethylase 1 (LSD1), was discovered by Shi and colleagues in 2004 
(Yujiang Shi et al. 2004). Since then several other demethylases have been 
discovered making the methyl mark a highly dynamic histone PTM (for a review 
see Mosammaparast & Yang Shi 2010). 
1.4.2 Exchange and repositioning of histones 
The primary function of chromatin remodelers is to dynamically regulate 
DNA accessibility and to control nucleosome positioning (Clapier & Cairns 2009). 
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There are four main families of chromatin remodeling enzymes (Table 1.7). All four 
families use a DNA-dependent ATPase to remodel and translocate along the DNA 
that, working like an icebreaker, weakens the nucleosome-DNA interactions. The 
four families can be distinguished on the basis of their specialisation imparted by 
unique domains and subunits (Table 1.7). Overall remodelers have an affinity for 
nucleosome beside the ability to recognise specific histone PTMs. Chromatin 
remodelling machines play a crucial role in several biological processes such as 
replication, dosage compensation, DNA repair and also gene regulation. Regarding 
nucleosome positioning and its role in gene activation it is important to consider the 
antagonising effect of remodelers that organise chromatin and those that 
disorganise or eject nucleosomes (Clapier & Cairns 2009). Organised chromatin 
mostly correlates with repressed chromatin as the assembly of nucleosome arrays 
restricts DNA accessibility. On the other hand disordered chromatin and histone 
ejection favours gene activation (Lorch et al. 2006). A further strategy to activate 
expression of target genes is to replace canonical histones with variants that 
associate with the DNA less stably. This is the case with the SWR1 enzymes which 
are capable of replacing the canonical dimer H2A-H2B, with the variant H2A.Z-H2B 
generating a less stable nucleosome at promoters of active genes (Schones et al. 
2008; Ruhl et al. 2006; Jin et al. 2009).  
1.4.3 Chromatin states 
One of the major challenges in studying the chromatin template is the 
generation of predictive models aiming to relate chromatin signatures to regulatory 
elements. The ability to unequivocally assign a determined histone signature to cis-
regulatory DNA elements or silenced/active genes would provide an immense tool 
to understand diverse biological outcomes.  
This systematic approach was recently pursued by the Bernstein lab. Ernst 
and collaborators made use of a high-throughput pipeline to systematically map 
nine chromatin marks within nine cell lines (J. Ernst et al. 2011). They used a 
series of antibodies recognising marks associated with: active promoters (H3 lysine 
4 tri-methylated named H3K4me3, di-methylated named H3K4me2 and the histone 
variant H2A.Z), enhancers (H3K4me2 and mono-methylatednamed lysine 4 of the 
histone H3 named H3K4me1), active regulatory elements (H3 lysine 9 acetylated 
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and K27 acetylated named respectively H3K9ac and H3K27ac), actively 
transcribed regions (H3 lysine 36 tri-methylated named H3K36me3 and H4 lysine 
20 mono-methylated named H4K20me1), associated with Polycomb repression 
(H3 lysine 27 tri-methylated named H3K27me3) and heterochromatin regions (H3 
lysine 9 tri-methylated named H3K9me3). A hidden Markov model was applied to 
summarize the data into nine annotations, corresponding to the nine cell lines in 
combination with RNA expression data and Pol II distribution. From this analysis it 
was possible to discriminate 15 chromatin states (Figure 1.7). The distribution of 
these chromatin states changes across the different cell lines reflecting lineage-
specific gene expression. Furthermore enhancers showed a high cell line specificity 
being proximal to lineage-specific genes. Using this framework it was also possible 
to predict cis-regulatory elements and in particular TF binding sites within cell-type-
specific enhancers. This study was recently expanded using human tissues, blood 
cells and stem cells corroborating the view that specification is accompanied by a 
marked transition from diverse possible states to limited configurations (Zhu et al. 
2013). 
This innovative approach was integrated thereafter with the combinatorial 
patterning of chromatin regulators. Using a meso-scale localisation assay Ram and 
colleagues generated a genome-wide map of 29 chromatin regulators (CRs) (Ram 
et al. 2011). Several observations came out from this study: genomic loci with the 
same signature show coherent modules of CRs, composed of both activating and 
repressing enzymes, suggesting a possible tuning mechanism; specific CRs 
associate to genes with related functions; within different cells CRs are part of the 
same module but the distribution of these modules changes. Altogether these 
conclusions are reminiscent of the organisation of TF networks. Garber and 
colleagues recently described the importance of TF binding networks and their 
dynamic behaviour in response to stimuli (Garber et al. 2012). The tight correlation 
between TF binding, transcription dynamics and chromatin changes highlights the 
leading role of TFs in seeding the primary causal variable.  
1.4.4 Signalling to Chromatin and the histone crosstalk 
Having described the most recent advance in interpreting the chromatin 
signature it become clear that histone modification per se cannot represent a code 
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(J.-S. Lee et al. 2010; Sims & Reinberg 2008). Histone PTMs are no different than 
PTMs associated within any other protein in the cell. It is instead true that groups of 
modifications can encode a signature or state that correlates with functional 
elements or outcomes (E. Smith & Shilatifard 2010). Most intriguingly it is possible 
to consider histone modification as a part of signalling pathways required to 
assemble these states. A key question therefore is how the chromatin states are 
set up. Several studies have tried to understand how defined patterns of chromatin 
modifications are assembled in response to cell differentiation, tissue 
morphogenesis and acute ectopic stimulation. 
A remarkable example comes from the study of mechanisms involved in 
maintenance or abrogation of Embryonic Stem cell (ESC) pluripotency. ESCs are 
characterised by a highly plastic and permissive chromatin that allows them to 
maintain a wide spectrum of differentiative capacity (Meshorer et al. 2006). ESCs 
are indeed marked by defined chromatin states that are maintained through a 
signalling-crosstalk. A well-characterised mechanism to establish silenced 
chromatin comes from the study of DNA methylation (Z. D. Smith & Meissner 2013). 
This repressive mechanism is initiated by DNA methyltransferases (DNMT). The 
establishment of repressive chromatin at these loci is caused by an interplay 
between DNMTs, histone methyltransferase, HDACs and remodelling complexes 
(for a review see Z. D. Smith & Meissner 2013). This mechanism in ESCs is 
controlled by specific TFs. Elegant experiments, targeting SP1 to endogenously 
methylated loci, demonstrated that TF activities are sufficient to induce 
demethylation (Macleod et al. 1994; Brandeis et al. 1994). 
Long-term chromatin silencing opposes the silencing of lineage-specific 
genes, later required for ESC differentiation. This group of promoters is 
characterised by the presence of the polycomb group of proteins (for reviews see 
Morey & Helin 2010; Voigt et al. 2013). This complex could be recruited at genomic 
loci through a plethora of different mechanisms including specific cis-regulatory 
DNA elements, defined histone modifications, TFs and non-coding RNA (ncRNA) 
(Morey & Helin 2010). Although the way polycomb complexes are specifically 
recruited still remains unclear, their distribution correlates with the establishment of 
inactive - or poised - promoters and repressed transcription (Barski et al. 2007; 
Mikkelsen et al. 2007; J. Ernst et al. 2011). It was observed that the distribution of 
polycomb protein is complementary to the presence of transcriptional activator and 
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transcribing Pol II (Ku et al. 2008). This and other studies are now leading to the 
view that polycomb proteins are excluded from active regions instead of being 
recruited to target regions.  
The establishment of active chromatin states in response to extracellular 
stimuli yields a notable perspective of how dynamic the histone crosstalk could be. 
As mentioned earlier several kinases are found associated to promoters in 
response to stimuli (Frangini et al. 2013; H.-M. Zhang et al. 2008a; Madak-Erdogan 
et al. 2011). Different transcription factors have been shown to harbour defined 
docking sites recognised by specific kinases. The location of kinases at gene 
promoters activates histone crosstalks, which in turn establish a specific chromatin 
signature. One example comes from studies on active nuclear Erk. In fact, Erk is 
able to activate the progesterone receptor and the protein kinase MSK1, leading to 
their specific association to target promoters (Vicent et al. 2006). As a 
consequence, active Msk1 is able to phosphorylate H3S10, which displaces HP1 
from the repressed chromatin and allows recruitment of Pol II. A further example 
comes from a recent study of stem cell differentiation into neurons where JNK was 
seen in association with chromatin loci together with NF-Y (Tiwari et al. 2012). As 
for the other kinases JNK also seems to be able to phosphorylate H3S10.  
Phosphorylation of histone H3 allows recruitment of 14-3-3 adaptor proteins 
which was reported to induce a histone crosstalk at the Fosl1 gene following serum 
stimulation (Zippo et al. 2009). At Fosl1 enhancer PIM1 kinase is responsible for 
the phosphorylation of H3S10 while MSK1/2 seems to affects its promoter (Zippo et 
al. 2007; Zippo et al. 2009). In this case, 14-3-3 seems to allow specific recruitment 
of the acetyltransferase MOF only at the Fosl1 enhancer. MOF-dependent 
acetylation of H4K16 was shown to be responsible and sufficient for BRD4/pTEFb 
recruitment and productive transcription. Although captivating, this study leaves 
several open questions. How are different kinases targeted at different loci? How 
does H3S10 phosphorylation induce different crosstalks at the Fosl1 enhancer and 
promoter?  
1.5 The SRF transcription network 
Most transcriptional networks embody several of the regulatory mechanisms 
described so far. Among them, the Serum Response Factor (SRF) regulates the 
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expression of growth-related IE, cytoskeletal and muscle-specific genes. In 
particular, SRF was reported to be essential for the control of growth, differentiation, 
cell motility and circadian clock oscillations.  
SRF was initially discovered through a series of studies based on c-fos gene 
expression. C-fos is a proto-oncogene, a homolog of the FBJ murine osteosarcoma 
gene v-fos (Curran et al. 1982). C-fos has always been of high interest in the 
transcription field due to its rapid RNA synthesis after exposure to growth factors 
and mitogens (Greenberg & Ziff 1984; Greenberg et al. 1985). Studies of the 5’-
flanking region of c-fos identified a cis-element named Serum Response Element 
(SRE) required for c-fos serum induction with enhancer-like characteristics 
(Treisman 1985; Deschamps et al. 1985). Soon after, through a series of 
biochemical studies the isolation of the protein encoding for the factor associated to 
the c-fos SRE led to the discovery of SRF (Treisman 1986). SRF and its consensus 
sequence - the SRE - were then found to be associated with several other IE genes 
and surprisingly muscle-specific genes (Mohun et al. 1987; M. Taylor et al. 1989).  
1.5.1 MADS-Box transcription factors and SRF DNA recognition 
In vitro functional studies of the SRF-DNA binding activity identify a 90 
amino acid domain embedded within the SRF polypeptide, which suffices for 
normal DNA binding activity (Norman et al. 1988; Schröter et al. 1990). Sequence 
comparisons show several SRF relative factors, including the two S. Cerevisiae 
MCM1 and ARG80, involved in extracellular signal-regulated and cell type-specific 
transcription (Norman et al. 1988; Passmore et al. 1988). The DNA binding domain 
of SRF, MCM1 and ARG80 all include a conserved 56 amino acid sequence, 
named MADS-box after its founding members (MCM1-Agamous-Deficiens-SRF) 
(Shore & Sharrocks 1995). All MADS-box containing factors exhibit a conserved 
core DNA-binding domain composed of an N-terminal MADS box and a C-terminal 
extension of approximately 30 amino acids (Shore & Sharrocks 1995). The MADS-
box is what determines the DNA specificity of each factor allowing them to bind 
related, but distinct consensus sequences (Pollock & Treisman 1991; Wynne & 
Treisman 1992). The C-terminal half however is required for dimerization, and in 
part for co-regulator interactions (Mueller & Nordheim 1991; Shaw 1992; Primig et 
al. 1991).  
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The crystal structure of the SRF homodimer, together with its DNA target 
sequence provided surprising insight into the MADS-box family of TFs (Pellegrini et 
al. 1995). The SRF homodimer organises on top of the DNA into a three-layered 
structure, each one composed of the interaction with the same unit from each 
monomer. As shown in Figure 1.9 at the base of the SRF-DNA structure lays an 
antiparallel coiled coil, constituted by two amphipathic α–helices contacting the 
minor grooves of the underlying DNA. The second layer, consisting of a four-
stranded antiparallel β–sheet, sits on top of the antiparallel coiled coil layer. Above 
the β–sheet layer, the C-terminal unit forms irregular coiled pairs of helices with a 
pair of α–helices on top. The binding of SRF to the DNA forces the latter to bend by 
72°, allowing the basic N-terminal regions and loops to contact the major grooves 
of each half site. The N-terminal regions contact the minor grooves on the opposite 
side. The disposition and the specific contacts of the N-terminal region provide 
rationales for the different sequence specificity of MAD-box containing factors such 
as SRF, MCM1 and MEF2A (Sharrocks et al. 1993; Nurrish & Treisman 1995). The 
SRF-DNA structure shows how SRF specifically recognises its consensus 
sequence, named CArG-box which is conserved across all the SREs studied at 
that time. The CArG-box is defined by a central A/T-rich sequence that allows the 
formation of a narrow minor groove while flanking GG bases favour bending into 
the major groove. Structural and functional analysis of the SRF-DNA binding allows 
the definition of the SRF consensus sequence as CC(A/T)6GG (Pellegrini et al. 
1995; Pollock & Treisman 1990; Treisman 1985). 
Recently the specificity of SRF for the CArG consensus was addressed 
using genome-wide approaches (Valouev et al. 2008; Sullivan et al. 2011; Esnault 
et al. 2014). SRF binding in vivo occurs at perfect or slightly degenerated CArG 
sequences (70% of SRF’s binding events with 0-1 mismatch and 90% of SRF’s 
binding events with 0-2 mismatchs) and its binding intensity correlates directly to 
the quality of the CArG consensus (Esnault et al. 2014). In contrast to what has 
been proposed in the past (Herrera et al. 1989), most SRF binding is inducible and 
surprisingly, inducible SRF sites exhibit a better match to the CArG-box sequence 
than constitutive sites (Esnault et al. 2014). As introduced previously the 
association of SRF to its consensus in the genome most probably relies on 
nucleosome displacement, provided by co-regulators and TF binding nearby. The 
quality of the consensus reflects the binding cooperation with co-regulators with no 
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DNA preferences and TFs that are not directly interacting with SRF. On the other 
hand degenerated consensus seems more associated with loci where SRF directly 
associates and interacts with co-regulators harbouring defined DNA recognition 
features (see later).  
1.5.2 SRF transcriptional network: The TCF and MRTF branch 
Besides studies focused on SRF-DNA interaction, much effort was devoted 
during the late 80s to characterise SRF’s activities and functions (Treisman 1995b). 
SRF is a constitutive nuclear TF with a poor transactivation activity (Johansen & 
Prywes 1993; Hill et al. 1993). Indeed most of SRF’s functional features were 
mapped within or in close proximity to its DNA binding domain and its C-terminal 
activation domain, fused to the GAL4 DBD, showed weak transactivation functions 
(Treisman 1995a; Johansen & Prywes 1993). However, SRF was reported to be 
essential for the expression of several genes and in particular to be required for 
signal-dependent gene activation (Treisman 1986; Prywes & Roeder 1987).  
Shedding light on this problem was the discovery of a novel factor of 62 KDa 
able to form a ternary complex with SRF at the c-Fos promoter (Shaw et al. 1989). 
Diverse studies led to the isolation of three ETS-related factors (see Table 1.1) 
named Elk-1 (Rao et al. 1989), SAP-1a (Dalton & Treisman 1992) and NET/SAP-
2/Erp (Giovane et al. 1994; Lopez et al. 1994), able to form a ternary complex with 
SRF and therefore named Ternary Complex Factors (TCF). These factors are 
constituted by three main domains: an N-terminal EST DNA binding domain (Rao 
et al. 1989; Dalton & Treisman 1992), a basic B-box required for interaction with 
SRF (Dalton & Treisman 1992; Janknecht & Nordheim 1992) and a C-terminal 
transactivation domain (Dalton & Treisman 1992) (Figure 1.10). The TCF activation 
domain is phosphorylated via Erk, which is the ending point of the Ras cascade 
(Gille et al. 1992; Marais et al. 1992; Janknecht, W. H. Ernst, Pingoud, et al. 1993b). 
The discovery of the TCFs clearly explained how activation of the MAPK signalling 
pathway via mitogens would target SRF regulated genes. However, it was not 
sufficient to explain other observations. Serum and polypeptide growth factors or 
TPA (12-O-Tetradecanoylphorbol-13-acetate) were activating distinct pathways 
leading to SRF activation (Treisman 1995b). Furthermore activation of SRF 
dependent genes could occur independently of the TCFs in several cell lines (Hill et 
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al. 1994; Hill & Treisman 1995a). The involvement of a further signalling pathway 
was disentangled by studies aimed to characterise this TCF-independent activation. 
SRE containing promoters were shown to respond to active RhoA, CDC42 and 
Rac1 (Hill et al. 1995). Furthermore changes in actin dynamics could directly 
influence genes controlled by SRF in the absence of TCFs (Sotiropoulos et al. 
1999; Mack et al. 2001; Posern et al. 2002). The hunt for SRF co-regulators 
involved in muscle-specific gene activation led to the identification of Myocardin (D. 
Wang et al. 2001a). Later, the identification of Myocardin homologues potentiating 
SRF activity provided additional clues (D. Z. Wang et al. 2002). Miralles and 
colleagues finally demonstrated that Myocardin-related transcription factors 
(MRTFs) are indeed SRF co-activators, linking RhoA and actin dynamics to SRF-
dependent transcription activation (Miralles et al. 2003). 
In summary SRF is the endpoint of two signalling pathways (Figure 1.8). 
The Ras-Erk signalling pathway allows SRF-associated TCF activation and gene 
induction (see chapter 1.6). On the other hand activation of Rho, and the 
concomitant remodelling of the actin cytoskeleton, induces MRTF’s association 
with SRF and gene activation (see chapter 1.7).  
1.6 Signalling to SRF part I: The RAS-Erk signalling pathway 
and the TCF co-factors 
Mitogen-activated protein kinases (MAPKs) belong to a family of kinases 
whose function is conserved throughout evolution (Widmann et al. 1999). These 
kinases link receptor tyrosine kinase activation to effector proteins via a protein 
kinase cascade. MAPKs are able to phosphorylate specific serine and threonine 
residues on target proteins, regulating diverse cellular activities. MAPKs work like 
triggers to switch target proteins on or off. MAPK is part of a so-called 
“phosphorelay” system composed of three sequentially activated kinases that 
ultimately lead to MAPK phosphorylation and activation (G. L. Johnson & Lapadat 
2002).  
Multicellular organisms present several MAPK subfamilies including, among 
others, the p38 kinase family, the c-Jun N-terminal kinase family (JNK or SAPK) 
and the extracellular signal-regulated kinase (ERK) family. 
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1.6.1 RAS activation and the phosphorelay to ERKS 
ERK1 and ERK2 are widely expressed mitogen-activated protein kinases 
involved in different cellular processes. ERKs were shown to be involved in the 
regulation of cell adhesion, cell cycle progression, cell migration, cell survival, 
differentiation, metabolism, proliferation and activation of transcription (Roskoski 
2012a). 
The activation of Ras within cells is what leads to the activation of the 
phosphorelay culminating in ERK nuclear accumulation. Ras is a small GTPase 
that works as a molecular switch changing its status from inactive to active as it 
releases GDP and associates with GTP (Marshall 1988). This process of activation 
is guided by guanine nucleotide exchange factor (GEF). The activation of Ras is 
the result of ligand-induced activation of protein tyrosine-linked receptors (PTKRs). 
Binding of growth factors to the PTKR extracellular domain induces dimerization 
and auto-phosphorylation of the receptor in its intracellular domain (Ullrich & 
Schlessinger 1990). The cytoplasmic phosphorylated residues are therefore 
recognised by adaptor proteins harbouring specialised domains such as the Src 
homology 2 (SH2) domain or the phosphotyrosone binding domain (PTB) (Pawson 
2004; Schlessinger 2003). These adaptor proteins (e.g. Grb2, Nck, Crk, Shc) bring 
different factors involved in signal transduction at the plasma membrane. In 
particular Grb2, using its SH2 domain, brings the GEF Sos at the PTKR in 
proximity to its target Ras (Schlessinger & Bar-Sagi 1994; Pawson 1995). Sos 
favours the exchange of GDP with GTP activating Ras at the plasma membrane. 
Further mechanisms could lead to Sos recruitment at the plasma membrane, 
including Shc recruitment, PTB adaptor proteins or through interaction with IRS1 or 
FRS2α (Margolis et al. 1999; X. J. Sun et al. 1993; Kouhara et al. 1997).  
Ras can also be activated by other GEFs such as the Ras guanyl nucleotide 
releasing proteins (RasGRPs) (Ebinu et al. 1998). This GEF harbours a domain 
able to interact with diacylglycerol (DAG). DAG is well known for its action on PKC 
(reviewed in Griner & Kazanietz 2007). Increased DAG levels at the plasma 
membrane, in response to PTKRs or G-protein-coupled receptors (GPCRs), leads 
to phospholipase C (PLC) stimulation. Activation of PLC leads to the hydrolysis of 
phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) in turn generating 
soluble inositol trisphosphate (IP3) and DAG. Proteins harbouring specialized 
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domains, such as PKC or, as mentioned, RasGRPs, are activated upon recognition 
of DAG. Phorbol, a natural diterpenes-derivative obtained from plants of the 
Euphorbiacaeae family, is a widely used substitute for DAG. The most common 
phorbol ester is 12-O-tetradecanoylphorbol-13-acetate (TPA), also called phorbol-
12-myristate-13-acetate (PMA). TPA is able to induce Ras activation independently 
of mitogen stimulation (Zheng et al. 2005).  
Active Ras at the plasma membrane is known to interact and activate 
several effector proteins such as PI3K and Raf, stimulating numerous intracellular 
processes (Howe et al. 1992). Raf is a kinase with a limited spectrum of action. Its 
activity is restricted to MEK1 and MEK2 that ultimately induce ERK activity (Ray & 
Sturgill 1988; Roskoski 2012b). 
1.6.2 Control of Erk activity and their nuclear targets 
Erk activity is under the control of scaffold and anchor proteins. Scaffolds 
are proteins interacting and bringing together multiple components of the signalling 
module, working as facilitators, enhancing the propagation of the signal. ERKs bind 
to several scaffold proteins in the cytoplasm including KRS1/2, IQGAP1, MP1, 
MORG1, β-arrestine, SEF, MKK1 and paxilin (for review see Roskoski 2012a). 
Anchor proteins on the other hand bind to single elements of the signalling module, 
maintaining Erk in the cytoplasm in resting conditions. Upon activation, Erk 
detaches from these anchors and translocates into the nucleus. Erk kinases were 
shown to shuttle between the cytoplasm and the nucleus and the relative 
concentration between the two compartments was proposed to control diverse 
cellular processes (Zehorai et al. 2010).  
The mechanism accounting for Erk nuclear translocation has been a matter 
of debate for several years. Erk could be accumulated in the nucleus as a result of 
passive diffusion or active transport (Adachi et al. 1999). Erk does not contain 
either conventional or non-conventional NLS sequences; therefore several 
complementary mechanisms were proposed (Zehorai et al. 2010). Recent insight 
into the mechanism of ERKs nuclear localisation has elucidated an alternative 
mechanism involving a nuclear translocation signal (NTS) (Zehorai et al. 2010; 
Plotnikov et al. 2011). Phosphorylation of this sequence allows Erk to interact with 
importin 7 that mediates Erk translocation into the nucleus via the nuclear pore.  
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Changes in Erk localisation have a profound effect on Erk functions. Recent 
quantitative proteomic works have shown that a fifth of Erk interaction partners 
change upon stimulation (Kriegsheim et al. 2009). Most of these interactions are 
dedicated to controlling Erk spatio-temporal behaviour. Nuclear ERK 
phosphorylates and activates several TFs including, among others, NF-κB, AP-1, c-
Myc and members of the ETS family.  
1.6.3 The ETS family of TFs and the TCFs  
The ETS family of TFs is a crucial end point of the RAS-RAF-MEK-Erk 
signalling pathway. The ETS proteins are TFs harbouring a conserved ETS domain 
responsible for their DNA binding specificity and comprising members of the 
previously described TCF factors (see Table 1.1). ETS belongs to the helix-turn-
helix (HTH) superclass of TFs. HTH domains comprise three α-helices. A first α-
helix inserts into the major groove of the DNA, accounting for specific DNA 
recognition; a second α-helix is necessary in the HTH domain to exert unspecific 
interaction with the DNA backbone; a third α-helix is present in only a few HTH 
domains, such as the ETS, and stabilises the entire DNA-binding module. The ETS 
domain is a variant of the HTH superclass (variant termed winged helix 
architecture) as the three α-helices are articulated on a four-stranded, antiparallel 
β-sheet layer (Sharrocks 2001). The consensus sequence recognised by this 
domain presents a central invariant GGA(A/T) core.  
The TCFs are a specialised subfamily of ETS TF, able to directly interact 
with SRF at specific loci where the ETS DNA binding motif flanks the CArG box. 
TCFs are a good and well-studied example of modular TFs characterised by 
multiple domains all contributing to a specific function of the protein (Brent & 
Ptashne 1985). In addition to the ETS domain, the TCFs harbour a unique 
hydrophobic motif named B box required for direct interaction with SRF (Figure 
1.10) (Dalton & Treisman 1992; Shore & Sharrocks 1994). Recently it has been 
shown that through direct interaction the TCFs are able to specifically drag SRF at 
its consensus sequence, stabilising the SRF-DNA association even when the CArG 
motif is heavily degenerated (Esnault et al. 2014). Hassler and Richmond 
described the structure of the ternary complex SAP-1a, SRF and DNA by X-ray 
crystallography (Hassler & Richmond 2001 and reviewed in Sharrocks 2002). As 
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shown in figure 1.9 the dimeric SRF core and the ETS domain of a single SAP-1a 
molecule are binding to opposite sides of the DNA with the ETS domain occupying 
the major groove. The unresolved linker between the ETS domain and the B-box 
suggests a highly flexible region accounting for the already proposed flexibility in 
spacing between the CArG box and the ETS binding sequence (Treisman et al. 
1992). The B-box arranges into a 310-helix/β-strand/310-helix structure, contacting 
the DNA in its major groove and SRF. Extensive hydrophobic contacts, mediated 
by residues within the 310-helix and the β-strand of the B-box, make the β-strand 
join the β-sheet provided by SRF in an antiparallel fashion. The TCFs are also 
capable of binding genomic sequences independently from SRF at high affinity 
ETS sequences, as reported in several studies (Esnault et al. 2014; Hollenhorst et 
al. 2011). 
Several ETS members harbour additional domains able to respond to active 
ERKs. In particular, one-third of the ETS members encode the PNT (or pointed) 
domain (for a review see Hollenhorst et al. 2011). The PNT domain acts as a 
docking module for the active kinase interacting via a three-dimensional surface. 
This interaction allows Erk to mediate phosphorylation of several residues adjacent 
to the PNT domain in response to mitogens. In contrast, members of the TCF 
subfamily lack the PNT domain and interact with MAPKs via linear peptide 
sequences (Sharrocks 2002; Buchwalter et al. 2004). In the following section, 
major insights into the functional role of the activation domain of the TCFs are 
going to be described. 
1.6.4 Transcriptional activation via TCFs 
The stimulation of the MAPK signalling pathway via mitogen leads to SRF-
TCF target gene activation (Gille et al. 1995; Hill & Treisman 1995b). The TCFs are 
the only members of the ETS family harbouring an extended C-terminal domain 
that upon mitogen activation becomes heavily phosphorylated (Marais et al. 1993). 
Several consensus S/T-P sites for MAP kinases are scattered throughout this 
domain (Dalton & Treisman 1992; Hill et al. 1993; Marais et al. 1993). All three 
TCFs are equipped with two MAPK docking sites. The D box is located upstream of 
the C domain while the FXFP motif lies within the C domain (Figure 1.10). The D 
domain and the FXFP motif forms a bi-partite docking module recognised by both 
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Erk and JNK. The phosphorylation of several S/T-P sites was shown to occur both 
in vitro and in vivo via Erk activation (Marais et al. 1993; Zinck et al. 1993; 
Janknecht, W. H. Ernst, Houthaeve, et al. 1993a). An extended comparative 
analysis of the three TCFs highlights the conservation between seven major S/T-P 
sites and two hydrophobic amino acids (residues F378 and W379 in the Elk-1 
peptide) (M. A. Price et al. 1995; Cruzalegui et al. 1999). In addition Elk-1 presents 
two further unique S/T-P motifs. Deletion of the nine S/T-P sites or of the 
hydrophobic residues abolishes transcription in response to Erk activation. A loss 
of active transcription is caused by the inhibition of steps beyond Elk-1 DNA 
binding, as under these conditions the ternary complex remains unaffected. 
Interestingly, mutation of the F and W residues leaves the Erk-dependent 
phosphorylation unchanged, suggesting that transcriptional activation via Elk-1 
cannot reflect a simple addition of negative charges but that the hydrophobic 
residues might be involved in direct interaction with components of the 
transcriptional machinery (Cruzalegui et al. 1999).  
Elk-1 was shown to constitutively interact, through its C domain, with p300 
at target promoters (Janknecht & Nordheim 1996; Q. J. Li 2003). Mitogen-
dependent phosphorylation of the Elk-1 enhances p300-Elk-1 association and p300 
activity. P300 activity is counteracted by HDAC, stably associated with 
unphosphorylated Elk-1 (S.-H. Yang et al. 2003). Erk-induced phosphorylation of 
Elk-1 causes de-repression reversing its sumoylation and disassociation from 
HDAC (Clayton et al. 2006). Although clear under these circumstances, the 
generality of this mechanism and how TCFs are interacting with p300 remain to be 
elucidated. A systematic study of the genetic interaction between the TCFs and the 
known chromatin modifying enzymes remains to be inspected. 
A better-characterised mechanism, concerning the Elk-1 activation domain, 
involves the specific and direct recruitment of MED23, a subunit of the Mediator 
Complex (see Chapter 1.3.3). Studies based on the E1A conserved region 3 (CR3) 
lead to the identification of the Mediator subunit Sur-2 (later re-named MED23 
(Bourbon et al. 2004), required for both CR3-dependent and Elk-1-dependent gene 
activation (Boyer et al. 1999; G. Wang et al. 2001b; Cantin et al. 2003). Compelling 
genetic studies of the C.elegans homologue Sur-2 showed that this Mediator 
subunit is required for Ras-dependent vulval development (Singh & Han 1995). 
This genetic interaction was lead back to Lin-1, a TF harbouring an ETS domain. 
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Functional studies, using MED23-/- mouse embryonic stem cells (mESc), 
demonstrated that Med23 is a subunit of the Mediator complex that is specifically 
required for E1A and Elk1-mitogen-dependent activation (Stevens et al. 2002). 
Furthermore, direct interaction between Elk-1 and MED23 requires the activation 
domain of Elk-1 to be phosphorylated (Cantin et al. 2003). Further studies identified 
additional residues required for this interaction. In particular, the already identified 
hydrophobic residues are fundamental for Med23 direct interaction (Balamotis et al. 
2009). The complete loss of Elk-1 dependent activation in the absence of MED23 
suggests that direct recruitment of the Mediator complex is the main mechanism of 
activation (G. Wang et al. 2005). The mechanism underling the interplay between 
TAD activation, chromatin changes and transcription remains to be fully dissected 
and elucidated.  
The present thesis addresses these issues using the RAS-TCF branch as a 
model system. 
1.7 Signalling to SRF part II: The Rho-actin signalling pathway 
and the MRTF co-factors 
A major part of this thesis will focus on the regulation of SRF via the co-
regulars MRTF. As introduced earlier this branch of regulation is governed by the 
Rho-Actin signalling pathway and by dynamic changes in the G-actin concentration. 
In this section I am going to outline the main mechanisms leading to Rho activation 
and changes in actin filamentation. Focus will be dedicated to the nuclear functions 
of actin and the regulation of the MRTF co-factors within the nucleus. 
1.7.1 Globular and filamentous actin regulation 
Actin is the most abundant protein in living cells, having an estimated 
concentration ranging from tens to hundreds of micromoles (Remedios et al. 2003). 
Furthermore actin is also one of the most conserved proteins across all phyla 
(Remedios et al. 2003).  
Major mechanisms are under the control of this simple globular protein 
including, among others, muscle contraction, cell motility, cell division, vesicle and 
organelle movement, cell shape and transcription. All these functions and 
processes are influenced by the dynamic equilibrium between monomeric globular 
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actin (G-actin) and polymerized filamentous actin (F-actin) (Pollard & Cooper 2009). 
Actin filamentation is a tightly controlled process that includes the interplay of 
several actin-binding proteins (ABP).  
The structure of the actin monomer is composed of two α/β lobes or 
domains of different size representing the “ATPase fold” (for review see Dominguez 
& Holmes 2011). Small contacts are observed between the two domains allowing 
the assembly of two separate clefts. The upper cleft is able to bind ATP or ADP 
and the divalent cation Mg2+, providing further interaction between the two lobes. 
The lower cleft is instead composed of several hydrophobic residues essential for 
contacts between actin subunits within the filament and most ABPs. Monomeric 
actin is an inefficient ATPase while its activity is enhanced several fold once 
incorporated into filaments. The high ATP concentration in cells, the actin avidity for 
ATP rather than ADP and the slow ATPase activity of monomeric actin lead to an 
overall higher concentration of G-actin associated with ATP.  
F-actin is a double helical polymer of G-actin molecules arranged head-to-
tail (Dominguez & Holmes 2011). This disposition gives a functional polarity to the 
actin filament defining two distinct extremities: barbed and pointed ends. Overall, 
due to defined association and disassociation constants, at steady state ATP-actin 
associates at the barbed end while ADP-actin disassociate from the pointed end 
leading to a slow treadmilling of actin subunits from the barbed end to the pointed 
end. This process involves a cycle of “exhausted” ADP-actin and regenerated ATP-
actin that respectively associates and disassociates from the growing filament.  
The regulation of ATP hydrolysis and ADP to ATP exchange is crucial for 
the regulation and the speed of treadmilling (Pollard & Borisy 2003). Cells are 
equipped with several ABPs, falling into more than 60 classes, known to regulate 
diverse aspects of actin polymerisation. These proteins include, among others, 
Profilin, thymosin, ADF/Coffilin and gelsolin (for review see Dominguez & Holmes 
2011; Bugyi & Carlier 2010). In particular thymosin associates with G-actin in order 
to buffer the polymerizing process while Profilin favours the exchange of ADP for 
ATP, promoting the addition of ATP-actin at the barbed end. As mentioned the 
disassembly of exhausted ADP-actin at the pointed end is also crucial to promote 
filament growth at the barbed end. Cofilin and gelsolin are notable factors that 
directly bind actin monomers within the filament producing a cut by changing the 
actin conformation. 
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Beside the regulation of actin microfilament growth and treadmilling, the 
formation of new filaments and branches is also highly controlled. Nucleation of 
filaments by monomeric G-actin is unfavourable due to the high instability of short 
actin oligomers (Pollard & Cooper 2009). The initiation and branching of new 
filaments within cells is favoured by an actin-filament’s nucleation process and 
involves different proteins such as formin, the ARP2/3 complex and several 
nucleation-promoting factors (NPFs) (for review see Pollard 2007; Bugyi & Carlier 
2010). ARP2/3 with its structure mimics a G-actin dimer favouring the nucleation of 
new filaments. In addition ARP2/3 directly interacts with F-actin, promoting the 
growth of branches from already existing filaments. Formin is instead involved in 
the control of filament growth or elongation. Formin catalyses the rapid addition of 
actin monomers at the barbed end of the filament through profiling-actin 
recruitment and prevents capping proteins from associating and blocking the 
filament growth.  
All these processes are accurately regulated in response to extracellular 
and intracellular signals and the Rho-family of GTPases play a crucial role in 
mediating this intracellular response. 
1.7.2 The Rho signalling pathway 
Rho GTPases are small monomeric G proteins belonging to the Ras family 
of G proteins. They comprise 20 members including the most studied RhoA, Rac1 
and CDC42 (Heasman & Ridley 2008). As described for Ras, Rho GTPases switch 
between active GTP-bound forms and an inactive GDP-bound form. The transition 
between active and inactive is regulated by three sets of proteins. Guanine 
nucleotide exchange factors (GEFs) promote the release of GDP and association 
with GTP, leading to activation of the Rho GTPases (Schmidt & A. Hall 2002). 
GTPase-activating proteins (GAPs) enhance Rho catalytic activity, leading to its 
inactivation (Tcherkezian & Lamarche-Vane 2007). Finally guanine nucleotide-
disassociation inhibitors (GDIs) maintain Rho in an inactive state by inhibiting 
exchange and preventing their localisation at the membrane (DerMardirossian & 
Bokoch 2005). Rho GTPases regulate several effector proteins controlling the 
polymerisation equilibrium of G-actin and F-actin in the cytoplasm. The activation of 
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Rho GTPases is associated with a net increase in F-actin at the expenses of G-
actin.  
The activation of Rho GTPases is mediated by receptor tyrosine kinases 
and G-protein coupled receptors (GPCRs). Several GEFs are induced upon signal 
stimulation, leading to the activation of the Rho GTPases. Active Rho GTPases 
imping on several mechanisms affecting actin polymerisation. These include the 
activation of WASP (Wiskott-Aldrich syndrome protein) that leads to ARP2/3 
activation and actin polymerisation, activation of LIM kinase that phosphorylates 
and represses cofilin and the stimulation of Diaphanous-related formins. 
Changes in G- to F-actin ratio have diverse functional outcomes. Beside the 
mechanisms involved in actin filament assembly, dedicated to motile cellular 
behaviours, actin itself works as a signalling molecule affecting several effectors 
and takes part in diverse complexes. In particular, recent works devoted a lot of 
effort in elucidating the existence and the functional role of actin within the nucleus. 
1.7.3 Nuclear actin 
The presence of actin in the nucleus has always been a matter of debate 
(reviewed in Pederson & Aebi 2002). Its low abundance in the nucleus and the 
difficulty of detecting any stainable filament made it hard to believe in its existence. 
In 1977 is was reported that actin is in dynamic equilibrium between the cytoplasm 
and the nucleus of Xenopous oocytes (T. G. Clark & Merriam 1977). Later on 
microinjection experiments of ABPs and actin antibodies showed that nuclear actin 
is required for transcription of several genes (Scheer et al. 1984). Actin was also 
reported to interact directly with all three Polymerases, to be part of chromatin 
remodelling complexes and to play a crucial role in pre-mRNA processing and 
export (Percipalle 2013).  
To understand all the potential processes controlled by nuclear actin, it is 
essential to understand its regulation. Recent works have investigated this topic, 
trying to elucidate how nuclear actin dynamically communicates with the cytoplasm 
and how it could be potentially regulated by polymerisation. 
Dopie and collegues recently showed that cytoplasmic and nuclear actin are 
in dynamic exchange (Dopie et al. 2012). The characterisation of nuclear actin 
exports and imports using both fluorescence loss in photobleaching (FLIP) and 
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fluorescence recovery after photobleaching (FRAP) experiments suggest a three-
step mechanism for actin import and retention. In particular, most nuclear G-actin is 
quickly exported from the nucleus via exportin-6. The remaining nuclear actin is 
likely to be associated with transcriptional machinery as nuclear filaments are 
highly unstable. On the other hand monomeric G-actin import relies on importin 9 
and cofilin. Analysis of the import kinetic showed that the stabilisation of the 
imported actin could be initially promoted by short, highly unstable, polymeric actin 
pools and subsequently by its incorporation into stable nuclear complexes.  
The polymerisation of nuclear actin could also affect its functions. Several 
regulators of actin polymerisation and turnover, including formins, have been 
detected in the nucleus. Indeed actin can form highly dynamic and submicron long 
filaments within the nucleus as shown by McDonald and colleagues (McDonald et 
al. 2006). Furthermore dynamic exchange of G- to F-actin within the nucleus is 
subject to signal-induced regulation of formin proteins (Baarlink et al. 2013). The 
activation of actin filamentation within the nucleus leads to a net reduction of 
monomeric G-actin with obvious functional effects including activation of the MRTF 
co-factors (see later). A further mechanism controlling actin polymerisation in the 
nucleus was described recently and involves the so-called Molecules Interacting 
with CasL (MICAL) family of flavoprotein monooxygenases (for a review see 
Giridharan & Caplan 2014). MICAL proteins use their redox potential to oxydize 
actin, causing disassembly of actin filaments. In particular, MICAL-2 is enriched in 
cell nuclei and its activity leads to reduced monomeric nuclear G-actin (Lundquist 
et al. 2014). This observation seems contradictory as MICAL-2 induces F-actin 
depolymerisation within the nuclear compartment and the mechanism leading to a 
possible export of the oxidized actin is not yet understood. A further intriguing study 
suggests a potential role for the nuclear envelope protein emerin in modulating 
nuclear actin polymerisation (C. Y. Ho et al. 2013). Although more studies are 
needed to elucidate the role and regulation of actin within the nucleus, it starts to 
become clear that cells have developed diverse mechanisms to control its 
behaviours. Furthermore changes in nuclear actin behaviours are not a simple 
consequence of cytoplasmic actin dynamics but they posses a dedicated set of 
tools and modes of regulation. 
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1.7.4 The Myocardin family of SRF co-factors 
As introduced earlier, activation of SRF target genes can occur 
independently of the TFCs in response to actin dynamics. The direct link between 
changes in actin behaviour and the activation of SRF target genes was 
disentangled with the discovery of the Myocardin family of transcription factors 
(Pipes et al. 2006). The discovery that MRTFs are under the direct control of Rho 
GTPases and actin dynamics offered the first evidence of a previously unknown 
link between the actin cytoskeleton and gene expression.  
Myocardin is the founding member of this family of factors, first identified in 
a bioinformatic screen for cardiac-associated genes (D. Wang et al. 2001a). 
Although named as TFs, Myocardin and members of its family are unable to bind 
DNA directly and their activity relies on SRF (D. Z. Wang et al. 2002). Myocardin 
was found to be able to stimulate transcription of CArG-box associated genes and 
it can form a stable ternary complex with SRF (D. Z. Wang et al. 2002). Myocardin 
expression is mainly restricted to the cardiovascular system and in subsets of 
smooth muscle cells (SMCs). Expressed in a broader range of cells and tissues are 
the Myocardin-related factors MRTF-A and MRTF-B (Mercher et al. 2001; D. Z. 
Wang et al. 2002; Ma et al. 2001). MRTF-A and -B are co-factors dedicated to SRF 
while Myocardin was also found associated to MEF2 (Wu et al. 2010; Creemers et 
al. 2006). 
Myocardin family members share homology in several functional domains 
(Figure 1.11). Focus will be dedicated to the description of major domains within 
the MRTF co-factor proteins. 
At the N-terminal part of MRTF proteins, three RPEL motifs are organised in 
a domain required for direct G-actin interaction (Miralles et al. 2003; Guettler et al. 
2008; Mouilleron et al. 2008). The RPEL motif is composed of an RPxxxEL core 
sequence. The three RPEL motifs in the MRTF co-factors contain this conserved 
core sequence while Myocardin shows divergent RPEL1 and 2, devoiding it of actin 
regulation (Guettler et al. 2008). Recently a new role for Myocardin’s RPELs has 
been proposed, contacting Arps proteins (see section 1.7.5; Morita & Hayashi 
2014). Each RPEL motif of MRTF is assembled in an L-shaped structure 
composed of two α-helices contacting the hydrophobic lower cleft of monomeric 
actin (Mouilleron et al. 2008). The R residues are essential for MRTF-actin 
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interaction as MRTF mutants with R to A substitutions show reduced actin affinity 
(Guettler et al. 2008). In the context of the three RPEL motifs the whole domain is 
able to interact with up to five actins (Mouilleron et al. 2011). Cooperative binding 
occurs between the three RPELs allowing a primary three-actin structure. Linker 
sequences between RPEL1-2 and RPEL2-3 provide further interaction for two 
additional actins with low affinity (Mouilleron et al. 2011). The information provided 
by different crystal structures and the functional dissection of this domain suggests 
that the interaction between each motif and actin does not occur independently 
from each other. Cooperative association between the actin molecules associated 
to the same RPEL domains makes the MRTF-actin interaction unique (Guettler et 
al. 2008).  
Embedded within the REPL motifs is an extended bipartite nuclear 
localisation signal, composed of two basic elements B3 and B2, which is required 
for import of MRTF proteins (Pawłowski et al. 2010). The extended NLS sequence 
interacts with importin α and β. The basic elements are also conserved in 
Myocardin and its dependency on importin β was reported in the lab (MK Vartiainen, 
unpublished data). Importin proteins are going to be in direct competition with actin 
at MRTFs’ N-terminal domain. Oppositely, at the Myocardin N-teminal domain 
permissive interaction of importins will result in Myocardin constitutive nuclear 
localisation. However in the context of MRTF mutants, without their N-teminal 
domain, deletion of a further basic region, B1, downstream of the RPEL motif 
accounts for MRTF nuclear localisation (Miralles et al. 2003; Zaromytidou et al. 
2006).  
The B1 box is an element primarily required for ternary complex formation 
(Miralles et al. 2003). Several hydrophobic and positively charged residues within 
the C-teminal half of the B1-box are crucial for the association of SRF with the 
target DNA (Zaromytidou et al. 2006). Residues, within this element, required for 
MRTF nuclear localisation can be separated from the one required for ternary 
complex formation. An additional hydrophobic region, named Q-box as it is rich in 
Q amino acids, provides further favourable interactions with SRF (Zaromytidou et 
al. 2006). Although not critical for MRTF activity, the Q-box was also found to affect 
MRTF nuclear localisation (Miralles et al. 2003).  
Several studies have shown that the TCFs and MRTFs are competing for 
SRF, suggesting that they interact with overlapping surfaces on SRF (Miralles et al. 
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2003; Murai & Treisman 2002; Zhigao Wang et al. 2004). The detailed 
characterisation of the ternary complex formation proposed that MRTF and Elk-1 
interact differently on the same surface (Zaromytidou et al. 2006). Footprint 
analyses have shown that MRTF also interacts with sequences of DNA proximal to 
the CArG-box, and the SRF-dependent DNA bending facilitates MRTF association 
(Zaromytidou et al. 2006). Genome-wide analysis showed AP-1 and TEAD 
associated cis-regulatory elements are frequently enriched at MRTF-specific SRF 
sites (Esnault et al. 2014). Direct, unspecific contacts between MRTF and these 
DNA elements are conceivable, although is not possible to exclude interplay 
between MRTF and these TFs.  
Moving further towards the C-terminal domain of MRTF it is possible to 
identify a 35 amino acid domain named SAP (SAF-A/B, Acinus, Pias). This domain 
is predicted to adopt two amphipathic helices with similar topology to several DNA 
binding proteins (Aravind & Koonin 2000). The SAP domain is conserved in all 
Myocardin-family members and deletion from the Myocardin protein shows 
impairment of a defined set of genes (D. Wang et al. 2001a). No significant 
reduction in gene expression and target association was observed for MRTF 
proteins lacking this domain (Miralles et al. 2003; Zaromytidou et al. 2006). In light 
of recent findings, analysis of the contribution of this domain to cooperative binding 
between MRTF and SRF on target DNA would provide further insights. 
Myocardin-family proteins are equipped with a leucine-zipper (LZ) like 
domain downstream of the SAP domain (Figure 1.11). The LZ motif mediates 
homo- and heter-dimerization both in MRTF-A, MRTF-B and Myocardin (Miralles et 
al. 2003; Selvaraj & Prywes 2003; Zaromytidou et al. 2006). Myocardin homo-
dimerization appears to be weaker when compared to MRTF, and does not occur 
in the context of ternary complex formation with SRF (Miralles et al. 2003; 
Zaromytidou et al. 2006; Zhigao Wang et al. 2003). However, full transcriptional 
activity of Myocardin requires in vivo a functional LZ (Zhigao Wang et al. 2003; Du 
et al. 2004).  
The C-terminal regions of Myocardin and the MRTFs are more divergent 
and work as a trans-activation domain (Miralles et al. 2003; D. Wang et al. 2001a). 
When fused to the LexA-DNA binding domain they activate a LexA reporter gene 
(Miralles et al. 2003). Our recent genome-wide studies have shown that active 
nuclear MRTF induces gene expression through different mechanisms (Esnault et 
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al. 2014). On one hand, active nuclear MRTFs are able to induce the recruitment of 
Pol II and the subsequent modification of its CTD in response to the Rho-actin 
pathway. On the other hand several SRF-MRTF targets still show a serum-
dependent recruitment of Pol II in the absence of nuclear MRTFs. At these target 
genes the modification of the Pol II CTD is under the direct control of nuclear MRTF 
and is required for gene stimulation (Esnault et al. 2014). The dissection of the 
MRTF activation domain, which is heavily phosphorylated upon nuclear localisation, 
would provide further insight into this mechanism. 
1.7.5 Actin-mediated regulation of MRTF 
MRTFs co-regulators are under the direct control of G-actin. Changes in 
actin dynamics have a drastic effect on MRTF functions. The regulation of nuclear 
import and export is the most well known mechanism under the control of G-actin. 
In low actin polymerisation states, MRTFs are found mainly in the cytoplasm 
(Miralles et al. 2003). The overall distribution of MRTF under resting conditions is 
caused by an actin-dependent promotion of MRTF nuclear export via Crm1 
(Vartiainen et al. 2007). MRTFs are constantly shuttling and blockage of Crm1, 
using LMB, allows MRTF nuclear accumulation leaving their interaction with actin 
unaffected (Vartiainen et al. 2007). Indeed induction of actin filamentation, via Rho 
stimulation, does not affects MRTF import rate while it reduces its rate of export 
(Vartiainen et al. 2007). However, exogenous overexpression of actin affects MRTF 
nuclear import, probably due to an increased occupation and occlusion of the B2 
and B3 boxes (see section 1.7.4; Pawłowski et al. 2010; Vartiainen et al. 2007). 
MRTF nuclear export can be accelerated using de-polymerizing agents such as 
Latrunculin B (LatB), which sequesters actin monomers, increasing the overall 
concentration of cellular G-actin (Vartiainen et al. 2007).  
MRTF can be specifically accumulated in the nucleus using Cytochalasin D 
(CD) (Miralles et al. 2003; Sotiropoulos et al. 1999). CD is an actin depolymerizing 
drug known to interact with the barbed end of actin filaments, inhibiting both the 
association and disassociation of actin monomers, it promotes ATP hydrolysis and 
induces dimerization of G-actin (Dominguez & Holmes 2011). Opposing LatB, CD 
directly competes with the RPELs on actin promoting MRTF release, nuclear 
accumulation and gene activation. The transcriptional response elicited by CD is 
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substantially different if compared to the Rho-dependent stimulation of MRTF 
(Esnault et al. 2014). CD can be envisioned as the minimal requirement to induce 
MRTF activity. 
The mechanism leading to MRTF nuclear accumulation is well studied and 
characterised, while its regulation once in the nucleus remains elusive. Recent 
studies have shown a new mechanism of regulation regarding the founding 
member Myocardin (Morita & Hayashi 2014). As already described, Myocardin 
does not interact efficiently with actin due to a degeneration of the RPEL 
sequences (Guettler et al. 2008). Morita and colleagues described an Arp5-
dependent repression of Myocardin transcriptional activity (Morita & Hayashi 2014). 
Arp5 is an actin related protein that was reported to directly interact with Myocardin 
via its degenerated RPEL motifs and to the SRF DBD. Furthermore Arp5 seems to 
affect ternary complex formation, directly impairing both SRF-DNA and Myocardin-
SRF interaction (Morita & Hayashi 2014). This mechanism of regulation seems 
dedicated to Myocardin as MRTFs are unable to interact with Arp proteins and 
MRTF activity seems unaffected. Preliminary evidence collected in the lab has 
shown that MRTF activity is negatively controlled by nuclear actin (Vartiainen et al. 
2007). Passive accumulation of MRTF into the nucleus via LMB does not promote 
target gene activation. Under this circumstance MRTF-DNA association with target 
promoters seems unaffected while its transactivation activity requires its 
disassociation from nuclear actin (Vartiainen et al. 2007).  
This thesis will address these issues in detail. 
Chapter 1 Introduction 
 81 
 




Table 1.1 Transcription factors family. 
The classification is based on the TFClass database (Wingender et al. 2013). This 
classification comprises five levels (superclass, classes, families, genera and factor 
species). In this table I have listed the first three levels of the database. 
 




Table 1.2 TFs post-translational modifications. 
Adapted from Filtz et al. 2014. 




Figure 1.1 Core promoter elements. 
Schematic representation of the main elements found at core promoters (adapted 
from Juven-Gershon & Kadonaga 2010). 




Figure 1.2 Major transitions during early transcription. 
Early transcription can be divided into five major transitions. The graph shows the 
progression of the transcriptional process on the x axis while the y axis depicts the 
energy barrier that need to be overcome to transit from one condition to another. 
The energy barrier between each state can be increased or decreased by 
regulators (double-headed arrows). (Adapted from Michel & Cramer 2013). 
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Figure 1.3 Transcription regulation. 
Step by step description of the mechanisms involved in transcriptional regulation. 
Emphasis is placed on the regulation of transcriptional elongation through 
promoter-proximal pausing of Pol II. Steps are outlined starting with the assembly 
of PIC at gene promoters to productive synthesis of RNA (adapted from Fromm et 
al. 2013). 




Figure 1.4 Modular structure of Mediator and interactions with diverse factors. 
The recently published EM structures of the human Mediator complex and CDK8 
module are shown (Tsai et al. 2013; Tsai et al. 2014). On the left hand side of the 
figure the EM structure of the main Mediator complex is coloured according to the 
main modules: Head (red), middle (blue) and tail (yellow). On the right hand side 
the CDK8 module (CKM) subunit organisation is shown. known TF interactions are 
highlighted. ER, oestrogen receptor; GR, glucocorticoid receptor; HNF4, 
hepatocyte nuclear factor; NHR49, nuclear hormone receptor 49; PPARγ, 
peroxisome proliferator-activated receptor-γ; SREBP1, sterol regulatory element-
binding protein 1; TGFβ, transforming growth factor-β; VDR, vitamin D3 receptor 
(Malik & Roeder 2010). 




Figure 1.5 Elongating Pol II and size of the CTD. 
On the right the 12 subunit of the elongating yeast Pol II is shown as a ribbon 
diagram with each subunit in a different colour. The DNA is shown schematically in 
blue while the nascent RNA in red. The relative size of the Pol II largest subunit 
linker is shown in green while the extended CTD is schematically represented in 
black. Four states of the CTD are represented: extended, loose or compacted 
spiral, and as a random coil (adapted from Meinhart et al. 2005). 




Table 1.3 CTD interacting proteins and their functions. 
Classification of the known CTD interacting proteins classified in “writers”, 
“readers”, and “erasers”, according to their function: CTD modification, recognising 
the modified CTD, or remove modification patterns. Kinases are the writers. 
Readers are classified into GTFs, histone and chromatin modifiers, RNA 
processing and with functions directed to CTD. Two heptad repeats are shown as 
is the sequence encompassing the functional unit. (*) Rpap2 has a dual function as 
is able to dock on Pol II CTD and modify Ser5-P. (Taken from Eick & Geyer 2013). 




Figure 1.6 Representative distribution of CTD modification based on ChIP-seq 
experiments in S. cerevisea. 
The signal shows the theoretical distribution of changes of CTD modification along 
the transcriptional cycle. Similar results have been shown for mammalian Pol II 
although differences have been also reported. The signals are not normalised for 
total Pol II abundance across the transcriptional unit. The dashed line shows the 
distribution of Threonine-4 in mammal cells. This figure was taken from Eick & 
Geyer 2013. 
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Table 1.4 Classification of HATs and their substrates. 
The table was adapted from K. K. Lee & Workman 2007.  
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Table 1.5 Known kinases phosphorylating histones and their functions. 
The table was adapted from Rossetto et al. 2012. 




Table 1.6 Histone Lysine Methylase Complexes. 
The table presented was adapted from Mohan et al. 2012. 




Table 1.7 Chromatin Remodelling Complexes. 
The table presented was adapted from Bao & X. Shen 2007. 
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Figure 1.7 Chromatin states. 
Tabular representation of the data presented in J. Ernst et al. 2011. A multivariate 
hidden Markov model was used to classify chromatin states across cell types. Each 
value represents the frequency at which a given mark is found at genomic positions 
corresponding to the chromatin state. The blue shading indicates the intensity, 
scaled by each column. WCE, whole cell extract. CNV, copy number variation 
(figure adapted from J. Ernst et al. 2011). 




Figure 1.8 The SRF transcription network. 
Serum Response Factor (SRF) controls the immediate-early transcriptional 
response to growth factors, and regulates numerous developmental processes 
including gastrulation, T-cell differentiation and muscle differentiation. To control 
transcription, SRF recruits signal-regulated co-activators, the Ternary Complex 
Factors (TCFs) and the Myocardin-Related Transcription Factors (MRTFs), which 
compete for a common site on its DNA-binding domain. The TCFs - SAP-1, Elk-1 
and Net - are ETS proteins that link SRF activity to Ras-Erk signalling. In contrast, 
the two MRTFs, MRTF-A and MRTF-B, link SRF activity to Rho-actin signalling. 
MRTF RPEL domain acts as a G-actin sensor, controlling MRTF nuclear 
accumulation in response to signal-induced depletion of the G-actin pool. Agents 
affecting the response to either MRTFs or TCFs are shown in blue: Latrunculin B 
(LatB) sequesters actin monomers increasing the overall amount of monomeric 
actin in the cell; cytochalasin D (CD) disassociate MRTF from actin by competing 
with MRTF for the same binding site on monomeric actin; Leptomycin B (LMB) is a 
potent Crm1 inhibitor that allows MRTF nuclear accumulation in absence of signal 
activation; U0126 is a MEK1 and MEK2 inhibitor. 
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Figure 1.9 SRF structures. 
The Figure was provided with permission by Sebastian Guttler. (A) Structure 
representation of the SRF DNA binding domain in combination with the SRE DNA 
binding consensus. The two dimers of SRF are shown in red and green in a ribbon 
diagram. The DNA is represented in purple with the SRE in yellow. The schematic 
representation was adapted from Pellegrini et al. 1995. (B) Representation of the 
structure of SRF in combination with SAP-1a. The orientation of the complex is as 
in panel A. SAP-1a is represented in orange. The parts of SAP-1a not resolved in 
the structure are represented in dashed lines and represent the linker between the 
B-box and the ETS domains. The ETS motif, flanking the SRE, is shown in yellow. 





Figure 1.10 Domain organisation of proteins of the TCFs family. 
The TCF subfamily of transcription factors belongs to the ETS-domain proteins and 
includes Elk-1, SAP-1a and Net. The domain organisation is described 
schematically. The ETS DNA binding domain (A, showed in light cyan) is at the N-
terminal end of each TCF protein and controls the DNA binding of the TCFs. NES 
and putative NLS were mapped within and in close proximity of the ETS motif. The 
B domain (yellow) is involved in the interaction between the TCFs and SRF. The R 
domain (green) was reported to be involved in repression of Elk-1 transcription 
activity (Salinas et al. 2004). The Transactivation domain (C, showed in purple) 
harbours the amino acids phosphorylated by MAP kinases. Two domains surround 
the transactivation domain and are both responsible for the interaction with 
activated MAP kinases (red). The D or DEJL domain was shown to interact with 
active kinases of the Erk, JNK and p38 subtypes. The DEF or FXFP domain is only 
interacting with activated Erk. This figure was adapted from Besnard et al. 2011. 





Figure 1.11 Domain organisation of proteins of the myocardin family. 
The myocardin family of transcription factors is composed of myocardin (MC) and 
the myocardin-related transcription factors (MRTF-A and MRTF-B). RPEL motif 
composing the actin binding module are shown in red; B3, B2 and B1 are basic 
regions involved in importin interaction (B3 and B2) and in ternary complex 
formation (B1 region); Q, Q-rich region; SAP, SAP (SAF-A/B, acinus, pias) domain; 
LZ, leucine zipper required for MRTF dimerization (homo and hetero); TAD, 
transactivation domain heavily phosphorylated once MRTF is in the nucleus and 
detached from actin. Myocardin RPELs are shown in green while MRTFs’ are 
shown in red. 
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Chapter 2. Definition of the transcriptional signature 
lead by MRTF 
2.1 Aim 
MRTFs are well characterised actin-binding proteins involved in the 
regulation of a defined set of SRF-dependent genes (Miralles et al. 2003). While 
the regulation of MRTF shuttling from the cytoplasm to the nucleus is relatively well 
understood, how they are regulated once in the nucleus is still uncharacterised. 
Previous work in our laboratory has shown that MRTF nuclear accumulation via 
Leptomycin B treatment (LMB) is sufficient for their recruitment to target promoters 
but disassociation from G-actin is indispensible for productive transcription 
(Vartiainen et al. 2007). My initial aim was to extend this analysis using genomic 
approaches in order to address generality and specificity. Within this chapter I am 
going to describe the transcriptional outcomes in response to active or inactive 
nuclear MRTF. I am going to characterise a specific set of genes that could be 
directly associated with MRTF either by function or proximity to SRF binding. I am 
going to describe the relationship between proximity to SRF and the level of 
transcription induction in response to the MRTF-activator Cytochalasin D (CD). 
Finally I am going to highlight the transcriptional defect observed in LMB treated 
cells. 
2.2 Nuclear MRTF is not sufficient for both pre-mRNA and 
mRNA transcription 
Impairment of MRTF-actin interaction by several means allows MRTF 
nuclear accumulation and productive activation of target genes (Miralles et al. 
2003; Sotiropoulos et al. 1999). Depletion of G-actin via Rho activation or direct 
disruption of the MRTF-actin interaction via the MRTF-activator Cytochalasin D 
(CD) induces SRF-MRTF specific genes. This evidence was recently confirmed 
using genomic approaches (Esnault et al. 2014). The established role of actin in 
MRTF import and export envisioned a model where in resting condition MRTF is 
constantly excluded from the nucleus through Crm1-dependent export (Vartiainen 
et al. 2007). MRTF nuclear accumulation can be also achieved through the LMB-
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dependent Crm1 blockage, fusing MRTF to Nuclear Localisations Signals (NLS) or 
by specifically increasing nuclear actin via NLS sequences (Posern et al. 2002; 
Miralles et al. 2003; Vartiainen et al. 2007). In these conditions known MRTF target 
genes are silenced. Any MRTF mutants unable to interact with monomeric actin will 
be instead competent for activation of target genes. 
In order to generalise these observations I optimised a defined set of 
conditions, assessing for MRTF nuclear localisation and expression of a few bona 
fide targets. As showed in Figure 2.1A NIH 3T3 treated for 30 minutes with either 
CD or LMB results in MRTF nuclear accumulation as previously reported (Miralles 
et al. 2003; Vartiainen et al. 2007). As LMB is a relatively hydrophobic compound, 
with low solubility in aqueous solutions and a tendency to stick to plastic (see 
lclabs.com web site), I tested the homogeneity of treated samples. LMB was 
handled in glass vials and added to cell layers at 50 nM allowing for complete 
MRTF nuclear accumulation comparable to CD treated cells (Figure 2.1A). Target 
activation was followed by RNA isolation from serum-starved cells or at 30, 45 and 
90 minutes after stimulation. Eight independent SRF-MRTF targets showed an 
acute synthesis of their first intron within 30 minutes after CD stimulation (Figure 
2.1B). On the other hand LMB treated cells showed no efficient induction despite 
complete nuclear accumulation of MRTF. A similar transcriptional defect was also 
observed measuring accumulation of Acta2 and Srf mature RNA (Figure 2.1C).  
Both CD and LMB are pleiotropic compounds, potentially affecting other 
factors beside MRTF proteins. In order to nail these behaviours down to the SRF-
MRTF signalling network two further conditions were analysed. 30 minutes LMB 
treated cells were further stimulated with either CD (LMBCD) or the MRTF-
inhibitor Latrunculin B (LMBLatB). In both conditions MRTF is retained in the 
nucleus (Figure 2.1A). As previously reported the addition of CD allows re-
activation of target genes at the level of pre- or mature RNA (Figure 2.1B and C). 
On the other hand the addition of LatB to LMB-treated cells does not affect either 
MRTF nuclear localisation or target gene activation (Figure 2.1A and C). 
These conditions are going to be analysed in more details within this 
chapter. In conclusion, as previously reported the LMB-dependent MRTF nuclear 
accumulation is not sufficient for bona fide target gene activation. Both pre-mRNA 
and spliced messenger are transcriptionally defective. Furthermore LMB treated 
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cells could be efficiently re-induced with the actin-depolymerising agent CD, but not 
with LatB, which excludes unspecific effects caused by Crm1 blockage.  
2.3 Genome-wide dissection of the CD and LMB response 
In order to generalise the observations collected using bona fide SRF-MRTF 
targets I used RNA sequencing (RNA-seq) aiming to see whether genes induced 
by CD and not blocked by LMB (where LMBCD would show transcription 
activation) are transcriptionally silenced in LMB. 
With the help of the bioinformatics facility I analysed both total RNA-seq 
reads and intronic RNA-seq reads for better sensitivity, maximising change 
detectability. The collected data was examined through a differential gene 
expression (DGE) analysis comparing each stimulus with the 0.3% FCS condition. 
We used the Deseq statistical method based on the negative binomial distribution 
(Anders & Huber 2010) in order to select genes changing in both CD and LMBCD 
conditions at an overall combined p-value less than 0.04 (each single condition 
scoring at p-value<0.2). 441 genes were identified showing an acute stimulation in 
both CD and LMBCD conditions after stimulation (Figure 2.2A and B). As shown 
in Figure 2.2C LMB treatment does not activate efficient transcription of these 
targets and does not affect their re-activation as shown by the LMBCD condition. 
Furthermore the addition of LatB to LMB showed no change if compared to the 
LMB condition. Such an unbiased approach allowed me to specifically select genes 
activated by CD regardless of any possible LMB-unspecific effect.  
2.4 CD-activated genes are functionally related to MRTF 
I next tested if the selected 441 genes could be directly linked to SRF-MRTF 
activities. As previously reported in the laboratory SRF-MRTF targets are 
significantly enriched in genes involved in actin filament dynamics, cell adhesion, 
cell motility, and other actin-linked processes (Esnault et al. 2014). I therefore 
performed a gene ontology (GO) analysis of the 441 selected targets using DAVID 
in order to assess any enrichment of similar functional classes (Huang et al. 2009). 
It was possible to reveal several genes involved in actin filament processes 
including focal adhesion, stress fibers, actomyosin complexes and contractile parts 
(Figure 2.3A). Furthermore a group of 48 genes defined a class of targets involved 
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in regulation of transcription including several transcription factors and co-
regulators controlling cell differentiation, morphogenesis and motility. 
To further examine the specificity of the described signature I directly 
compared the functional terms enriched in this analysis with the SRF-MRTF 
signature previously described by us (Esnault et al. 2014). As shown in Figure 2.3B 
there is a significant overlap in functional signatures associated with SRF and 
MRTF specific genes. From this first analysis it is possible to conclude that genes 
specifically activated by CD and unaffected by LMB are functionally related to SRF 
and MRTF target genes previously classified in the laboratory. 
2.5 CD-activated genes are associated with SRF binding 
To further characterise the association between SRF-MRTF to the selected 
441 target genes I performed an unbiased analysis of the distance to SRF of each 
selected target using the SRF binding distribution described previously in the lab 
(Esnault et al. 2014). As it was previously reported SRF binding occurs 
preferentially within 70 Kb of actively transcribed genes (Esnault et al. 2014). To 
assess if such a relationship was also observed within the analysed dataset, I 
examined the distance of active and inactive genes from the SRF binding sites 
defined in our previous work (Esnault et al. 2014). I defined active genes as those 
showing at least five RNA-seq reads mapping within intronic features and 
unaffected by the stimuli used. SRF-binding sites were again found most frequently 
within 70Kb of active genes, confirming our previous observation (Figure 2.4A and 
D).  
I then proceeded to analyse the average distance to SRF of the 441 targets 
compared to active un-induced genes or to genes that were scoring as induced 
only in one out of two conditions at p-value less than 0.2 (CD only and LMBCD 
only) (Figure 2.4B). As shown, only the 441 targets are overall significantly closer 
to SRF if compared to active genes. Furthermore genes induced only by CD or 
LMBCD are not closer to SRF than active un-induced genes. As it is possible to 
see in Figure 2.4C more than 60% of the 441 genes have an SRF binding within 70 
Kb from their TSS and 53% of these are proximal to an SRF binding event (35% of 
the 441 are within 2 Kb of an SRF binding site). In addition the distribution between 
“direct” (within 2Kb of an SRF site) and “near” (within 70Kb of an SRF site) for 
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genes responding only to CD or LMBCD is not significantly different from active 
un-induced genes (Figure 2.4C). 
In conclusion genes induced by CD and unaffected by LMB, besides being 
functionally related to SRF-MRTF target genes, are physically linked to SRF.  
2.6 Nuclear accumulation of MRTF via LMB is transcriptionally 
defective 
To further characterise whether it was possible to see any LMB-dependent 
induction of MRTF-specific genes I further assessed whether any of the 441 genes 
were statistically upregulated following LMB treatment. A group of 199 genes, 
overall closer to SRF, were significantly upregulated if compared to resting 
conditions (Figure 2.5A). 141 out of 199 were within 70kb of an SRF binding but the 
induction observed was still significantly reduced if compared to CD treated cells 
(Figure 2.5 B). Furthermore this induction showed LatB sensitivity only at the level 
of intronic-reads (Figure 2.4B). This observation is consistent with unpublished data 
collected in the lab showing a mild enhancement of a few highly expressed SRF-
MRTF targets following LMB stimulation (unpublished data discussed in Sebastian 
Guettler thesis 2007). 
With the help of the bioinformatics facility I assembled density profiles of 
RNA-seq data averaging reads mapped in intronic features - using the 288 CD 
induced genes within 70kb of an SRF binding site (Figure 2.5C). In CD induced 
conditions it is possible to see a strong accumulation of reads towards the 5’ end 
with a progressive reduction towards the 3’ end of the genes (Figure 2.5C). Such a 
profile could only partially provide information about travelling Pol II and in this 
context I used these profiles to measure the transcriptional induction relative to the 
distance from the TSS. It is possible to confirm that LMB treatment does not induce 
efficient transcription. Disassociation of MRTF from nuclear actin via CD is required 
to induce synthesis of precursor RNA.  
I further characterised the MRTF-dependent gene induction by assessing 
the RNA fold induction in CD over 0.3% FCS and its relation with the distance to 
SRF sites. As shown in Figure 2.6A highly induced genes are closer to SRF 
binding sites (Figure 2.6A). Such a relationship was only observed using intronic-
reads as opposed to total-reads, suggesting a direct relation between stimulation 
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and RNA precursor synthesis (Figure 2.6B). Furthermore it was possible to observe 
a partial induction of intronic-reads in LMB of highly induced genes (Figure 2.6A). 
This induction showed LatB sensitivity only for the top 40% induced genes (114 
genes). The addition of CD following LMB stimulation showed enhanced production 
of intronic-reads, rescuing the observed defect (Figure 2.6A). Despite the clear 
induction, the LMBCD condition showed reduced expression if directly compared 
with the CD condition.  
In order to see whether the relation between inducibility and SRF proximity 
was specific for SRF-MRTF controlled genes I examined the distribution of the 
distances to SRF for LMB-specific induced genes (Figure 2.6C). It was possible to 
select 758 genes within 70Kb of an SRF binding site showing a mild induction after 
LMB treatment (Figure 2.6C). No relation between inducibility and SRF binding was 
observed for this group of targets. The overall level of induction of these genes was 
less significant than the one observed in CD for SRF-MRTF specific genes. 
In conclusion MRTF nuclear accumulation does not promote efficient gene 
expression. A slight increase in intronic reads, which might reflect inefficient RNA 
synthesis, occurs only at highly CD-induced genes as previously reported in the lab 
(unpublished data). Given that such an LMB-dependent induction is sensitive to 
LatB treatments, it can be led back to MRTF-dependent nuclear activities. 
2.7 Summary 
This chapter has extended previous observations collected and published 
by the lab (Vartiainen et al. 2007). MRTF nuclear accumulation via LMB is not 
sufficient to activate productive transcription of bona fide SRF-MRTF targets. LMB 
is not unspecifically blocking transcription as re-addition of CD allows expression of 
selected targets. This transcriptional signature is specific for SRF-MRTF genes as 
targets fulfilling these criteria are functionally related to SRF-MRTF specific targets. 
Furthermore genes specifically activated by CD and unaffected by LMB are overall 
closer to previously defined SRF binding sites (Esnault et al. 2014). Induction of 
precursor RNA, observed in transcriptionally competent conditions, correlates with 
the distance to SRF. A mild induction of SRF-MRTF targets after LMB treatment is 
observed only at intronic-reads and is sensitive to the MRTF inhibitor LatB. 
Chapter 2 Results 
 108 
 
Chapter 2 Results 
 109 
Figure 2.1 MRTF nuclear localisation is not sufficient for target activation. 
(A) Immunofluorescence microscopy of MRTF-A in NIH3T3 fibroblasts. Cells were 
serum-starved and stimulated as indicated (CD, cytochalasin D; LMB, leptomycin 
B; LMBCD, 30 minutes LMB followed by 30 minutes CD; LMBLatB, 30 minutes 
LMB followed by 30 minutes Latrunculin B). Bottom right of panel A is the 
quantification where 150-300 cells were scored according to predominantly nuclear 
(N), pancellular (N/C) and predominantly cytoplasmic (C) MRTF-A localisation. (B) 
Accumulation of pre-mRNA of bona fide SRF-targets. NIH3T3 fibroblasts were 
serum-starved overnight and then stimulated with CD (blue), LMB (purple), 
LMBCD (orange) or LMBLatB (red) for 30, 45 or 90 minutes. RNA was isolated 
and abundance of the first intron of the SRF target genes Acta2, Srf, Cyr61, Vcl, 
Msrb3, Dstn, Ctgf and Sorb1 analysed by quantitative RT-PCR. Relative 
abundances obtained after normalisation for Gapdh message for Acta2 and an 
average profile normalised to the highest signal is shown. Data represent technical 
triplicates with SEM. (C) Accumulation of mature mRNA of Acta2 and Srf following 
the same time course as in panel B. Primers spanning an exon1-exon2 junction 
were used for both targets. 
Chapter 2 Results 
 110 
 
Figure 2.2 LMB stimulation is defective compared to CD stimulation   
(A) Venn diagram showing genes induced at the intronic or total reads in either CD 
or LMBCD if compared to 0.3% FCS (p-value<0.2 per single comparison). The 
green quadrant highlights 441 genes that are significantly induced in both CD and 
LMBCD if compared to resting condition at a combined p-value<0.04. (B) Scatter 
plot display of total (top) and intronic (bottom) RNA-seq read counts before and 
after CD (left) or LMBCD (right) stimulation. The 441 genes induced in both 
conditions are highlighted in green. (C) Display of the relative induction per gene 
across conditions. (Red bar) Median. Total (left) or intronic (right) RNA-seq read 
counts were normalised to the average across conditions. 
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Figure 2.3 Go analysis of CD-specific induced genes. 
(A) DAVID analysis of genes induced by CD and LMBCD. Functional classes 
enriched with a minimum p-value of 10-4 are highlighted in red. Post-hoc analysis 
(Bonferroni and Benjamini) is shown. (B) Comparison of functional classes 
enriched within the 441 data set (CD and LMBCD) and data collected in Esnault 
et al 2014 (SRF, MRTF) (Esnault et al. 2014). 
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Figure 2.4 Genes induced by CD and unaffected by LMB are spatially linked to 
SRF binding sites. 
(A) SRF sites are overrepresented within 70kb of transcriptionally active genes. 
The graph represents the frequencies of SRF sites relative to active and inactive 
genes (per 10kb bin relative to TSS) using coordinates of SRF sites published in 
Esnault et al. 2014. (Asterisks *) Significant at P < 0.05, multiple t-test with Holmes-
sidak correction. (B) 441 induced genes are significantly closer to SRF than 
constitutively active and genes that score as induced in CD only or LMBCD only. 
(Asterisks****) significant at P < 0.0001, Mann-Whitney test; (ns) non significant (C) 
Distribution of the distances to SRF per gene group. (Direct) Sites within 2Kb of 5’-
flanking sequences; (near) sites within 70kb of the TSS. (D) Distances distribution 
of SRF sites to uninduced genes. (Blue) All uninduced genes (n = 16385); (red) 
active un-induced genes with at least 5 RNA-seq read counts in intronic features (n 
= 7264); (white) inactive genes with no reads in intronic features (n= 5062). 
(Asterisks) significant at P < 0.0001, Mann-Whitney test; (ns) non significant. For 
the box plot graphs in panel B and D the middle line in each box plot indicates the 
median value, the top and bottom edges of the box plot are the 75th and 25th 
percentiles, and the small horizontal bars denote the 90th and 10th percentiles. 
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Figure 2.5 LMB stimulation does not induce efficient activation of MRTF-specific 
genes. 
(A) (Left) partitioning of the 441 CD/LMBCD induced genes in statistically 
changing in LMB (LMB+) or non-changing in LMB (LMB-) (p-value < 0.2). (Right) 
SRF binding sites are closer to genes showing change also in LMB. (Asterisk*) 
Significant at P < 0.05, Mann-Whitney test. For the box plot graphs the middle line 
in each box plot indicates the median value, the top and bottom edges of the box 
plot are the 75th and 25th percentiles, and the small horizontal bars denote the 90th 
and 10th percentiles. (B) Display of the relative induction per gene within 70Kb of 
an SRF binding site across conditions. All-reads (top row) or intronic (bottom row) 
RNA-seq read counts were normalised to the average across conditions. 
CD/LMBCD induced genes within 70Kb of an SRF binding site (Total 288, left 
column); CD/ LMBCD induced genes within 70kb non-changing in LMB (Group I 
LMB–, central column) and CD/LMBCD induced genes within 70kb changing in 
LMB (Group II LMB+, right column). (*) Significant at P < 0.05, (****) significant at 
P<0.0001, Wilcoxon test; (ns) non significant. (C) RNA-seq density profiles of 
intronic RNA-seq reads, for CD/LMBCD induced genes within 70kb of an SRF 
site (n = 288). 0.3% FCS (black line), CD (blue line), LMB (purple line), LMBCD 
(orange line) and LMBLatB (red line).  
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Figure 2.6 Highly induced genes are closer to an SRF site and show partial LMB-
dependent stimulation. 
(A) Highly induced genes show partial response to LMB at the intronic RNA-seq 
reads level and greater proximity to SRF binding sites. (Left) Quintiles ranked by 
CD induction compared to resting 0.3% FCS condition. Each condition is plotted 
per quintile. Asterisks shows comparison between LMB and LMBLatB. (*) P < 
0.05; (**) P < 0.01; (ns) non significant, Wilcoxcon test. (Right) Distribution of the 
distances to SRF binding sites per quintile. (*) P < 0.05, (**) P< 0.01, (***) P < 
0.001, Mann-Whitney test. (B) As panel A but using total RNA-seq reads ranked by 
CD induction over 0.3% FCS. (ns) non significant, Wilcoxcon test and Mann-
Whitney test for the right panel. (C) LMB induced genes are not linked to SRF. 
(Left) LMB fold induction ranking of genes within 70kb from an SRF binding site 
specifically changing only with LMB stimulation (n = 775). (Right) Distribution of the 
distances to SRF binding sites per quintile. (ns) non-significant, Mann-Whitney test.  
For the box plot graphs in each panel the middle line in each box plot indicates the 
median value, the top and bottom edges of the box plot are the 75th and 25th 
percentiles, and the small horizontal bars denote the 90th and 10th percentiles. 
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Chapter 3. Nuclear actin controls MRTF DNA 
binding 
3.1 Aim 
MRTF nuclear activities are directly affected by monomeric actin. As 
presented in Chapter 2 nuclear accumulation of MRTF is not sufficient for 
productive transcription of SRF-MRTF targets genome-wide. Efficient 
disassociation of G-actin from MRTF is essential for accumulation of both precursor 
and messenger RNAs. Furthermore MRTF nuclear accumulation under resting 
conditions does not affect transcriptional reactivation of MRTF specific genes, 
allowing us to exclude any unspecific transcriptional impairment. 
The mechanism by which MRTF activates transcription is still unclear. 
Recently we have been able to describe how serum activates the SRF signalling 
pathway and in particular how MRTFs are affecting Pol II recruitment and 
elongation (Esnault et al. 2014). A rigorous analysis of the signal-dependent Pol II 
recruitment allowed us to observe that MRTF DNA binding promotes both Pol II 
recruitment and escape according to the gene context (Esnault et al. 2014). 
Although required, the association of MRTF to target promoters seems not 
sufficient for productive transcription as shown in our laboratory for some bone fide 
MRTF-specific promoters (Vartiainen et al. 2007). 
Within this chapter I am aiming to elucidate, using both genomic and 
biochemical approaches, how MRTF-DNA binding is controlled. This chapter will 
focus on two central questions: is MRTF nuclear accumulation sufficient for MRTF-
DNA binding genome-wide, and does nuclear actin affect MRTF-DNA association? 
3.2 Actin affects MRTF DNA binding and SRF-MRTF 
cooperative binding 
Nuclear MRTF activities might be controlled at the level of DNA binding. 
Although preliminary observations collected in the laboratory have shown that 
MRTF nuclear accumulation is sufficient for its association with Srf, Vcl and Cyr61 
promoters, it is not yet clear if actin affects MRTF-DNA binding. I used chromatin 
immunoprecipitation (ChIP) combined with deep sequencing (ChIP-seq) to define, 
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at the genome scale, both MRTF-A and SRF binding behaviours (Figure 3.1A and 
3.2A). The conditions described in chapter 2 where used so that DNA binding and 
gene activity could be correlated. Instead of defining de-novo a set of SRF and 
MRTF binding sites I analysed my data in relation to our already defined set of SRF 
and MRTF-binding sites (Esnault et al. 2014). As published by us, in fibroblasts it is 
possible to define a core set of 3133 SRF-binding sites and 2416 MRTF-binding 
sites (Esnault et al. 2014). 95% of the MRTF-binding sites are associated with SRF 
and two thirds of the SRF binding relies on nuclear MRTF. Despite what was 
reported in the past (Herrera et al. 1989), the majority of SRF-binding sites show 
cooperative binding with nuclear MRTF. LatB-dependent inhibition of MRTF impairs 
both MRTF and SRF binding at inducible sites. Inducible and constitutive sites 
could be defined using an inducibility threshold such that the linear regression 
curve was closer to 1 for the constitutive sites. 
With the help of the bioinformatics facility I defined peaks scoring as 
significantly enriched over background using a MACS threshold of P<10-5 for both 
SRF and MRTF-A (Y. Zhang et al. 2008b). We defined an SRF data set based on 
the 3133 SRF-binding sites published by the lab (Esnault et al. 2014). 2547 SRF 
binding sites, detected in at least one out of five analysed conditions (0.3% FCS, 
CD, LMB, LMBCD and LMBLatB), besides being called by MACS, coincides 
with the 3133 set. Using this core of SRF peaks I defined de-novo inducible and 
constitutive SRF binding sites using the CD stimulation as a reference. A threshold 
of 1.9 fold induction allowed me to define constitutive and inducible sites with a 
mean inducibility of 1.01 ± 0.01 and 3.1 ± 0.05 respectively. I then asked whether I 
could see any inducibility in CD in the remaining 586 SRF-binding sites not called 
by MACS. 115 peaks showed inducible behaviour in CD if compared to 0.3% FCS. 
Out of the remaining 471 SRF-binding sites 104 showed no signal in any condition 
while the remaining 367 showed ChIP-seq read distribution with good correlation if 
compared with our previous dataset. I therefore included this final group obtaining a 
data set of 3029 SRF-binding sites. 1604 MRTF-A binding sites were defined as 
scoring in at least one out of the four conditions where MRTF-A is nuclear (CD, 
LMB, LMBCD and LMBLatB), and coinciding with the 3133 data set. In addition 
I considered as MRTF associated those binding sites where SRF signal was 
inducible in CD, obtaining a set of 2188 MRTF-A sites.
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I then analysed the binding behaviour of MRTF-A across the defined 2124 
binding sites in the different conditions used. MRTF-A nuclear accumulation via 
LMB showed to be sufficient for DNA binding at constitutive and inducible binding 
sites as shown for the Acta2 and Cofilin promoters (Figure 3.1A). The binding 
intensity in LMB compared to CD was 3 to 4 times weaker (Figure 3.1B). Strikingly 
the addition of CD or LatB changed the MRTF-A signal dramatically across all the 
2124 binding sites (Figure 3.1B). In particular it was possible to observe an 
increase in signal in LMBCD while in the LMBLatB condition MRTF-A was 
completely removed from all binding sites (Figure 3.1B). This phenomenon could 
be ascribed to a possible actin-dependent inhibition of MRTF-DNA binding.  
To further corroborate this observation I analysed the behaviour of SRF 
binding at inducible sites. As published SRF binding at these sites relies on MRTF 
probably for nucleosome displacement and exposure of consensus sequences 
(Esnault et al. 2014). As shown in Figure 3.2 SRF DNA binding at the 1884 
inducible sites occurred also in LMB treated cells. The SRF binding induction 
observed in LMB was half that observed CD (Figure 3.2B and C). Constitutive sites 
showed to be mostly unaffected with a mean inducibility of 0.8 and a high 
spearman r, confirming the linear relation between invariant binding sites as shown 
by the metaprofile (Figure 3.2C). I then analysed the behaviour of the SRF binding 
sites in LMB following the addition of either CD or LatB (Figure 3.3A). Strikingly, 
only the inducible sites were affected, with a 40% increase in CD and a 57% 
decrease in LatB (Figure 3.3A), while constitutive sites remained unaffected (Figure 
3.3B). Furthermore it was possible to observe a good correlation between SRF and 
MRTF-A binding at inducible sites in CD, LMB and LMBCD conditions (Figure 
3.4A). These observations were confirmed by quantitative PCR on an independent 
set of chromatin (Figure 3.4B). 
In conclusion nuclear MRTF is sufficient for its association to genomic sites. 
Inactive nuclear MRTF shows reduced binding intensity and its disassociation from 
actin via CD enhances its association to target sites. Unexpectedly, an increase in 
nuclear monomeric actin using LatB impairs MRTF-DNA association although 
MRTF is still nuclear (see previous chapter). The association and disassociation of 
MRTF from target sites also affects SRF binding at inducible but not constitutive 
sites. 
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3.3 Actin-dependent DNA binding inhibition requires intact 
RPEL motifs 
The observations described above strongly suggest that nuclear 
accumulation of MRTF is indeed sufficient for its association to genomic loci but 
nuclear actin might control it. As previously reported nuclear accumulation of MRTF 
via LMB preserves its interaction with nuclear actin (Vartiainen et al. 2007). 
Experiments collected in the lab have shown that the FRET efficiency between 
nuclear MRTF and actin in LMB is comparable to resting conditions. Furthermore 
incubation with LatB drastically enhances the MRTF-actin FRET efficiency while 
CD treatment completely abolishes this interaction (Vartiainen et al. 2007). 
To further investigate if the effects observed at MRTF binding loci are actin 
mediated I compared the DNA binding activity of MRTF derivatives via ChIP. In 
particular I generated Doxycycline inducible cells lines expressing either MRTF 
fused to an NLS signal (MRTF-HA2-NLS, FigureA) or lacking essential residues for 
actin binding within the RPEL motif (MRTF123-1A-HA2, Figure 3.5A). As shown in 
Figure 3.5B and C both variants are able to associate with bona fide SRF-MRTF 
targets following overnight Doxycycline induction. No detectable signal was 
observed in a cell line harbouring only the empty vector or expressing MRTF fused 
to a mutated NLS signal, confirming the specificity of the assay (Figure 3.5D and 
3.6A and B). Addition of LatB completely abolished MRTF-HA2-NLS DNA binding 
while MRTF123-1A-HA2 was only partially affected (Figure 3.5B and C and average 
binding in E). The reduced binding of the MRTF123-1A-HA2 following LatB stimulation 
seemed site specific as several binding sites were left completely unaffected 
(Figure 3.5B). 
I further investigated the role of the RPEL motif in controlling MRTF-DNA 
association by assessing Myocardin binding behaviours. MRTF belongs to the 
Myocardin family of transcription co-regulators. Myocardin, like MRTF, associates 
to target promoters together with SRF and possesses an N-terminal RPEL domain 
comprising three RPEL motifs (Figure 3.7A). The actin-binding properties of 
Myocardin’s RPEL motifs are different than MRTFs’ RPELs. Specifically, MRTF’s 
RPEL motifs show an overall greater affinity for monomeric actin than those of 
Myocardin (Figure 3.7 A) (Guettler et al. 2008). MRTF RPEL1 and 2 bind actin 
relatively strongly while MRTF RPEL3 binds actin weakly. No or weak actin-binding 
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is recorded for Myocardin RPEL1 and 2 while RPEL3 displays an actin-affinity 
comparable with that of MRTF RPEL3. RPEL3 was indeed shown to be 
exchangeable between the two proteins. Differences in RPEL domains define the 
distinct regulatory behaviours of MRTF and Myocardin. In particular while MRTFs 
are subject to an actin-dependent import-export regulation, Myocardin is 
constitutively nuclear and its activity is mostly unaffected by monomeric actin 
(Guettler et al. 2008). To assess if Myocardin DNA binding was affected by LatB 
treatments I generated Doxycycline inducible cell lines expressing either Myocardin 
or chimaeras of MRTF fused to either RPEL1-2 (MC-N12-MRTFA) or RPEL1-2-3 
(MC-N123-MRTFA) of Myocardin (Figure 3.7B and C) (Guettler et al. 2008). 
Efficient DNA binding was observed for all clones at the Cyr61 and Acta2 
promoters (Figure 3.7 D). Furthermore addition of LatB did not affect the DNA 
binding of Myocardin or of the MRTF variant. This observation implies that the 
actin-mediated MRTF DNA binding inhibition requires intact RPEL1 and 2. 
Chimeras of MRTF fused to the RPELs of Myocardin become resistant to the LatB 
effect (Figure 3.7D). 
In order to elucidate if actin directly impairs MRTF-DNA association I 
isolated recombinant MRTF-A wild type, obtained from baculovirus-infected SF9 
cells, and monomeric actin obtained in large quantities from rabbit skeletal muscle. 
A DNA-pull down assay was optimised in order to obtain an efficient ternary 
complex between SRF, MRTF and the specific DNA sequences recognised by SRF 
(Figure 3.8B). The addition of increasing actin quantities was shown to gradually 
reduce the association of MRTF with the SRF-DNA complex (Figure 3.8A). 
Although this preliminary data confirms that actin may directly affect MRTF-DNA 
association, further investigations are required including the analysis in vitro of 
MRTF mutants unable to interact with actin. 
3.4 MRTF DNA binding is controlled dynamically after Rho-
activation 
MRTF nuclear accumulation and subsequent DNA binding can also be 
achieved through Rho activation (Miralles et al. 2003). This effect is caused by a 
drastic reduction in monomeric actin as it is assembled into filaments (Vartiainen et 
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al. 2007). Upon serum stimulation the kinetic of Rho activation changes over time 
and the formed filaments start to depolymerise.  
Following these notions I wanted to see if MRTF DNA binding was 
controlled over time after serum-dependent Rho activation. As shown in Figure 
3.9A MRTF is rapidly accumulated in the nucleus 15 minutes after serum 
stimulation. Afterwards its nuclear export occurs slowly still being 60-70% nuclear 
1h after serum stimulation. Addition of LatB at minute 15 showed a drastic drop in 
overall MRTF nuclear accumulation that within 2.5 minutes becomes ~60% nuclear 
(Figure 3.9A). I therefore followed both MRTF and SRF binding at seven 
independent inducible sites where SRF binding changes with MRTF nuclear 
accumulation. Both MRTF and SRF bindings are strongly induced within 15 and 
17.5 minutes after serum stimulation respectively (black lines in Figure 3.9B and C). 
MRTF and SRF binding were reduced over time showing a different kinetic than 
MRTF nuclear export, reaching a plateau 30 to 45 minutes after serum stimulation 
(Figure 3.9B and C). The LatB pulse chase experiment combined with ChIP assay 
showed a drastic reduction in both SRF and MRTF binding (red lines in Figure 3.9 
B and C). In particular treatments with LatB for 2.5 minutes were sufficient to 
reduce both MRTF and SRF binding by 90 - 100% (Figure 3.9B and C) although 
MRTF is still 60% nuclear (Figure 3.9A). These data are consistent with 
observations already published where, after serum stimulation, MRTF and actin 
quickly disassociate 10-15 minutes after serum stimulation and re-associate 
showing efficient FRET at 30 minutes after serum stimulation (Vartiainen et al. 
2007). 
In order to investigate the relationship between MRTF DNA binding and 
gene activation I followed the induction of 26 target genes after serum stimulation 
(top 9% of the 288 genes induced specifically by CD and within 70Kb of an SRF 
binding site, see chapter 2). All 26 targets showed a rapid increase followed by a 
slow decrease in their pre-mRNA accumulation (black lines in Figure 3.9D). 
Addition of LatB at minute 15 was shown to drastically affect pre-mRNA 
accumulation that rapidly decreased within a few minutes (red lines in Figure 3.9D). 
LatB treatments show strong consequences in mature RNA accumulation for all 28 
targets (Figure 3.9E).  
I further investigated the mechanism of MRTF-dependent activation by 
tracking Pol II, Serine 5 and Serine 2 phosphorylation, following serum stimulation, 
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over the bone fide SRF-MRTF target Acta2. Several probes have been designed 
spanning the Acta2 ORF from the upstream SRF binding site (~300 bp upstream 
the TSS) down to the 3’ UTR region (Figure 3.10A). As shown in Figure 3.10B 
serum stimulation quickly induces Pol II recruitment and phosphorylation of both 
Ser5 and Ser2. It is intriguing to point out that at early time points after serum 
induction the signal of Pol II detected at the TSS is greater that the signal in the 
gene body (Figure 3.10B). Over the time this difference decreases and the 
phospho marks are sequentially reduced. I also followed the consequence of 
drastically removing MRTF from Acta2 promoter via LatB treatment on Pol II 
recruitment and phosphorylation. Addition of LatB was shown to reduce the overall 
Pol II quantity at Acta2 and immediately flatten its profile (Figure 3.10B red labelled 
profiles). This effect might be caused by reduced re-initiation. Furthermore LatB 
treatment also caused a loss of Ser2 and Ser5 apparently greater than the 
reduction in overall Pol II (Figure 3.10B). In conclusion the dynamics in MRTF DNA 
binding might have direct effects in Pol II re-initiation and phosphorylation, clearly 
resulting in a loss of productive transcription. 
3.5 Summary 
In this chapter I have presented a new role for nuclear actin in controlling 
MRTF DNA association. Nuclear accumulation of MRTF is sufficient for partial 
association of MRTF with target loci and the removal of actin using CD enhances 
MRTF signal. On the other hand forcing MRTF and actin interaction via LatB 
completely impairs MRTF-DNA association throughout the genome. Similarly SRF 
binding is affected at inducible sites whereas at constitutive sites SRF binding is 
unaffected. Furthermore inhibition of MRTF-DNA binding via LatB requires intact 
RPEL motifs and does not affect the related protein Myocardin. In addition MRTF 
DNA binding changes over time after Rho activation and addition of LatB enhances 
loss of MRTF binding. Changes in MRTF-DNA association correlate with the 
dynamic accumulation of precursor and mature RNA. Finally MRTF DNA binding 
seems to directly affect Pol II re-initiation and phosphorylation as shown for the 
Acta2 model gene. 





Figure 3.1 MRTF DNA binding is controlled by nuclear actin. 
(A) Representative MRTF-A profiles as normalised reads per base pair at Cofilin 
(CFL1) and Acta2 promoter. The five conditions are serum starved (0.3, black line), 
CD (blue line), LMB (purple line), LMBCD (orange line), LMBLatB (red line). (B) 
Metaprofile of MRTF-A binding centred on SRF peak summit.  
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Figure 3.2 MRTF nuclear accumulation is sufficient to induce SRF binding. 
(A) Representative SRF profiles as normalised reads per base pair at Cofilin 
(CFL1) and Acta2 promoter. (B) MRTF nuclear accumulation via CD or LMB 
enhances SRF binding at inducible sites. Scatter plot comparing ChIP-seq read 
counts in CD (right) or LMB (left) stimulation and resting cells. Each graph is 
divided in constitutive sites (<1.9 fold increase black) and inducible (>1.9 fold 
increase, blue for CD stimulation left panel or purple for LMB stimulation right 
panel). Solid lines show linear regression plots for the two populations. (C) 
Metaprofiles of SRF binding at constitutive (left) and inducible (right) sites. 





Figure 3.3 Nuclear actin controls SRF inducible binding via MRTF. 
(A) (Left) Scatter plot of SRF binding at inducible sites comparing ChIP-seq read 
counts in LMBCD (orange) or LMBLatB (red) and LMB stimulated cells. (Dotted 
line) bisector of the scatter plot distribution representing invariant binding sites 
compared to LMB stimulation. Solid lines shows linear regression plot for each 
condition. (Right) Metaprofile of SRF binding in LMB, LMBCD and LMBLatB at 
inducible sites (n=1884). (B) (Left) Scatter plot of SRF binding at constitutive sites 
comparing ChIP-seq read counts in LMBCD (orange) or LMBLatB (red) and 
LMB stimulated cells. (Dotted line) bisector of the scatter plot distribution 
representing invariant binding sites compared to LMB stimulation. Solid lines shows 
linear regression plot for each condition. (Right) Metaprofile of SRF binding in LMB, 
LMBCD and LMBLatB at constitutive sites (n=1145). 





Figure 3.4 SRF and MRTF binding correlates at inducible sites. 
(A) Correlation between SRF and MRTF ChIP-seq reads at inducible sites. Both 
SRF and MRTF normalised ChIP-seq read counts were scaled to the highest signal 
across condition (with maximum at 100%). The scatter plot represents correlation 
in CD (blue), LMB (purple) and LMBCD (orange) conditions. Solid line shows 
linear regression plot for each condition. (B) ChIP validation of SRF binding (left) 
and MRTF binding (right) at nine sites including: two SRF constitutive MRTF bound 
sites (Srf and Cyr61), five SRF inducible MRTF associated sites (Acta2, Actg1, 
Mir145, Filamin A and Col1a1), one SRF constitutive TCF specific site (Egr1) and 
one negative control site where both SRF and MRTF are not associated (Zfp37). 
The IP was quantified using quantitative RT-PCR and plotted as percentage of the 
input material. 
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Figure 3.5 Actin mediated MRTF DNA binding inhibition requires intact RPEL 
motifs. 
(A) Western blot analysis of cell lines carrying Empty vector, MRTF123-1AHA2, 
MRTF-NLS-HA2. Cells were stimulated with 2µg/ml doxycycline (Dox) and treated 
with LatB for 5 minutes to minimise unspecific LatB effects. (B to D) ChIP using an 
anti-HA antibody of MRTF-NLS-HA2, MRTF123-1AHA2 and cells harbouring the 
empty vector. The immune-precipitated material was quantified using quantitative 
RT-PCR and plotted as percentage of the input material. The binding sites 
assessed include nine bona fide SRF-MRTF targets and a negative control (zfp37) 
(E) Average binding across targets and cell lines. The signal across cell lines per 
binding site was normalised to the highest signal measured. 





Figure 3.6 Expression of MRTF linked to a mutated NLS does not induce DNA 
binding. 
Control experiment related to figure 3.5. (A) Western blot analysis of cell lines 
carrying Empty vector or MRTF-NLSmut-HA2. Cells were stimulated with 2µg/ml 
doxycycline (Dox) and treated with LatB for 5 minutes to minimise unspecific LatB 
effects. (B) ChIP using an anti-HA antibody of MRTF-NLSmut-HA2 (C) Average 
binding across targets and cell lines. The signal per binding site was normalised to 
the maximum signal measured including the experiment seen in Figure 3.5. 
 




Figure 3.7 Actin-mediated MRTF DNA binding inhibition requires RPEL1-2. 
(A) (Left) Multiple sequence alignment of RPEL motifs of mouse MRTF and MC. 
This figure was modified from (Guettler et al. 2008). The brackets indicate the 
RPEL motif as defined by PFAM. “x” denotes the first most conserved R residue of 
the RPEL motif targeted by the R to A mutation in MRTF123-1AHA2. (Right) Kd of 
each RPEL motif for monomeric actin is listed (Guettler et al. 2008). (B) Schematic 
representation of the MC and MC-MRTF chimeras with MC sequences in green 
and grey and MRTF sequences in red and blue (panel adapted from Sebastian 
Guettler’s thesis). (C) Western blot analysis using an anti-HA antibody of cell lines 
carrying Empty vector, MC, MC-N12-MRTFA and MC-N123-MRTFA. Cells were 
stimulated 2µg/ml doxycycline (Dox) and treated with LatB. (D) Anti-HA ChIP of the 
MC, MC-N12-MRTFA, MC-N123-MRTFA and control cell line. The immune-
precipitated material was quantified using quantitative RT-PCR and plotted as 
percentage of the input material. The binding sites assessed include two bona fide 
SRF-MRTF targets and a negative control (Zfp37). 






Figure 3.8 Monomeric actin directly affects MRTF DNA binding in vitro. 
(A) DNA-protein binding assay performed using an SRF-MRTF specific binding 
site. The DNA-protein complex was pulled down using Dynabeads M-280 
Streptavidin. SRF and MRTF pure components were coupled to the DNA. After 
extensive washes increasing amounts of pure monomeric LatB:actin were added to 
the DNA-SRF-MRTF complex and incubated for 15 minutes at 30 ºC. (B) 
Optimisation of the DNA-pull down conditions using a biotinylated DNA probe with 
(Biot-SRE) or without (Biot-MCM1) the specific SRF binding site.  
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Figure 3.9 MRTF DNA binding changes after Rho activation. 
(A) (Left) MRTF-A nuclear localisation time course after serum stimulation of serum 
starved cell. 150-300 cell were scored according to predominantly nuclear (N), 
pancellular (N/C) and predominantly cytoplasmic (C) MRTF-A localisation. (Right) 
MRTF-A nuclear localisation following a quick pulse of LatB (2.5 minutes). (B and 
C) SRF (left) and MRTF (right) ChIP time course at seven inducible binding sites. 
The signal per binding site was normalised to the highest point across the time 
course. The Black dotted lines represent each independent binding site while the 
solid black line represent the average binding intensity per time point after serum 
stimulation. The red dotted lines represent each independent binding site while the 
solid red line represent the average binding intensity per time point after LatB pulse 
chase following 15 minutes of serum stimulation. (D) Time course expression of 26 
independent SRF-MRTF target genes following accumulation of their first intron 
after serum stimulation (Black line) or LatB pulse chase after 15’ serum shock (red 
line). Dotted lines represent individual genes while the solid lines represent an 
average per time point across the 26 genes. Quantitative PCR were performed for 
each gene and the values were normalised to Gapdh. Each kinetic was normalised 
to the highest point across the time course. (E) As in D but following accumulation 
of mature RNA of the 26 targets analysed in panel D. (The 26 targets are: Ctgf, Vcl, 
Srf, Acta2, Dusp5, Pdlim5, Cyr61, Serpine1, Tpm1, Thbs1, Palld, Bok, Ankrd1, 
Wdr1, D4Bwg0951e, Pdlim7, Dstn, Vgll3, Slc2a1, Klf6, Rheb, Tpm4, Klf7, Zyx, 
Pdcl3 and Actb). 
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Figure 3.10 MRTF DNA binding promotes Pol II recruitment and phosphorylation 
after serum stimulation. 
(A) Representation of the Acta2 gene illustrating the positions of different probes 
along the gene. Exons are indicated with 5’UTR and 3’UTR in grey and coding 
sequences in black; SRF binding site is indicated with a red circle. (B) ChIP of Pol 
II (N20 antibody), Serine 5-P (H14 antibody) and Serine 2-P (H5 antibody) over the 
time course illustrated in Figure 3.9. Black lines represent the profile of Pol II and 
the phosphorylated CTD forms after serum stimulation. In red is the profile 
following LatB pulse chase added 15 minutes after the serum shock. 
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Chapter 4. Nuclear actin controls Pol II productive 
transcription 
4.1 Aim 
Activation of transcription follows defined sequential events. Pol II 
recruitment together with the GTFs is the first mandatory bottleneck to go through 
in order to induce transcription (see Chapter 1 for a full description). Following Pol 
II recruitment other barriers need to be overcome including recruitment of CTD 
kinases, release from pausing and elongation. These processes are directly 
influenced by a plethora of effectors either promoting or inhibiting the transcriptional 
flow. The definition of each step is often misleading, as the exact contribution of 
each transcriptional factor is not yet understood. Furthermore several PTMs 
decorate Pol II CTD as it crosses each step. However, their relation with escape, 
elongation and the synthesis of mRNA is not clear. 
Accumulation of MRTF into the nucleus after Rho activation influences both 
Pol II recruitment and activation (Esnault et al. 2014). The association of MRTF to 
defined genomic loci could potentially affect the transcriptional outcome directly 
recruiting transcriptional kinases, promoting chromatin modification and favouring 
nucleosome clearance at selected TSS. To further investigate how MRTF 
influences transcription I analysed the steps in transcriptional activation under the 
productive and unproductive conditions described in chapter 2 and 3 (CD and LMB 
stimulation). In this chapter I am going to describe how nuclear actin impacts on the 
transcriptional outcome affecting steps beyond Pol II recruitment and escape. 
4.2 MRTF nuclear accumulation is sufficient for Pol II 
recruitment and escape 
As described in Chapter 2 and 3 MRTF nuclear accumulation via LMB is 
sufficient for partial DNA binding but productive transcription requires 
disassociation from nuclear actin. Furthermore, as mentioned at the end of the 
previous Chapter and as recently published, MRTF-DNA binding induces Pol II 
recruitment and activation (Esnault et al. 2014). To further understand how nuclear 
actin negatively regulates productive transcription of MRTF-target genes I 
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assessed the recruitment of Pol II at the Acta2 gene in the conditions previously 
described (Figure 4.1A and B). Surprisingly Pol II showed to be efficiently recruited 
and released from Acta2 promoter after LMB treatment (Figure 4.1B). Pol II signal 
shows to be only partially reduced if compared to the productive conditions CD and 
LMBCD (Figure 4.1B). Furthermore both NELF-A and SPT5 were shown to be 
recruited together with Pol II and, consistent with efficient Pol II release, only SPT5 
showed a further distribution within Acta2 ORF (Figure 4.1 B). This observation 
contradicts to the complete loss of efficient precursor and messenger RNA 
accumulation after LMB stimulation as described with the RNA-seq analysis (Figure 
4.1C). 
In order to validate this observation I performed a genome-wide analysis of 
the Pol II ChIP (Figure 4.2A). I considered the specific set of genes induced by CD 
and unaffected by LMB within 70kb of an SRF binding site as described in Chapter 
2. It was possible to observe an increase in Pol II signal across all 288 MRTF-
specific targets in both CD and LMB (Figure 4.2B and D). Furthermore the LMB-
dependent induction of Pol II recruitment showed a marked sensitivity to LatB 
treatment (Figure 4.2B). This increase in Pol II occurred identically at MRTF-
specific genes where LMB does not induce any transcription and at genes where 
LMB just mildly enhances the intronic-reads base line (see Chapter 2 for a 
definition of the gene group, Figure 4.2C). No change was observed at 
constitutively active genes while strong recruitment of Pol II, travelling within the 
gene body, was specifically recorded for the 288 MRTF-specific target genes 
(Figure 4.2D). Overall the Pol II signal in LMB was half that of observed in CD but 
no difference was observed for the LMBCD condition (Figure 4.2D).  
In conclusion, in the absence of productive transcription nuclear MRTF is 
sufficient to recruit and release Pol II from MRTF-specific target genes. The 
detected Pol II specifically requires MRTF DNA binding as treatment with LatB 
induces Pol II loss. This change in Pol II distribution is specific for MRTF-targets, as 
it is not observed at any constitutively active genes. 
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4.3 Pol II recruitment correlates with MRTF binding but actin 
disassociation is required for RNA-synthesis 
In order to asses whether MRTF binding correlates with Pol II recruitment I 
compared the distribution of the Pol II signal at the TSS of each MRTF-specific 
target and the highest, closest peak of MRTF (Figure 4.3). Although it was 
challenging to establish a unique relation between MRTF-binding sites and target 
genes, it was still possible to record a correlation in CD, LMB and LMBCD 
treatments (Spearmen r=0.3 P-value <0.0001). LatB treatments showed no 
correlation between MRTF and Pol II signal (Figure 4.3).  
4.4 Pol II escape is accompanied by RNA synthesis and R-loop 
accumulation  
The relationship between travelling Pol II and the production of RNA has 
been shown to be linear (Tippmann et al. 2012). Also in my assays, the comparison 
of Pol II signal and RNA synthesis after CD stimulation showed a good linear 
correlation with a slope of 0.85 and Spearman r of 0.4 (P-value<0.0001) (Figure 
4.4A). The comparison of Pol II signal and RNA synthesis in LMB treated samples 
showed a distribution with slope of 0.18 and Spearman r 0.2 (p-value<0.0001) 
implying that most increases in Pol II signal are not followed by a proportional 
increase in RNA synthesis (Figure 4.4B). A proportional stimulation of Pol II signal 
and RNA synthesis is re-established by addition of CD (Figure 4.4C left panel), 
while LatB treatment reduces the Pol II signal observed in LMB (Figure 4.4C right 
panel). 
In order to asses if the engaged unproductive Pol II is transcriptionally 
competent I performed Run-on assays after short CD or LMB stimulations. 
Accumulation of labelled RNA was detected in both CD and LMB condition across 
the Acta2 gene (Figure 4.5 A left panel). Furthermore the amount of RNA detected 
in LMB could easily be related to the amount of Pol II seen by Pol II ChIP over 
Acta2 ORF (Figure 4.1B). The use of conventional RNA extraction methods, 
following a short time course after either CD or LMB stimulation, did not show any 
accumulation of Acta2 precursor in LMB treatment compared to CD (Figure 4.5A).  
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I further studied the ability of the engaged Pol II to synthesise RNA, 
assessing R-loop accumulation. R-loops are three stranded nucleic acid structures 
formed by RNA:DNA hybrids plus a displaced DNA strand (ssDNA) (Aguilera & 
García-Muse 2012). This structure is a transcriptional by-product. The RNA 
associated with the DNA strand is a fairly stable hybrid that could be detected using 
specific antibodies (Boguslawski et al. 1986). Similarly to the observed Pol II 
distribution, R-loops are accumulated following Pol II elongation in CD, LMB and 
LMBCD conditions over Actb and Acta2 (Figure 4.6 B top two panels) and the 
detected signal showed sensitivity to RNAseH treatments (Figure 4.6 B bottom two 
panels).  
These observations suggest that MRTF-DNA binding is sufficient for Pol II 
elongation but actin disassociation is required so that the synthesised RNA can be 
efficiently accumulated. In addition these results confirm that the phenomenon 
observed following LMB stimulation is not caused by an impairment of Pol II 
enzymatic activity. 
4.5 Nuclear actin affects Pol II phosphorylation 
To further understand which step in transcription is affected by nuclear actin 
I assessed the phosphorylation of Pol II CTD in the panel of conditions analysed so 
far. As extensively described in the introduction (see Chapter 1) Pol II CTD is 
phosphorylated throughout the transcriptional cycle. Five key residues have shown 
to be phosphorylated by diverse kinases and their function in yeast, drosophila and 
mammals have been partially described (Figure 4.6A). The pattern of 
phosphorylation has been correlated with some transitions that Pol II has to cross 
in order to efficiently transcribe. Furthermore several complexes have been shown 
to specifically interact with phosphorylated Pol II CTD and directly affect steps in 
RNA synthesis, maturation, release and export.  
Using the Acta2 model gene I compared the signal distribution of five 
phospho-specific antibodies. Induction of productive transcription via CD induces 
phosphorylation at all residues (Figure 4.6B to F). As described by others, both 
Serine 5 and 7 are enhanced at the Acta2 TSS (Figure 4.6B and C) and spread 
down towards the end of the gene following the Pol II distribution (Figure 4.6 G). 
Serine 2, on the other hand, showed a bell shaped distribution starting to 
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accumulate immediately after the TSS and peaking towards the 3’ UTR (Figure 
4.6D). Tyr1, one of the least described markers together with Thr4, shows high 
signal at the Acta2 promoter and a small spike after the 3’ UTR (Figure 4.6 E). On 
the contrary Thr4, as recently described (Hintermair et al. 2012), is accumulated 
immediately after the termination site at Acta2 3’ UTR (Figure 4.6 F). LMB 
treatment showed a different scenario than CD stimulation. Only Serine 5 
phosphorylation accompanied the engaged Pol II from the promoter down to the 3’ 
UTR (Figure 4.6 B and G). Serine 5 signal in LMB showed LatB sensitivity again 
suggesting the direct requirement of MRTF bound at the Acta2 promoter. On the 
other hand Serine 7, Serine 2 Tyrosine 1 and Threonine 4 were all defective 
(Figure 4.6 C to F). Stimulation with CD following LMB was shown to enhance only 
a few phospho-marks. In particular Thr4 was still defective showing only a barely 
detectable signal down the 3’ UTR.  
In order to generalise these observations I performed a genome-wide 
analysis of both Serine 5 and Serine 2 ChIP (Figure 4.7). As shown in Figure 4.8A 
and C LMB stimulation induces Serine 5 accumulation at all 288 MRTF-target 
genes. This stimulation similarly occurred at MRTF-specific genes where LMB has 
no effect and at genes where LMB mildly enhances the base line of intronic-reads 
(Figure 4.8 A). Addition of CD partially enhances the Ser5-P signal following LMB 
stimulation while LatB treatment specifically impairs the LMB-induced Ser5-P signal 
(Figure 4.8 A and C). No changes in Serine 5 phosphorylation were observed at 
active uninduced genes (Figure 4.8 C). Analysis of Serine 2 phosphorylation over 
the MRTF-specific genes showed a different scenario. Complete loss of phospho-
Serine2 in LMB treatment occurred at all MRTF-specific genes (Figure 4.8 B and 
D). No difference was recorded for genes where LMB partially enhances the RNA 
base line (Figure 4.8B). Addition of CD following LMB partially enhances Serine 2 
phosphorylation (Figure 4.8B and D). 
In conclusion the synthesis of stable RNA reflects a correct phosphorylation 
of Pol II CTD. During unproductive stimulations, even though Pol II is engaged and 
released, the phospho-signature at Pol II CTD is affected. Further studies are going 
to be essential to fully characterise this unproductive condition including genome-
wide analysis of the remaining three CTD modifications. However it is clear that 
nuclear actin via MRTF affects steps beyond Pol II recruitment and escape. In 
particular, given the effect of actin on MRTF-DNA binding, it would be important to 
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study how a TF or co-regulator such as MRTF can affect steps in transcription by 
changing its persistence at target promoters. 
4.6 MRTF nuclear accumulation does not influence Pol II 
escape 
To further characterise the process of MRTF-dependent transcription 
activation, given the data collected, I analysed the distribution of Pol II signal in the 
conditions used. As reported by the Adelman and Lis groups Pol II promoter 
recruitment is followed by a step of pausing within a few hundred base pairs from 
the TSS (Adelman & Lis 2012). This mechanism relies on the so-called pausing 
factors NELF and DSIF that play a dual role in PIC formation and Pol II release 
repression. Several studies described how different TFs are capable of recruiting p-
TEFb, a complex required for pause release induction (Rahl et al. 2010). As 
previously described within this chapter MRTF nuclear accumulation allows Pol II 
recruitment and release with a correct redistribution of SPT5 and NELF eviction 
suggesting that, even though no RNA is being detected, p-TEFb might be correctly 
recruited.  
During the process of gene activation two main steps seem to be the 
bottleneck in productive elongation: Pol II recruitment and escape. Several works 
have tried to characterise which of these two is the rate-limiting step able to predict 
the degree of activity of a given gene. The ratio between the signal at the 5’ end of 
a gene and the one observed in the gene body (GB) provides a way to measure 
the rate of entry and escape for a given gene. I defined the elongation index as the 
ratio between the GB density and the 5’ region density (Figure 4.9 A). This value is 
the reverse of the so-called Travelling ratio or Pausing index described by others 
(Reppas et al. 2006; Rahl et al. 2010; Zeitlinger et al. 2007).  
The relative rates of Pol II recruitment and escape combine to determine the 
level of transcription of a given gene (Core & Lis 2008). I therefore analysed the 
relation between 5’ and GB signals for constitutively active genes and for the 
selected set of MRTF-specific genes in resting, CD and LMB conditions (Figure 
4.10 B). In particular I compared the top 20% of constitutively expressed genes 
with the 288 MRTF-dependent targets. On average, across conditions, the 5’ 
region shows a signal that was ~60% higher than the GB region in constitutive 
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active genes (Figure 4.9B red populations). Within this set of genes this difference 
did not change in any condition. I then focused on the 288 targets. As shown in 
Figure 4.9B the 5’ to GB ratio did not change when the 288 genes were stimulated 
with either CD or LMB. This observation would imply that the elongation index per 
gene does not change when these genes are specifically and rapidly turned on. 
Indeed it was possible to observe a good relation between elongation indexes in 
resting and stimulated conditions for both constitutively active and MRTF-specific 
gene sets (Figure 4.9C). Furthermore LMB stimulation was not shown to differ from 
the CD stimulation.  
Analysis of the changes observed at 5’ and GB regions (as fold over 0.3% 
FCS) showed a proportional increase upon stimulation of both values (Figure 4.10). 
No increase was detected at highly expressed-constitutive genes while the MRTF-
dependent targets showed, in both CD and LMB, an overall equal induction if 
compared to 0.3% FCS of the 5’ Pol II peak and the GB signal. 
Taking together these observations it is possible to conclude that MRTF-
DNA binding primarily controls Pol II recruitment. The observation that the 
elongation index is maintained unchanged across conditions, suggests that the 
extent of Pol II escape may be modulated by mechanisms intrinsic to the 
transcription machinery. Corroborating this hypothesis is the fact that the rate of Pol 
II escape does not change even in LMB, where no accumulation of stable 
messenger RNA is detected. 
4.7 Pause Pol II inversely correlates with SRF binding and 
gene induction 
As no differences in Pol II escape are measured following MRTF nuclear 
accumulation, I assessed whether the rate of escape could be defined on a gene-
by-gene bases as a function of the transcription induction. I therefore analysed both 
elongation and pausing indexes in 0.3% FCS. The 288-gene set of targets was 
ranked on the basis of the change in gene expression observed following CD 
stimulation (Figure 4.11A). Considering the top 80% induced genes (top four 
quintiles) it was possible to see that highly induced genes had a higher elongation 
rate (and a lower pausing index) than less induced genes in resting conditions 
(Figure 4.11B). As described in the previous section the rates did not change upon 
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stimulation with either CD or LMB. This implies that a gene, in order to be highly 
induced, should have lower paused Pol II to start. In addition it was possible to 
observe that lowly induced genes showed a higher pausing-index (Figure 4.11B) 
and also a higher base-line expression (Figure 4.11C). Activation of transcription 
via CD induces accumulation of RNA-seq intronic reads in all quintiles, but the top 
20% induced genes showed the greatest change (Figure 4.11C). These changes 
were not observed in LMB as already discussed in Chapter 2. 
Taking together these observations it is possible to conclude that the rate of 
Pol II escape is context specific and does not change when MRTF is retained in the 
nucleus. It is important to bear in mind that for the MRTF-specific set of targets 
there is a direct relation between inducibility and SRF proximity (see Chapter 2 and 
Figure 4.11D). It is therefore conceivable to suggest that for SRF-distal genes other 
TFs favour Pol II initiation and MRTF contributes to enhance its rate. On the other 
hand, for SRF-proximal genes MRTF is the primary source of initiation, therefore 
no Pol II and base-line expression is detected.  
4.8 Summary 
In this Chapter I characterised how MRTF-dependent genes respond 
following MRTF nuclear accumulation. I analysed the distribution of components of 
the PIC, including pausing factors, and modifications of the Pol II CTD in productive 
and un-productive conditions. MRTF DNA binding directly affects Pol II initiation. 
MRTF-actin disassociation is essential for the correct phosphorylation of Pol II CTD. 
Indeed nuclear accumulation of MRTF via LMB is sufficient for Pol II entry and 
escape in absence of transcript accumulation. These observations allowed me to 
verify that Pol II escape can be in part disentangled from its phosphorylation. A 
further characterisation of the modifications at Pol II CTD in these conditions will 
provide further insight into this mechanism. 





Figure 4.1 MRTF nuclear accumulation is sufficient for Pol II recruitment and 
escape at Acta2 gene. 
(A) Representation of the Acta2 gene illustrating the positions of different probes 
along the gene. Exons are indicated with 5’UTR and 3’UTR in grey and coding 
sequences in black; SRF binding site is indicated with a red circle. (B) ChIP of total 
Pol II, NELF-A and SPT5 at Acta2 genes. (C) RNA-seq normalised read counts 
either total (right) or mapping in intronic features (left) of Acta2 gene. 
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Figure 4.2 MRTF nuclear accumulation is sufficient for Pol II recruitment and 
escape at SRF-MRTF target genes. 
(A) Representative Pol II (N20 antibody) ChIP-seq tracks on Acta2, Ctgf and 
Cyr61. (B) Nuclear accumulation of MRTF shows induced recruitment and escape 
of Pol II at all 288 MRTF-target genes. Pol II ChIP-seq read counts from -2Kb to pA 
site per bp. (C) Comparison of Pol II recruitment and escape at group I-II genes, as 
described in Chapter 2. Group I are genes out of the 288 selected targets showing 
no LMB induction while group II are genes out of the 288 selected target showing 
partial induction after LMB stimulation. (B and C) The middle line in each box plot 
indicates the median value, the top and bottom edges of the box plot are the 75th 
and 25th percentiles, and the small horizontal bars denote the 90th and 10th 
percentiles. Statistical significance, Wilcoxon test, (*) P < 0.05 (****) P < 0.0001, 
(ns) non-significant. (D) Metaprofile of Pol II ChIP-seq of the 288 MRTF-target 
genes selected from RNA-seq studies in Chapter 2. Normalised ChIP-seq read 
counts are shown across gene loci, standardised to 20kb, and flanking 5 kb. 
Dashed box represents the zoom in towards the end of the metaprofiles from 15Kb 
from the theoretical TSS down to +5 Kb. The third panel from the left represents 
constitutively active un-induced genes. 





Figure 4.3 Correlation between MRTF binding and Pol II recruitment at target 
gene promoters. 
MRTF-A binding intensity correlate with recruited Pol II at target gene promotes in 
CD (blue), LMB (purple), LMBCD (orange) but not in LMBLatB (red) conditions. 
The highest closest MRTF binding site in CD was selected per target gene. Both 
Pol II signal and MRTF-A were scaled to the highest signal observed across 
conditions. The significance of the Spearman r shows value with P < 0.001 for CD, 
LMB and LMBCD correlations. The LMBLatB did not show any significant 
correlation.  





Figure 4.4 Correlation between travelling Pol II and RNA production. 
(A and B) Correlation between increase in Pol II signal within the gene body of 
target genes and the fold induction observed at the RNA level. Data obtained from 
total Pol II ChIP-seq was crossed with the RNA-seq data described in Chapter 2. 
The fold increase was normalised to the highest increase observed across 
conditions. Graph A (blue) shows the correlation between Pol II and RNA induction 
after CD stimulation. Graph B (purple) shows the correlation between Pol II and 
RNA induction after LMB stimulation. (C) As in graph A and B shows the relation 
between Pol II and RNA increase when CD or LatB are added following the LMB 
stimulation. 




Chapter 4. Results 
 
 154 
Figure 4.5 RNA synthesis following MRTF nuclear accumulation during 
productive and unproductive stimulation. 
(A) (Left) nuclear run-on assay on the nascent Acta2 transcript. Gene structure and 
probe positions are indicated at the bottom of the panel. Nuclei were extracted 
following 7.5 minutes of either CD (blue) or LMB (purple) stimulation (see materials 
and methods). (Right) Intronic Acta2 RNA accumulation time course following 
either CD or LMB stimulation. Total RNA was extracted with conventional protocol 
and analysed by RT-qPCR. (B) DIP-IP on either Actb (left) or Acta2 (right) genes 
using the S9.6 antibody. Bottom two panels show the DIP signal following RNase H 
treatment. 
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Figure 4.6 MRTF nuclear accumulation is not sufficient for correct Pol II 
phosphorylation at Acta2 gene. 
(A) Schematic representation of the heptad sequence within Pol II C-terminal 
domain. In red are highlighted the residues that can be modified by 
phosphorylation. At the top within each box are listed the kinases known to modify 
the presented residues. At the bottom are listed the functions that have been 
reported to correlate with the modified residues. (B to F) ChIP experiments at 
Acta2 model gene of different phospho-specific antibodies recognising defined 
residues: Serine 5-P (H14 antibody), Serine 7-P (4E12), Serine 2-P (H5), Tyrosine 
1 (3D12), Threonine 4-P (6D7). (G) Pol II ChIP as in Figure 4.1 for comparison. 





Figure 4.7 Serine 5 and Serine 2 ChIP-seq across conditions. 
Representative Serine 5 phosphorylation (S5P) and Serine 2 phosphorylation 
(S2P) ChIP-seq on Acta2, Ctgf and Cyr61 genes. 
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Figure 4.8 MRTF nuclear accumulation is sufficient for Ser5 but not Ser2 
phosphorylation. 
(A) Comparisons of the average ChIP densities of Serine 5-P (H14 antibody) from -
2Kb to pA site for the 288 MRTF-SRF selected targets (left panel), or Group I and II 
as defined in Chapter 2 across conditions. (B) As panel A but assessing Serine 2-P 
(H5 antibody). (A and B) The middle line in each box plot indicates the median 
value, the top and bottom edges of the box plot are the 75th and 25th percentiles, 
and the small horizontal bars denote the 90th and 10th percentiles. Statistical 
significance, Wilcoxon test, (*) P < 0.05 (****) P < 0.0001, (ns) non-significant. (C) 
Metaprofile of Pol II Serine 5-P ChIP-seq of the 288 MRTF-target genes selected 
from RNA-seq studies in Chapter 2. Normalised ChIP-seq read counts are shown 
across gene loci, standardised to 20kb, and flanking 5 kb. Dashed box represents 
the zoom-in towards the end of the metaprofiles from 15Kb from the theoretical 
TSS down to +5 Kb from the PAS. The third panel from the left represents 
constitutively active un-induced genes. (D) As in panel C but showing Pol II Serine 
2-P CHIP-seq reads counts merged into a metaprofile. 
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Figure 4.9 Nuclear MRTF controls Pol II entry and escape.  
(A) Schematic illustrations representing possible changes in Pol II profiles after 
stimulation. We considered changes in the 5’ region density (-2Kb to 250bp) and 
gene body density (250bp to PAS) as defined by others (Min et al. 2011). 
Elongation rate is defined as the ratio of gene body density to pause peak density 
(that is the reverse of the Pausing index). (B) Relation between 5’ density and gene 
body (GB) density per condition at (top) top 20% constitutive expressed in red 
(n=527) and (bottom) target genes (n=288) (black for 0.3% FCS, blue for CD and 
purple for LMB). In grey within each graph are all the constitutive active genes 
(n=2885). Dashed line represent the linear regression excluding outliers for each 
group of genes. (C) Correlation between elongation indexes in resting and 
stimulated condition for (top) top 20% constitutively expressed in red (n=527) and 
(bottom) target genes (n=288) (blue for CD and purple for LMB). In grey within 
each graph are all the constitutively active genes (n=2885). 






Figure 4.10 Nuclear MRTF equally enhances Pol II recruitment and escape. 
Correlation between changes at the pause Pol II peak and Gene body Pol II signal 
(as CD or LMB stimulated over 0.3% FCS). (Top) in red top 20% constitutively 
expressed genes (n=527) and in grey all the constitutive genes (n=2885). (Bottom) 
coloured in blue (CD stimulation) or purple (LMB stimulation) are the 288 
SRF/MRTF-targets while in grey are all the constitutively expressed genes 
(n=2885). 





Figure 4.11 Paused Pol II inversely correlates with gene inducibility and SRF 
proximity 
(A) RNA-seq fold induction in CD ranking per quintiles using intronic reads. (B) 
Elongation (left) and Pausing (right) indexes changes in 0.3% FCS for top 80% 
quintile as defined in panel A. (C) RNA intronic reads for top 80% quintiles in 0.3% 
FCS (left), CD (centre) and LMB (right). (D) SRF distance to genes’ TSS per 
quintile. The middle line in each box plot indicates the median value, the top and 
bottom edges of the box plot are the 75th and 25th percentiles, and the small 
horizontal bars denote the 90th and 10th percentiles. (*) P < 0.05, (**) P< 0.01, (***) 
P < 0.001, (****) P < 0.0001, Mann-Whitney test. 
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Chapter 5. TCF-dependent chromatin signature in 
response to Ras activation 
5.1 Aim 
In recent years several chromatin changes have been reported to be a 
hallmark of transcriptional outcomes (Bernstein et al. 2007). Correlation studies 
based on genome-wide approaches have defined signatures that could potentially 
predict the transcriptional blueprint of a defined cell (J. Ernst et al. 2011). How 
these signatures are established is of great interest in order to understand the 
relationship between causes and effects and refine their predictive potential.  
Several reports describe how signal influences chromatin changes, 
including histone modifications and nucleosome remodelling, often taking the role 
of TFs for granted (see Chapter 1). In this Chapter I am going to describe how the 
transcription factors TCF control the establishment of a defined chromatin signature 
in response to Ras-Erk signalling. The characterisation of the relationship between 
signal transduction, chromatin changes and the concomitant activation of defined 
target genes will be addressed. 
Mouse Embryonic Fibroblasts (MEFs) lacking all three TCFs (named ESN 
standing for, Elk-1-/-SAP-1-/-Net∂/∂) were previously generated in the lab (Costello et 
al. 2010) providing a clean tool to define targets induced by specific stimuli. In this 
chapter, having defined a bona fide set of targets and the stimuli that specifically 
activates the TCFs, I am going to describe how the TCFs control both chromatin 
changes and assembly of the transcriptional machinery. Finally, using 
reconstitution experiments, I am going to uncouple signal-dependent chromatin 
changes and mechanisms in transcriptional activation. The pivotal role of the Elk-1 
activation domain will be emphasised. 
This project was done in collaboration with Cyril Esnault. 
5.2 TCFs but not MRTFs are required to induce IEGs in 
response to TPA 
The Ternary complex factors (TCFs) are nuclear MAPK substrates. Each 
TCF protein is able to form a ternary complex with SRF at IE genes such as c-Fos, 
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Egr1, Egr2 and others (Dalton & Treisman 1992; Esnault et al. 2014). Although 
TCFs can act redundantly with other ETS proteins independently of SRF 
(Hollenhorst et al. 2011), a defined subset of SRF-dependent genes are regulated 
in response to MAPK activation and require TCFs’ functions (Esnault et al. 2014). 
TCF-dependent gene activation involves the recruitment of subunits of the Mediator 
complex, Pol II entry and escape in response to Erk activation (G. Wang et al. 
2005; Stevens et al. 2002). Erk activation has been shown to favour defined 
chromatin modifications and gene activation in other contexts (Vicent et al. 2006). 
We used the RAS/Erk/TCF signalling pathway as a working model in order 
to dissect specifically the establishment of active chromatin signatures in response 
to ectopic stimulation. Mouse Embryonic Fibroblasts (MEF) available in the lab 
lacking Elk-1, SAP-1 and Net activities (named ESN standing for, Elk-1-/-SAP-1-/-
Net∂/∂) provided us with a powerful tool to study the mechanism of transcriptional 
activation and chromatin modification. As described in Chapter 7 this cell line 
shows a reduced growth rate and a block in cell cycle. Reconstitution experiments 
with Elk-1 suggest that all three members are required for normal proliferation, as 
Elk-1 alone seems insufficient (see chapter 7 for full description and chapter 8 for 
discussion). 
In order to define the adequate stimulus to specifically activate the TCFs, 
Cyril Esnault compared serum and TPA stimulation (12-O-Tetradecanoylphorbol-
13-acetate, a potent PKC activator able to induce Ras stimulation; see Chapter 1) 
in wild type and ESN MEFs. A panel of eight genes were selected, including known 
SRF/TCF-dependent (Egr1, Egr2, Fos, Egr3, Ier2 and Nr4a1) and SRF/MRTF-
dependent genes (Srf and Vcl). TPA specifically activates the SRF/TCF-dependent 
gene set in wild type MEF leaving Srf and Vcl unaffected (Figure 5.1A and 5.2A). 
On the other hand ESN MEF showed no accumulation of RNA for both SRF/TCF 
and SRF/MRTF specific targets upon TPA stimulation (Figure 5.1A and 5.2A). We 
noticed that LatB and U0126 (a MEK specific inhibitor) had context specific effects. 
Genes such as Egr1, Ier2, Fos and Nr4a1 showed sensitivity to U0126 while no 
effect following LatB was observed. On the other hand genes like Egr2 and Egr3 
were shown to be impaired by both compounds following TPA activation. Although 
this observation would imply that MRTF could also be involved in the activation of 
these genes, it is important to consider that in ESN MEF following TPA both Egr2 
and Egr3 did not show efficient induction. By contrast serum stimulation induced 
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most of the SRF/TCF and SRF/MRTF-specific genes, in both wild type and ESN 
MEFs (Figure 5.1B and 5.2B). The serum response detected in ESN MEF at 
SRF/TCF targets showed LatB sensitivity, suggesting that the TCFs could be 
substituted with the MRTFs in response to Rho activation. This is supported by the 
fact that in ESN MEF the response to serum was not affected by U0126 treatments 
while a clear LatB sensitivity was recorded across all targets (Figure 5.1B). We 
therefore considered TPA a good way to specifically activate TCF-dependent target 
genes. As shown in Figure 5.2A TPA quickly activates IE genes allowing 
accumulation of mature mRNA within 45 minutes of stimulation.  
In order to confirm that the defect observed in ESN MEF was uniquely due 
to a loss in transcriptional-related mechanism we compared the kinetic of Erk 
activation in wild type and ESN MEFs using a phospho-specific antibody for Erk1/2 
(Figure 5.3A). ESN MEF, like the wild type cell line, showed a quick Erk1/2 
activation within 5 minutes of TPA stimulation (Figure 5.3A and B). Furthermore, 
while in wild type MEF the quick activation was followed by a rapid shutdown, in 
ESN MEF the attenuation of active Erk1/2 was shown to be slower (Figure 5.3B). 
This phenomenon might be caused by loss of expression of Dusp phosphatases in 
ESN MEF. Dusp phosphatases are SRF-TCF targets involved in the down-
regulation of MAP Kinases by de-phosphorylation (Kondoh & Nishida 2007).  
The defect in activation could also be caused by a dishomogeneous 
response by the ESN MEF cell pool. To exclude this scenario we monitored the 
accumulation of Egr1 protein using FACS analysis across the cell population. 
Stimulation with serum for one hour allowed accumulation of Egr1 protein in both 
wild type and ESN MEFs confirming that the knock out cell line was 
transcriptionally competent and the response homogenous within the cell 
population (Figure 5.4A). On the other hand Egr1 protein was not expressed in 
ESN MEF following TPA stimulation corroborating the already described 
transcriptional defect (Figure 5.4B). 
5.3 Defined chromatin changes occur at Egr1 promoter 
following activation 
Activation of transcription correlates with defined chromatin changes 
including: histone H3 serine 10 phosphorylation (H3S10-P), a modification involved 
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in both transcription and cell division (S.-H. Yang et al. 2013); histone H3 lysine 4 
trimethylation (H3K4me3), a modification associated with promoters (Guenther et 
al. 2007); histone H3 lysine 9 and 14 acetylation (H3K9K14ac), H3K27ac and 
H4K16ac, associated with active genes and enhancers (Creyghton et al. 2010; 
Taylor et al. 2013), and macroscopic changes in nucleosome density (Gilchrist et 
al. 2010).  
In order to establish how chromatin changes occur in response to Ras 
activation we performed a chromatin IP time course of the listed chromatin 
modifications at the Egr1 model gene (Figure 5.5A). Following activation a clear 
reduction in H3 signal was observed starting at 15 minutes and continuing at 30 
minutes after TPA stimulation (Figure 5.5B). This change occurred mainly at the 
Egr1 TSS and within its ORF, probably due to PIC assembly and Pol II release. 
H3S10-P was shown to be the fastest mark to occur at the SRF-TCF binding site of 
Egr1 promoter (Figure 5.5C). Most of the H3S10-P signal was already detected 5 
minutes after TPA stimulation. Due to the possibility of epitope masking caused by 
acetylation of K9, further analyses are required. The use of different H3S10-P 
antibodies and antibodies able to recognise H3 N-terminal tail modified at both S10 
and K9 will be shown later in this chapter. 
Acetylation of lysine residues in positions 27, 9 and 14 of the histone H3 and 
lysine 16 of histone 4 showed similar kinetics with most signal detected 15 minutes 
after TPA stimulation and maintained at 30 minutes (Figure 5.5D, E and F). 
H3K27ac and H4K16ac occurred mainly at the SRF-TCF binding site while 
H3K9K14ac signal spread down to the TSS (Figure 5.5F). H3K4me3 was shown to 
be the most stable mark, being detectable also in resting conditions (Figure 5.5G). 
Noticeable changes occurred 30 minutes after TPA stimulation where the 
enhanced signal, like H3K9K14Ac, spanned from the SRF-TCF binding site down 
to the Egr1 TSS. 
Using this time course we also assessed Mediator and Pol II recruitment 
kinetics (Figure 5.6A). As showed in Figure 5.6 Med1, a major subunit of the 
Mediator complex, was recruited 15 minutes after TPA stimulation while Pol II was 
observed at 30 minutes (Figure 5.6A and B). The recruitment of Pol II at 30 minutes 
correlated with Egr1 RNA precursor accumulation, showing a marked spike at 30 
minutes following TPA stimulation (Figure 5.6C). 
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Taken together these observations show that TPA stimulation induces a set 
of chromatin modifications at Egr1 promoter. These modifications occur with a 
defined kinetic and spatial distribution. Mediator recruitment occurs concomitantly 
with the establishment of the chromatin signature. Finally Pol II recruitment and 
release occur in a separate time frame than the assessed histone modifications 
and correlates with the accumulation of RNA precursor. 
5.4 Signal induced chromatin changes at Egr1 promoter 
require the TCFs 
Having defined a set of chromatin modifications induced upon TPA 
stimulation we asked whether this chromatin signature required the presence of the 
TCFs. Using the bona fide Egr1 gene we assessed the distribution and appearance 
of the defined set of chromatin modifications comparing wild type and ESN MEFs. 
We considered 0.3% FCS and 30 minutes following TPA as informative time points. 
As described before, 30 minutes is the time point where we could observe changes 
at each selected chromatin mark, Mediator recruitment, Pol II recruitment and 
escape and importantly, accumulation of pre-mRNA (see previous section).  
As described, Egr1 expression was initially shown to be defective in ESN 
MEF when compared to the wild type cell line (Figure 5.7A). This defect was 
observed with both pre-mRNA and mature mRNA. Furthermore, not only were the 
ESN cells unable to activate Egr1 in response to TPA, they also showed a reduced 
baseline in resting condition. This defect was consistent with a loss in Pol II 
recruitment and escape, while SRF binding was mostly unaffected (Figure 5.7B). 
Occupancy of histone H3 in wild type and ESN MEFs was significantly different 
(Figure 5.7C). In ESN MEF overall H3 showed a higher signal than in wild type 
cells and upon TPA stimulation there was no change in H3 density within the ORF, 
corroborating the missing Pol II. In response to TPA H3S10-P, H3K27ac, H4K16ac 
and H3K9K14ac showed no change in ESN MEF while, as described before, in a 
wild type context a marked increased was measured at the SRF/TCF binding site 
with H3K9K14ac spreading down to the TSS (Figure 5.7D to G). H3K4me3 as 
previously described was the least changing chromatin mark in response to TPA. In 
ESN MEF it was possible to see an overall reduction of H3K4me3 (Figure 5.7H). 
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In conclusion TCFs are essential to activate bona fide targets and establish 
a signal-dependent chromatin signature at the Egr1 promoter. In the following 
sections I am going to provide further insight using reconstitution experiments of 
the ESN MEF using Elk-1 wild type and different mutants. 
5.5 IE gene activation requires two defined features in Elk-1 
activation domain 
TCFs are transcription factors equipped with a well-characterised activation 
domain (AD) towards their C-terminus. The role of the activation domain in 
transcription has been extensively studied. As reported by our lab and the Arnold 
Berk lab, a series of Ser/Thr sites decorate Elk-1 AD and are phosphorylated upon 
Ras-dependent Erk activation (Marais et al. 1993; Balamotis et al. 2009). These 
phospho residues are not the only elements required to induce transcription. Two 
key hydrophobic residues, embedded within the AD, are also required in order to 
activate target genes in response to signal. Studies conducted in the Berk lab 
elucidated the interplay between phospho and hydrophobic elements in 
coordinating the interaction with subunits of the Mediator complex (Balamotis et al. 
2009). In particular Elk-1, a member of the TCF family, was shown to specifically 
interact with subunit 23 of the Mediator complex. Such an interaction occurs in a 
signal-dependent manner and requires both phospho and hydrophobic residues. 
Intriguingly, mutations or deletion of the hydrophobic residues (FW), although 
detrimental for Med23 interaction and gene activation, do not affect Elk-1 
phosphorylation (Figure 5.8A). 
In order to investigate the role of the Elk-1 activation domain in TCF-
dependent gene activation I ectopically expressed Elk-1 variants in ESN MEF. As 
previously reported in the lab SAP-1 and Elk-1, but not Net, are functionally 
equivalent and can be substituted for thymocyte positive selection (Costello et al. 
2010). ESN MEFs were infected with retroviruses expressing Elk-1 wild type, Elk-1 
FW (variant with FW residues in position 378 and 379 deleted) or Elk-1 Nona 
(variant with alanine substitutions for each of the nine S/T-P site within Elk-1 AD), 
together with GFP (see Matherials and Methods). Each infected cell population was 
FACS-sorted into three subpopulations (low, medium and high) according to the 
GFP expression and cell pools expressing comparable amounts of Elk-1 protein 
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were selected for further analysis (Figure 5.8A and B). The knock out cell line was 
also infected with retrovirus harbouring only the vehicle as control. 
Stimulation with TPA for 30 minutes reduced the mobility of the wild type 
and FW Elk-1 protein but left the Nona mutant unaffected (Figure 5.8B). This 
observation is consistent with a complete loss of Erk-dependent phospho-residues 
within the Elk-1 Nona AD. To further characterise the reconstituted cell lines I 
compared the binding of exogenous Elk-1 proteins expressed (Figure 5.9A). 
Chromatin IP experiments using a FLAG antibody did not show a detectable signal 
in any of the reconstituted cell lines (data not shown). The FLAG epitope was 
probably masked as fused to the N-terminal region of each mutant, close to the 
DNA binding domain. I therefore purified an in-house anti-mouse Elk-1 (aa309–
429) antibody, able to recognise sequences at the C-terminal part of each mutant, 
against a peptide mapping across Elk-1 AD with alanine substitutions at each S/T-
P site. As shown in Figure 5.9 A ChIP experiment using this antibody showed a 
comparable signal for each mutant at the Egr1 promoter. Furthermore SRF binding 
was partially induced by each Elk-1 variant, if compared to the ESN MEF infected 
with vehicle only (Figure 5.9B). Furthermore TPA stimulation allowed Med1 and Pol 
II recruitment only in cells expressing Elk-1 wild type, consistent with the model that 
both phospho and hydrophobic residues are required for Mediator recruitment and 
target gene activation (Figure 5.10A and B). 
Finally I characterised the transcriptional outcome of each reconstituted cell 
line compared to the parental wild type and ESN MEFs (Figure 5.11). 
Reconstitution with Elk-1 wild type allowed similar TPA-induced expression of Egr1, 
Fos, Ier2 and Egr2 if compared to parental MEF carrying all three TCF (Figure 
5.11). On the other hand Elk-1 FW and Nona reconstituted cell lines did not show, 
in response to TPA, efficient gene induction (Figure 5.11). 
In summary we established a set of reconstituted cell lines expressing 
comparable amounts of Elk-1 wild type, Elk-1 FW and Elk-1 Nona. Each Elk-1 
mutant showed comparable binding efficiency and as previously reported only Elk-
1 wild type was able to induce transcription via Mediator and Pol II recruitment. 
Mutation of the FW hydrophobic residues, although affecting Mediator recruitment 
and activation of transcription, allows Erk-dependent phosphorylation of Elk-1 AD. 
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5.6 Elk-1 wild type is sufficient to re-establish signal induced 
chromatin changes at Egr1 promoter 
The experiments described in section 5.3 strongly suggest that any signal-
induced chromatin modification can occur only in the presence of defined TFs. 
Within this context the TCFs might work as anchoring factors, dictating the exact 
positioning of modifications in relation to the targeted gene.  
Having established a set of reconstituted ESN MEF cell lines (see section 
5.4) we initially assessed if Elk-1 wild type was sufficient to allow a correct 
chromatin signature at the Egr1 promoter. Strikingly, wild type Elk-1 (Elk-1 WT) 
established a correct chromatin signature, comparable to wild type MEF (Figure 
5.12). In particular H3 showed a reduced signal when the Elk-1 WT cell line was 
induced via TPA at Egr1 TSS and within its ORF (Figure 5.12 B). H3S10-P, and co-
occurrence of S10-P and K9Ac, showed a marked induction at the SRF/TCF 
binding site (Figure 5.12C and D). Similarly acetylation of residues K27, K9 and 
K14 of histone H3 together with K16 of histone H4 were induced upon TPA 
stimulation in ESN MEF rescued by Elk-1 WT (Figure 5.12 E to G). A similar 
H3K9K14ac profile was also achieved (Figure 5.12G). Lastly H3K4me3 was 
enhanced in ESN MEF expressing Elk-1 WT (Figure 5.12H).  
In conclusion chromatin changes at the Egr1 promoter relies on the TCFs. 
Elk-1 is sufficient to re-establish a correct response in terms of transcriptional 
activation and chromatin signature modifications. This framework provides us with 
an immense tool to dissect the relationship between signal, chromatin changes and 
transcription.  
5.7 Contribution of Elk-1 features in establishing chromatin 
signatures at Egr1 promoter 
As introduced earlier the mechanism of transcriptional activation guided by 
the TCFs involves the recruitment of subunits of the Mediator complex that in turn 
allow Pol II promoter entry. This mechanism requires defined features within the 
TCF AD including S/T-P sites and hydrophobic residues. Elk-1 is the best-
characterised TCF. Two defined residues (FW) surrounded by a series of S/T-P 
sites could be specifically targeted to impair Elk-1 mediated transcription without 
Chapter 5. Results 
 
 172 
affecting their association to genomic loci (see Chapter 1 and previous sections). 
These observations imply that the Ras induced signalling cascade can still reach 
the Elk-1 FW mutant at target gene promoters. 
To our surprise it was possible to observe, upon TPA stimulation, the 
induction of several chromatin marks in cells reconstituted with Elk-1 FW (Figure 
5.13). No change was observed at the level of histone H3 signal for both Elk-1 FW 
and Nona (Figure 5.13A). On the other hand a marked induction of H3S10-P, 
H4K16ac and H3K9K14ac was detected only at the SRF-TCF binding site in Elk-1 
FW (Figure 5.13B,C, E and F). Elk-1 Nona showed no enhancement of these 
modifications. H3K27ac was overall higher in resting and stimulated conditions in 
both Elk-1 FW and Nona (Figure 5.13 D). Despite this higher baseline H3K27ac did 
not show any induction upon TPA in cells harbouring Elk-1 FW or Nona. In addition, 
direct comparison of H3K27ac signals highlights an overall impairment in cells 
reconstituted with the FW and Nona mutants (Figure 5.14 A). H3K4me3 was highly 
enhanced in both Elk-1 FW and Nona with a different distribution than with Elk-1 
WT (figure 5.13 G and 5.14 A for comparison). Intriguingly H3K9K14ac also 
showed a different distribution in Elk-1 FW when compared to the Elk-1 WT (Figure 
5.13 F and 5.14 A). In particular the TPA-dependent enhancement of this 
modification in Elk-1 FW was restricted at the SRF-TCF binding site while in the 
wild type context this modification spread towards Egr1 TSS (figure 5.14 A). 
Recently provocative publications proposed that defined chromatin 
signatures could per-se induce transcription via recruitment of the pTEF-b complex 
(Zippo et al. 2009). To this end we assessed the recruitment of CDK9 at the Egr1 
promoter following TPA stimulation in reconstituted ESN MEF. While cells 
expressing Elk-1 wild type showed detectable signal for p-TEFb at Egr1 TSS, no 
signal could be detected in cells expressing Elk-1 FW or Nona (Figure 5.14 B). 
In conclusion it is possible to uncouple defined chromatin changes from the 
transcription process. Chromatin modification can occur in response to Elk-1 DNA 
binding or as a result of Elk-1 AD phosphorylation at the SRF/TCF binding site. A 
complete shaping of the chromatin changes is achieved through recruitment of the 
transcription machinery that seems to enhance H3K4me3 and H3K9K14ac at Egr1 
TSS. The histone modifications observed in cells expressing Elk-1 FW are not 
sufficient to induce recruitment of p-TEFb at Egr1 promoter. 
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5.8 Elk-1 activation domain is required to maintain a 
permissive chromatin at Egr1 ORF 
It has been recently reported that Erk2 and Elk-1 genomic distribution 
account for diverse transcriptional states in human ESc (Göke et al. 2013). Elk-1 
and Erk2 co-localisation describe actively transcribed genes involved in cell cycle 
and proliferation while Elk-1 alone seems to enhance H3K27me3 and repress 
transcription. Lysine 27 tri-methylation at histone H3 (H3K27me3) is a modification 
associated with silenced and bivalent polycomb-associated chromatin (Bernstein et 
al. 2006). In order to assess if TCF activities provide an antagonistic mechanism to 
silenced chromatin we analysed the distribution of H3K27me3 in different cell 
contexts.  
The signal for H3K27me3 was overall low for both ESN MEF and wild type 
MEF (Figure 5.15 A). H3K27me3 showed no enrichment at Egr1 promoter and 
gene body in any of the conditions examined. This observation was consistent with 
the ability to stimulate IE genes in ESN MEF with serum instead of TPA, probably 
through MRTF activity (see section 5.1). To our surprise MEF expressing Elk-1 
Nona showed the opposite, a striking enhancement of H3K27me3 that from the 
TSS was invading the Egr1 gene body (Figure 5.14 B). ESN MEF infected with Elk-
1 WT or FW did not show this enrichment in H3K27me3 suggesting that the S/T-P 
sites per-se were sufficient to maintain a permissive chromatin even in resting 
conditions. Elk-1 Nona possibly works as a dominant negative overcoming the 
positive effects of other TFs at the Egr1 promoter. Recent publications have 
described how Erk constantly shuttles from the cytoplasm to the nucleus 
maintaining a basal level of transcription (Aoki et al. 2013). These stochastic events 
might be responsible for maintaining permissive chromatin at IE genes. Further 
studies are required to highlight the mechanisms responsible for H3K27me3 
appearance in MEF expressive Elk-1 Nona and the possible role of polycomb in 
establishing this chromatin signature. 
5.9 Summary 
In this chapter I described how a defined chromatin signature could be 
established in response to TPA at the IE gene Egr1. All TCFs are required to 
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induce several changes at the Egr1 promoter and reconstitution of knock out cells 
with Elk-1 wild type protein is sufficient to re-establish a correct chromatin signature 
and gene expression if compared to wild type MEF. The contributions of defined 
features embedded within Elk-1 AD were dissected highlighting the requirement of 
both S/T-P sites and the two hydrophobic residues FW for IE gene stimulation. 
Furthermore it was possible to disentangle chromatin changes and transcriptional 
activation. Phosphorylation of Elk-1 is sufficient per-se to enhance several 
chromatin modifications while others only require Elk-1 DNA binding activity. 
Furthermore it was possible to observe that in resting conditions intact S/T-P sites 
within the Elk-1 AD are required to maintain a permissive chromatin at Egr1 
promoter. 





Figure 5.1 TCF-dependent gene activation in response to serum or TPA. 
(A) Activation of TCF and MRTF dependent genes in response to TPA in wild type 
MEF and ESN. Cells were serum starved for 48h and stimulated for 30 minutes 
with TPA. Pre-treatment of U0126, LatB or a combination of the two was done 30 
minutes before TPA stimulation. (B) Activation of TCF and MRTF dependent target 
as in panel A in response to serum stimulation. Egr1, Egr2, Egr3, Fos, Ier2 and 
Nr4a1 are TCF-dependent targets. Srf and Vcl are MRTF dependent targets. RNA 
was collected and quantified by RT-PCR. The values are expressed as relative to 
Gadph abundance (This data was collected by Cyril Esnault). 





Figure 5.2 TCF-dependent IEGs activation. 
(A and B) Time course stimulation of wild type or ESN MEFs with TPA (panel A) or 
serum (panel B) for TCF-dependent targets. Cells were serum starved for 48h and 
stimulated for 15, 30, 45, 60, 90 and 120 minutes. The collected RNA was 
quantified with RT-PCR and normalised to gapdh. Red line shows the expression in 
wild type MEF while the black line shows the induction in ESN MEF. 





Figure 5.3 Erk1/2 activation in response to TPA in wild type and ESN MEFs. 
(A) Western blot analysis of cell extract obtained from either wild type MEF (left) or 
ESN MEF (right) after treatment with TPA for 5, 15, 30, 45, 60, 90 and 120 minutes 
following 48h serum starvation. The antibodies used are phospho-p44/42 (Erk1/2) 
(Thr202/tyr204) (top) or control antibody p44/42 MAPK (Erk1/2) (bottom). (B) 
Quantification of the phospho-p44/42 antibody signal from a triplicate experiment 
as in panel A normalised to control p44/42 signal. 





Figure 5.4 Egr1 protein accumulation after serum or TPA in wild type or ESN 
MEFs. 
Analysis by flow cytometry of Egr1 protein expression after FCS (panel A) or TPA 
(panel B) stimulation for wild type or ESN MEFs. Cells were starved for 48h and 
stimulated for 1h with either FCS or TPA. Cells were ethanol fixed, permeabilised 
and stained with primary antibody against Egr1 following a secondary antibody Cy3 
labelled recognising the primary antibody. A negative control was included where 
only the secondary Cy3 labelled antibody was used (black line, ‘Negative 
population’) 
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Figure 5.5 Establishment of a chromatin signature at Egr1 promoter in response 
to TPA. 
(A) Representation of the Egr1 gene illustrating the positions of different probes 
along the gene. Exons are indicated with 5’UTR and 3’UTR in grey and coding 
sequences in black; SRF binding site is indicated with a red circle. (B to G) ChIP 
experiments using the indicated antibody. At the top of each panel is the profile at 
Egr1 gene while at the bottom is the kinetic of the signal at the coordinate showing 
the best signal (for Total H3 at the TSS, for H3S10-P, H3K27Ac, H4K16ac and 
H3K9K14ac at the SRF binding site while for H3K4me3 at the Egr1 TSS).  





Figure 5.6 Med1 and Pol II recruitment following TPA stimulation at Egr1 
promoter correlates with pre-mRNA accumulation. 
(A and B) ChIP time course of Med1 (panel A) and Pol II (panel B). At the top of 
each panel is the profile at Egr1 gene while at the bottom is the kinetic across the 
time course of the signal at the coordinate showing the best signal (for Med1 at the 
SRF binding site while for Pol II at Egr1 TSS). The coordinates on the x-axes refer 
to Figure 4.5A. (C) Egr1 pre-RNA accumulation over the same time course and 
including 45, 60, 90 and 120 minutes following TPA stimulation.  





Figure 5.7 Egr1 chromatin signature requires the TCFs. 
(A) Expression of pre-RNA (left) and mRNA (right) of Egr1 after 30 minutes TPA 
stimulation in wild type MEF (red) and ESN MEF (black). (B to H) ChIP using the 
indicated antibodies at Egr1 gene. Dashed lines indicate resting condition while the 
continuous line shows 30 minutes TPA stimulation. In red is the wild type MEF 
profile while in black are the ESN MEF profiles. The coordinates on the x-axes refer 
to Figure 4.5 A. 
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Figure 5.8 Establishment of reconstituted ESN MEF cell lines. 
(A) Schematic representation of the mutants used in the reconstitution. Human Elk-
1 is a 428 amino acid polypeptide consisting of three domains: ETS DNA-binding 
domain (green) at the N-terminal part; a B-box involved in SRF interaction (yellow); 
activation domain (red) harbouring S/T-P sites and two hydrophobic residues FW. 
The ability of each mutant to interact with Mediator, being phosphorylated by Erk 
and to activate transcription is reported on the right hand side of the panel. (B) 
Western blot of protein extract obtained for each reconstituted cell line in serum 
starved (top) and TPA stimulated conditions (bottom). SRF was used as a loading 
control while an anti-FLAG antibody was used to show the exogenous proteins. 
The samples are obtained from Chromatin preparations later used for ChIP 
experiments. Each replicate correspond to the one used in ChIP experiments. 





Figure 5.9 Elk-1 and SRF binding at Egr1 promoter in reconstituted cell lines. 
ChIP using an anti-Elk-1 antibody (A) and an anti-SRF antibody (B) across cells 
expressing different Elk-1 derivatives and vehicles (black line). Dashed lines 
represent serum-starved cells while continuous lines represent TPA stimulated 
conditions. In red are ESN MEF infected with retrovirus expressing Elk-1 wild type, 
in blue with Elk-1 FW and in purple with Elk-1 Nona. The coordinates on the x-axes 
refer to Figure 4.5 A. 





Figure 5.10 Elk-1 AD coordinates Mediator and Pol II recruitment at Egr1 
promoter. 
ChIP experiments using an anti-Pol II (8WG16) (A) and an anti-Med1 antibody (B) 
across the reconstituted cell lines. The coordinates on the x-axes refer to Figure 
4.5 A. 





Figure 5.11 SRF/TCF-target genes expression in reconstituted cell lines. 
Expression analysis of reconstituted cell lines after TPA stimulation. At the left hand 
side of each panel is the expression level in parental cell lines: Wild type MEF 
(grey) and ESN MEF (white). On the right hand side of each panel the expression 
of target genes is shown in reconstituted ESN MEF: control infection (black), Elk-1 
wild type (red), Elk-1 FW (blue), Elk-1 Nona (purple). The targets analysed are 
Egr1 at pre-RNA and mRNA, Fos at pre-RNA and mRNA, Egr2 and Ier2 at the 
mRNA level. 





Figure 5.12 Elk-1 wild type is sufficient to re-establish chromatin changes at Egr1 
promoter. 
(A) Representation of the Egr1 gene illustrating the positions of different probes 
along the gene. Exons are indicated with 5’UTR and 3’UTR in grey and coding 
sequences in black; SRF binding site is indicated with a red circle. (B to H) ChIP 
experiments using the indicated antibody.  
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Figure 5.13 Elk-1 DNA binding and activation domain activities contribute to 
defined chromatin changes in absence of transcription. 
(A to G) ChIP experiments using the indicated antibody in ESN MEF reconstitute 
with either Elk-1 FW (blue) or Elk-1 Nona (purple) across the Egr1 gene. The 
coordinates on the x-axes refer to Figure 4.12 A. 
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Figure 5.14 Chromatin changes are not sufficient for p-TEFb recruitment. 
(A) Comparison of the ChIP signal across Egr1 promoter of reconstituted ESN 
MEFs with control (black), Elk-1 wild type (red), Elk-1 FW (blue) and Elk-1 Nona 
(purple) for the TPA stimulated condition. The data presented is as in Figure 5.13. 
The antibodies used are shown at the top of each graph. Dotted line shows the 
TSS position of the Egr1 gene. (B) ChIP of CDK9 at Egr1 gene in ESN MEF 
reconstituted with Elk-1 derivative using the same colour code as in panel A. The 
dashed line shows 0.3% FCS condition while the continuous line shows the TPA 
stimulated conditions 





Figure 5.15 Elk-1 activation domain is required to maintain a permissive 
chromatin at Egr1 ORF. 
(A) ChIP using an H3K27me3 antibody in Wild type MEF (red) or ESN MEF 
(black). The signal is shown relative to the signal obtained with anti-H3 (see Figure 
5.7, 5.12 and 5.13). (B) ChIP using an H3K27me3 antibody in ESN MEF 
reconstituted with Elk-1 wild type (red), Elk-1 FW (blue) and Elk-1 Nona (purple). 
The signal is shown relative to the signal obtained with anti-H3 (see Figure 5.12 
and 5.13). 
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Chapter 6. TCF-dependent activation requires a 
defined set of chromatin remodellers and modifiers 
6.1 Aim 
TCF-dependent activation, as described in Chapter 5, involves a defined set 
of chromatin changes that rely on the TCFs. Chromatin modifications per-se are 
not sufficient to induce transcription while a correct interplay between signal-
induced chromatin changes and the transcriptional machinery is mediated by the 
TCF AD. In order to characterise the role of the observed chromatin modifications 
we aimed to identify the modifiers and remodellers involved in TCF-dependent 
gene activation. The data presented in this chapter is preliminary as we are 
currently collecting further data in order to validate these observations. I am going 
to present what has so far been analysed. 
6.2 Medium-throughput siRNA screen and validation 
To identify chromatin modifiers involved in immediate-early gene expression 
we used a medium-throughput siRNA approach. To reduce complexity, we focused 
on catalytically active proteins amongst the ~1000 chromatin-modifiers and 
remodellers (Fazzio et al. 2008). We selected 50 genes including 13 
methyltransferases, 14 acetyltransfearses, 7 kinases, 5 phosphatases and 9 
remodellers (Figure 6.1A). The siRNA screen also included two control oligos, with 
no target in mouse cells, and two positive controls such as Srf and Med23, known 
to be essential for TCF-dependent gene activation. The siRNA screen was 
performed in wild type MEF harbouring all three TCFs. 
The initial phase of the screen was performed using the Dharmacon ON-
target plus siRNA pools for each of the 50 targets. Each pool comprises four 
independent siRNA duplexes against the target genes. Four readouts, consisting of 
pre-RNA and mature RNA of both Egr1 and Fos gene, were monitored by 
quantitative PCR. The knockdown of Srf was used as parameter for siRNA efficacy 
and as a threshold for significant reduction in gene expression after TPA 
stimulation.  
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An On-target pool was considered a hit if it was impairing at least 3 out of 4 
readouts, with a reduction of at least 20% (minimum reduction observed for Fos 
mRNA after Srf knockdown) (Figure 6.2). The expression of Egr1 and Fos showed 
a good correlation at both pre-mRNA and mature RNA (Figure 6.1B). A higher 
fluctuation was observed at the pre-RNA level reflecting its reduced stability if 
compared to mRNA of both targets. This initial screen allowed us to select 13 
potential candidates (Figure 6.2). 
To validate the hits selected from the initial phase, a deconvolution 
secondary screen was performed in which the four duplexes, from each of the 13 
hits were individually screened at a final concentration of 20nM (Figure 6.3). We 
considered hits those that showed at least two out of four oligos impairing at least 3 
out of 4 readout (using the same threshold as in phase 1) (Figure 6.3). We selected 
a final list of 7 targets shown to impair the TPA response of both Egr1 and Fos. 
This refined group included the methyltransferase MLL3, known to methylate lysine 
4 of the histone H3 (H3K4) (Y.-W. Cho et al. 2007); the chromatin remodeller 
CHD2, known to interact with H3K4me3 and deposit histone H3.3 at the TSS of 
active genes (J. A. Hall & Georgel 2007); the methyltransferase Set7 (KMT7), 
known to mono-methylate H3K4 and associate with Tat proteins to stimulate Pol II 
elongation (Rice 2010); the SET domain-containing protein SMYD2 (KMT3C), 
reported to methylate H3K4 and demethylate H3K36me2 (Brown et al. 2006); the 
helicase Ruvbl2 (Tip49b), part of the Nua4 complex involved in histone acetylation 
and chromatin remodelling in conjunction with the SWR1-like complex (Kanemaki 
et al. 1999); the acetyltransferase Tip60 (KAT5), shown to specifically acetylate 
Lysine 16 of the histone H4 (K. K. Lee & Workman 2007); and the kinase Aurora-B 
(AURKB) that phosphorylates histone protein during cell division and recently was 
shown to associate to defined promoters in quiescent lymphocytes (Frangini et al. 
2013). 
6.3 Aurora-B is specifically required for TCF-dependent gene 
activation 
The siRNA screen we performed provided us with a limited number of 
potential modifiers and remodellers involved in TCF-dependent gene activation. We 
initially focused on the validation of Aurora-B as for us it was the most unexpected 
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hit in the screen. Aurora proteins are kinases essential for cell proliferation, 
controlling chromatid segregation by phosphorylating H3S10 residues leading to 
HP1 disassociation from heterochromatin during mitosis (Fischle et al. 2005). 
Aurora-A is also involved in cell proliferation and cell division, therefore in order to 
discount negative effects in transcriptional activity we compared the knockdown of 
both Aurora A and B and their effects in Egr1 and Fos activity. Only Aurora-B 
knockdown was specifically affecting Egr1 and Fos expression after TPA 
stimulation (Figure 6.4 A). Strikingly this impairment was observed only at TCF-
dependent targets, as down-regulation of Aurora-B did not affect Acta2 expression 
(an SRF-MRTF-specific target) after CD or serum stimulation (Figure 6.4 B). 
In order to exclude long-term effects caused by impairing Aurora-B 
expression we selected two compounds affecting Aurora-A and Aurora-B activities 
(Figure 6.4 C). Cells were treated for 5 minutes with each compound before 
treating for 30 minutes with TPA. Most of these compounds have a wide spectrum 
of action, as they are designed to compete for ATP in the active site of the target 
kinase. Hesperidin, an Aurora-B specific drug with IC50 of 250nM and no effect on 
MAPKs (Hauf et al. 2003), reduced of 50% the induction in both Egr1 and Fos 
expression following TPA (Figure 6.4C). This observation corroborates a direct 
involvement of Aurora-B in TCF-dependent gene activation. The compound known 
to affect only Aurora-A did not show significant effect. 
6.4 Preliminary dissection of signal-induced chromatin 
modification at Egr1 promoter 
In order to investigate the role of the selected modifiers and remodellers in 
TCF-dependent gene activation we performed ChIP experiments following down-
regulation of each separate modifier and remodeller selected from the siRNA 
screen.  
This assay was optimised with SRF and MED23 siRNAs against a non-
targeting siRNA as a control. It was possible to observe a down-regulation of Egr1 
expression following SRF and MED23 knockdown (Figure 6.5A). Reduction of Egr1 
expression correlated with a reduction of SRF and Pol II ChIP signal for the SRF 
knockdown (Figure 6.5C and D). On the other hand MED23 knockdown did not 
affect SRF ChIP signal while it reduced Pol II signal at the Egr1 promoter (Figure 
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6.5C and D). Most chromatin changes were left unaffected after knocking down 
SRF (Figure 6.5E to H). SRF knockdown seemed detrimental for the TPA-
dependent H3K4me3 induction (Figure 6.5H). This observation suggests that the 
contributions of the TCFs and SRF for Egr1 activation are separable but both 
required for active transcription. TCFs are capable of interacting with genomic loci 
autonomously. The ETS binding motif, CAGGAT, initially found at the Fos promoter 
is degenerated at the Egr1 promoter. In particular the ETS motif CCGGAA at the 
Egr1 promoter could allow autonomous TCF DNA binding in the absence of SRF 
(Treisman 1994). Assessment of Elk-1, Sap-1 or Net binding in absence or reduced 
SRF levels could provide further insight. Is still important to consider the loss of 
H3K4me3 observed following SRF knockdown. This effect, together with the 
distribution of H3K4me3 mostly at the TSS, suggests that in a wild type context the 
transcriptional machinery might primarily control the distribution of this mark. 
Having established the assay we proceeded with impairing the remodellers 
and modifiers selected with the siRNA screen. Only four out of the seven hits 
showed a clear effect on the chromatin signature. In particular Aurora-B knockdown 
had a clear effect on H3S10PK9ac (Figure 6.6 C). Despite a clear impairment of 
Egr1 pre-RNA accumulation, it was possible to observe only a 20% reduction in Pol 
II recruitment (Figure 6.6A and B). H3K27 and H3K9K14ac enhancement following 
TPA were also partially affected (Figure 6.6D and E). In addition it was possible to 
observe a clear effect on H3K4me3 mostly at the Egr1 TSS (Figure 6.6F) 
MLL3, CHD2 and SMYD2 knockdown were shown to impair few marks at 
the Egr1 promoter (Figure 6.7). KAT5, Tip49b and SET7 did not show significant 
changes. MLL3 and CHD2 only mildly impaired Pol II recruitment (10-20% 
reduction at the Egr1 TSS) (Figure 6.7B). A marked reduction in H3K4me3 when 
either MLL3 or CHD2 were knocked down was observed, consistent with their 
presumed activity (Figure 6.7F). Furthermore MLL3 and CHD2 knockdown were 
also shown to impair H3S10PK9ac and H3K27ac and only partially H3K9K14ac 
(Figure 6.7C, D and E). SMYD2 knock down did not affect most of the chromatin 
modifications analysed (Figure 6.8). H3K4me3 was the only modification that was 
impaired by SMYD2 knock down following TPA induction at Egr1 TSS (Figure 6.8F).  
Although only preliminary, these data suggest that Aurora-B, MLL3, CHD2 
and SMYD2 are playing a role in establishing chromatin modifications at the Egr1 
promoter in response to Ras activation. It is complicated to establish an order of 
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events given the data obtained. Overall MLL3 and CHD2 show the greatest effect 
on H3K4me3 while Aurora-B primarily impairs H3S10PK9Ac. In addition, 
knockdown of MLL3 and CHD2 seems to affect H3S10PK9Ac. Despite the clear 
effect on Egr1 RNA synthesis and chromatin modifications, the knockdown of the 
modifiers selected seems to only modestly affect Pol II recruitment and escape. 
SMYD2 seemed specific for H3K4me3 at Egr1 TSS potentially being specifically 
recruited by active Pol II at the transcriptional start site. Analysis of Pol II CTD 
modification and CDK9 recruitment are going to provide further insights into the 
transcriptional role of the chromatin modification studied. 
6.5 Summary 
In this chapter I presented preliminary data aimed at identifying chromatin 
modifiers and remodellers involved in TCF-dependent gene activation. A group of 7 
hits was selected from a siRNA screen assessing the expression of Egr1 and Fos 
at the pre-mRNA and mRNA level after knocking-down a panel of 50 target 
proteins. Aurora-B, MLL3, CHD2, Set7, Tip60, Tip49b and SMYD2 were selected. 
Only Aurora-B, MLL3, CHD2 and SMYD2 showed detectable impairment of defined 
marks at the Egr1 promoter. Further analyses are going to be essential in order to 
corroborate these observed effects. Assessments of additional histone 
modifications are going to be pivotal in the understanding of the relationship 
between different chromatin marks. 
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Figure 6.1 Phase 1 medium-throughput screening for chromatin-associated IE 
gene regulators in primary MEFs. 
(A) Selected targets divided by activity. 50 siRNA against diverse chromatin 
modifiers and remodellers were selected including 5 phosphatases, 7 kinases, 9 
remodellers, 14 acetyltransferases and 13 methyltransferases. Two negative 
controls including untreated cells (MOC) and a scrambled oligo (SCR) were used. 
Two positive controls including Med23 and SRF were included in the screen. (B) 
Scatter-plot representation of the results. (Left) Correlation between Fos and Egr1 
pre-mRNA, (right) correlation between Fos and Egr1 mRNA. The values are 
relative to the negative controls (green). Non-scoring targets (black), 4 out of 4 
(red), 3 out of 4 (purple) and the positive control Srf (yellow) are plotted. Dotted 
lines represent 20% reduction in expression. 





Figure 6.2 Phase one medium-throughput screen result. 
Representation of the selected hits described in figure 6.1B. In each graph the top 
dotted line is 1 while the bottom line mark the 20% reduction threshold defined. Hits 
scoring in 4 out of 4 (red) and in 3 out of 4 (purple) readouts are shown. The 
knockdowns of SRF following TPA are shown in yellow. The transfections of 
scrambled sequence or untreated cells (MOC) are shown in green. 
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Figure 6.3 Phase 2 medium-throughput screening for chromatin-associated IE 
gene regulators in primary MEFs. 
(A and B) Deconvolution experiment showing in black the 7 hits impairing both Fos 
and Egr1 pre-mRNA and/or mRNA. The results obtained for 22 oligos are 
displayed: 2 for each selected hit (black), 2 for the Med23 positive control (black), 2 
for the Srf positive control (yellow) and 4 negative controls (green). 






Figure 6.4 Aurora-B validation 
(A) Comparison of Egr1 and Fos expression following Srf, Aurora-A and Aurora-B 
knockdown using two independent oligos for each target. (B) Effect of Aurora-B 
knockdown on Acta2 expression following TPA, FCS or CD. (C) Aurora-B 
(Hesperadin, 200nM) and Aurora-A specific drug (Aurora Kinase Inhibitor III at 
200nM, Calbiochem) treatments assessing Egr1 and Fos expression. 5 minutes 
pre-treatment step with the indicated compounds followed by 30 minutes TPA 
stimulation.  
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Figure 6.5 siRNA ChIP experiment setup following SRF and Med23 knockdown. 
(A) RT-PCR of Egr1 pre-mRNA after TPA stimulation following knockdown of either 
SRF or Med23. (B) Representation of the Egr1 gene illustrating the positions of 
different probes along the gene. Exons are indicated with 5’UTR and 3’UTR in grey 
and coding sequences in black; SRF binding site is indicated with a red circle. (C to 
H) ChIP experiment, following transfection of cells with siRNA against SRF (blue), 
Med23 (brown) or Scramble (black), with the indicated antibody across Egr1 
promoter and ORF as in Chapter 5. 





Figure 6.6 Aurora-B dependent histone modifications in response to Ras 
activation. 
(A) RT-PCR of Egr1 pre-mRNA after TPA stimulation following knockdown of 
AuroraB. (B to G) ChIP experiment, following transfection of cells with siRNA 
against AuroraB (purple) or Scramble (black), with the indicated antibody across 
Egr1 promoter and ORF as in Chapter 5. 





Figure 6.7 MLL3 and CHD2 dependent histone modifications in response to Ras 
activation. 
(A) RT-PCR of Egr1 pre-mRNA after TPA stimulation following knockdown of MLL3 
and CHD2. (B to F) ChIP experiment, following transfection of cells with siRNA 
against MLL3 (red), CHD2 (yellow) or Scramble (black), with the indicated antibody 
across Egr1 promoter and ORF as in Chapter 5. 
 
 




Figure 6.8 SMYD2 dependent histone modifications in response to Ras activation. 
(A) RT-PCR of Egr1 pre-mRNA after TPA stimulation following knockdown of 
SMYD2. (B to G) ChIP experiment, following transfection of cells with siRNA 
against SMYD2 (purple) or Scramble (black), with the indicated antibody across 
Egr1 promoter and ORF as in Chapter 5. 
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Chapter 7. A genomic perspective on TCF-
dependent gene activation 
7.1 Aim 
In Chapters 5 and 6, based on bona fide TCF target genes, I described the 
pivotal role of the TCFs in coordinating chromatin changes and transcriptional 
activation in response to Ras activation. In this chapter I am going to present 
preliminary data aiming to generalise these observations using genomic 
approaches. Initially I am going to dissect the response to TPA stimulation in wild 
type and TCFs knock out MEF cell lines using RNA-seq approaches. Focus will be 
dedicated primarily to TPA induced genes and genes that don’t respond to TPA but 
whose baseline expression required the TCFs. TPA-repressed and TCF-repressed 
genes are also going to be considered. This analysis will be crossed with RNA-seq 
data obtained assessing the TPA response in reconstituted cell lines described 
earlier in Chapter 5. A functional analysis using DAVID is going to highlight the role 
of the TCF in cell growth and proliferation. Finally I am going to assess changes of 
a few chromatin marks genome-wide in different cell background for a selected set 
of Elk-1 controlled genes. 
7.2 Genomic dissection of TCF-controlled genes 
To determine the transcriptional output following TPA stimulation we initially 
analysed RNA-seq data obtained from wild type and ESN MEFs. As mentioned in 
Chapter 5 the cell lines used are phenotypically different. In particular it was 
possible to observe a reduced growth for cells lacking all three TCFs with a 
corresponding blockage in the cell cycle transition (Figure 7.1). Reconstitution with 
Elk-1 protein did not restore normal growth suggesting the possibility that either 
Sap1, Net or a combination of all three TCFs is required in order to maintain the 
expression of genes involved in cell cycle and proliferation (Cyril Esnaut personal 
communication). These observations are going to be essential for the interpretation 
of the ontology analysis that I will present later in this Chapter, as several indirect 
effects could also affect our analysis. 
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A differential gene expression analysis, based on a negative binomial 
distribution (Deseq), was applied. 2898 genes were shown to be induced while 
2130 showed a reduced expression in wild type MEF following TPA stimulation 
(Figure 7.2A). 871 genes, induced by TPA in wild type MEF, were shown to be 
impaired in ESN MEF. On the other hand 531 genes, whose expression was 
reduced upon TPA stimulation, were shown to have a higher expression in ESN 
MEF in both resting and TPA stimulated conditions (Figure 7.2 B). Although 
statistically significant the differences between unstimulated and TPA repressed 
are subtle. Furthermore it is possible to observe that this group of genes shows a 
higher baseline in ESN MEF if compared to wild type MEF, possibly caused by a 
TCF-dependent repression of their expression (Figure 7.2 B).  
We also considered genes non-induced by TPA whose baseline was 
changing in ESN MEF if compared to wild type MEF. 3745 genes showed a lower 
expression in ESN MEF suggesting a possible role of the TCFs in positively 
controlling their baseline expression (Figure 7.2 C). On the other hand 3627 genes 
showed a higher expression in ESN MEF if compared to wild type MEF (Figure 
7.2C). 
As strictly relevant to the project we initially focused on TPA-induced genes. 
Considering the behaviour of the model genes presented earlier, we can consider 
three transcriptional signatures for genes induced by TPA. Genes like Egr1, 
besides being less induced by TPA in ESN MEF, are showing a reduced baseline 
expression. This transcriptional signature could be assigned to genes with a 
transcriptional outcome that stringently relies on the TCFs. Genome-wide we could 
select 507 genes out of the 871 set with an impaired baseline in ESN MEF (Figure 
7.3A). A second class including Egr2 and Fosl1, composed of 320 genes, showed 
no change in baseline expression, probably due to the activity of further ETS 
members controlling their expression (Figure 7.3A). Finally a small group of 44 
genes, including Nr4a1, Fos and Ier2, showed a higher baseline in ESN MEF 
although their induced expression upon TPA was affected in knockout cell (Figure 
7.3A). Investigation of specific sequence motifs differentially enriched at the 
promoters of genes within each group will be highly informative to further elucidate 
the transcriptional signatures observed. The analysis proceeded including the 
RNA-seq data set obtained with cells reconstituted with Elk-1 wild type, FW and 
Nona. These rescue experiments allowed us to identify 92 genes where TPA 
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induced expression could be restored with Elk-1 wild type (Figure 7.3 B). On the 
other hand reconstitution with FW or Nona did not, suggesting that the selected 
targets are indeed Elk-1 controlled (Figure 7.3B). The selected group of genes 
looked fairly small if compared to the 792 genes impaired in ESN MEF. Despite the 
functional redundancy that has been reported between Elk-1 and SAP-1 (Costello 
et al. 2010), is conceivable that at the genomic scale differences could be observed. 
Sap-1 or even Net could potentially control the remaining genes where Elk-1 
seems insufficient.  
As mentioned above we conducted the same analysis on TPA repressed 
genes. As mentioned earlier this group of genes showed a higher baseline 
expression in ESN MEF if compared to wild type MEF (435 out of 531) (Figure 7.4 
A). Only 92 showed no change in baseline expression and 4 genes showed a 
reduced baseline in ESN MEF (Figure 7.4 A). The changes observed across 
conditions for the last two groups were subtle and possibly excluded by increasing 
the stringency of the statistical test used. Reconstitution with Elk-1 wild type was 
shown to re-establish a statistical significant reduction following TPA stimulation at 
just 16 of the selected genes (Figure 7.4 B). Also cells reconstituted with Nona and 
FW showed a lower expression of these genes following TPA (Figure 7.4 B). This 
observation suggests that the repression observed is not directly caused by the 
Elk-1 AD. 
Considering genes whose baseline expression was changing in ESN MEF, 
a wider group of 507 genes was rescued by the ectopic expression of Elk-1 wild 
type if compared to the control cell line (Figure 7.5 A). Consistent with a potential 
function of uniquely controlling the baseline expression of these genes, ESN 
reconstituted with Elk-1 Nona or FW showed a higher baseline if compared to the 
control (Figure 7.5 B). This observation suggests that these genes only require Elk-
1 DNA binding activity rather than its ability to respond to Ras signalling. On the 
other hand 587 genes, whose expression was enhanced in ESN MEF, showed a 
reduced expression when Elk-1 was ectopically expressed (Figure 7.5 C). Also for 
these groups of genes the Elk-1 mutants Nona and FW were lowering the baseline 
if compared to ESN infected with vehicle (Figure 7.5 D).  
In conclusion the TCFs control 30% of the TPA response in MEF cells. Elk-1 
is sufficient to control 10% of the TCF-dependent genes suggesting that Sap-1 or 
Net could probably contribute to the control of the remaining TCF-dependent set. 
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Further analysis including cell reconstitution with the other TCF members and a 
description of the different promoter context is going to provide further insights into 
the TCF-dependent gene regulation. 
7.3 TCFs regulate cell proliferation and cell cycle progression 
We analysed the functional categories enriched in each selected group of 
genes using DAVID (Huang et al. 2009). Genes potentially controlled by the TCFs 
were revealed to be involved mainly in transcriptional regulation and cell cycle 
control (Figure 7.6). A similar signature was also found when we analysed the 92 
genes directly controlled by Elk-1 (Figure 7.6). Furthermore genes controlled at the 
baseline level by Elk-1 showed almost identical functional categories. The ontology 
analysis was also performed for repressed genes. TCFs seemed involved in the 
repression of genes involved in cell differentiation, tissues and organ development 
and actin-linked processes. ESN MEF reconstituted with Elk-1 seemed to also 
negatively control some genes with similar functions. 
The identification of genes involved in cell cycle progression was intriguing 
as it has been recently described that Elk-1 together with Erk2 could control cell-
cycle related genes (Göke et al. 2013). As introduced earlier within this chapter 
ESN MEF are blocked in the cell cycle showing a reduced proliferation. Despite a 
clear enrichment in cell cycle related functions for genes controlled by Elk-1 it was 
not possible to observe the reestablishment of a correct proliferation for ESN MEF 
reconstituted with Elk-1 wild type (see section 7.2). This observation implies that 
SAP-1 and possibly Net are also required for a correct cell cycle progression. On 
the other hand this observation also implies that the functional categories enriched 
for the Elk-1 specific set are not indirectly caused by the reestablishment of 
proliferation. Elk-1 seems therefore to directly control genes involved in cell cycle, 
rather than controlling a few pro-proliferative genes that could promote a secondary 
response in cell cycle related genes.  
Reconstitution with the other TCF members is going to be pivotal in 
understanding the potential role of the TCFs in controlling cell cycle progression. It 
is clear from the analysis conducted that Elk-1, although incapable of restoring the 
complete transcriptional response in ESN MEF, is still able to control a 
considerable fraction of cell cycle related genes. 
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7.4 TCF-dependent shaping of chromatin modification at target 
promoters 
The analysis conducted above, besides describing the transcriptional 
signature in response to Ras activation, had the aim of selecting a reliable set of 
Elk-1 targets with which we could generalise the observations listed in Chapter 5. 
We combined the ChIP experiments described in Chapter 5 with deep sequencing. 
Here I will briefly describe the profiles observed for H3K4me3 and H3K9K14ac 
(Figure 7.8). The data presented does not take into account changes in histone 
occupancy. We are currently analysing changes in distribution of the various 
chromatin modifications specifically at the SRF/TCF binding sites in order to gain 
further insights and corroborate the data collected based on the Egr1 model gene. 
We conducted a preliminary analysis focusing on changes observed at the 
TSS of targets whose expression was shown to be Elk-1 dependent and sensitive 
to both FW and Nona mutations at p-values less than 0.05 (Figure 7.7). The 
selected group of targets showed to be overall closer to SRF. Both H3K4me3 and 
H3K9K14ac in a wild type context were shown to be enhanced upon TPA 
stimulation and to invade the area downstream of the TSS (Figure 7.9 A and 7.10 
A). ESN MEF did not show such an enhancement for either modification. 
Reconstitution experiments using Elk-1 wild type re-established the profiles 
observed in wild type MEF for both modifications (Figure 7.9 B and 7.10 B). The 
situation observed for ESN MEF rescued with Elk-1 FW or Nona was shown to be 
different. While Elk-1 Nona showed no induction of either modification (Figure 7.9 D 
and 7.10 D), Elk-1 FW allowed a partial enhancement of both H3K9K14ac and 
H3K4me3 close to the TSS (Figure 7.9 C and 7.10 C). The data presented does 
not consider changes in histone occupancy around the TSS potentially affecting the 
signal distribution of the observed histone modifications.  
Despite being only preliminary, these data confirm that chromatin changes 
can occur in the absence of transcription. A detailed analysis of the spatial 
distribution of each chromatin modification together with changes in histone 
occupancy is going to further elucidate the relationship between transcriptional 
activation and chromatin modifications. Furthermore it is going to be crucial to 
analyse changes observed at the SRF-TCF binding sites. In particular is going to 
be important to analyse the distribution of H3K4me3 at the SRF/TCF binding site in 
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TCF null fibroblasts reconstituted with Elk-1 Nona and FW in order to confirm the 
observations collected using the Egr1 model gene. 
7.5 Summary 
In this chapter, I have presented our initial approach for the generalisation of 
the observations collected and presented in Chapter 5 and 6. Using an RNA-seq 
based approach it was possible to describe the transcriptional response following 
TPA stimulation in cells lacking all TCFs. In particular TCFs control 30% of the 
genes activated in response to TPA. Reconstitution experiments showing that Elk-1 
suffices for the expression of 10% of these genes imply that SAP-1 and Net are 
also required to control the rest of the selected targets. Analysis of H3K4me3 and 
H3K9K14ac across the different cell lines showed that signal-induced chromatin 
changes could be disentangled from the transcriptional process. This analysis is 
going to be extended to the other chromatin modifications presented in Chapter 5 
considering the diverse groups of genes described with the RNA-seq analysis. 
Furthermore we will also consider changes at the SRF-TCF binding sites across 
the different reconstituted cell lines. 
The RNA-seq analysis was also extended considering genes whose 
expression was unaffected by TPA but whose baseline activity was controlled by 
the TCFs. 20% of these genes were rescued by Elk-1 ectopic expression. Genes 
positively controlled by the TCFs were functionally involved in transcription and cell 
cycle control. On the other hand genes whose expression was impaired by the 
TCFs were involved in cell differentiation and development. Indeed, cells lacking all 
TCFs showed a reduced proliferation if compared to wild type MEF. Furthermore 
reconstitution experiments using Elk-1 wild type showed no change in proliferation 
rate while the rescued genes could be assigned to the same functional classes. 
This observation allowed us to exclude indirect effects possibly caused by re-
establishing the proliferation. These data are going to be corroborated by 
reconstituting cells with SAP-1, Net or a combination of the three TCFs.  
 




Figure 7.1 TCFs regulate MEF proliferation 
(A) Crystal violet staining of cells grown for three days at different seeding density. 
(Top) wild type MEF (MEF WT) (Bottom) ESN MEF. (B) Cell proliferation curve 
over 4 days. Cells were harvested and counted using flow cytometry. (red) wild 
type MEF, (black) ESN MEF. (C) Analysis of the DNA content using propidium 
Iodate (PI) staining against Bromodeoxyuridine (BrdU) incorporation performed for 
4h. (D) Quantification of each cell cycle phase done in triplicate as in panel C. 
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Figure 7.2 TCF-dependent gene control in MEF 
RNA-seq analysis of genes induced or repressed by TPA (panel A and B) or whose 
baseline expression changes in ESN MEF (panel C). (A) Genes induced by TPA in 
wild type MEF are shown. (Left) 871 TPA-induced genes are affected in ESN MEF 
(red quadrant), being probable TCF-dependent targets, while 2027 are still induced 
in ESN MEF upon TPA stimulation (yellow quadrant). (Right) relative expression of 
the TCF-dependent TPA induced genes (n=871) in wild type and ESN MEFs before 
and after TPA stimulation. (B) Genes repressed by TPA in wild type MEF are 
shown. (Left) 531 TPA-repressed genes are affected in ESN MEF (light green 
quadrant) while 1559 are still repressed in ESN MEF upon TPA stimulation (dark 
green quadrant). (Right) relative expression of the TCF-dependent TPA-repressed 
genes (n=531) in wild type and ESN MEFs before and after TPA stimulation. 
Genes repressed upon TPA in wild type MEF were analysed in ESN MEF. We 
considered as TCF dependent those genes that were not anymore showing a 
statistical significant repression in ESN MEF following TPA (C) Genes non-
inducible by TPA are shown. (Left) 11581 show no change comparing wild type 
and ESN MEFs. 3745 requires the TCFs for their basal expression (blue) while 
3627 are active in the absence of the TCF (pink). (Right) Relative expression for 
TCF-induced and repressed in wild type and ESN MEFs. 





Figure 7.3 Elk-1 controls 10% of the TCF-dependent TPA-induced targets 
(A) (Left) Analysis of the baseline expression in ESN MEF against wild type MEF 
for TPA-induced TCF-dependent genes (n=871). 507 genes induced by TPA in a 
TCF-dependent manner showed reduced baseline in ESN MEF. 320 showed no 
changes in baseline expression and 44 showed enhanced baseline in ESN MEF. 
(Right) Relative expression across cell lines and conditions for the selected group 
of genes described. (B) Elk-1 is sufficient to control 10% of the TPA-induced TCF-
dependent genes. (Left) 92 targets out of the 871 selected showed to be re-
activated in ESN MEF reconstituted with Elk-1 wild type. (Right) Relative 
expression across cell lines for the 92 selected targets. Parental lines uninfected 
and reconstituted cell lines are displayed. 




Figure 7.4 TCFs repress the baseline expression of defined targets 
(A) (Left) Analysis of the baseline expression in ESN MEF against wild type MEF 
for TPA-repressed TCF-dependent genes (n=531). 435 genes repressed by TPA in 
a TCF-dependent manner showed enhanced baseline in ESN MEF. 92 showed no 
changes in baseline expression and 4 showed reduced baseline in ESN MEF. 
(Right) Relative expression across cell lines and conditions for the selected group 
of genes described. (B) Reconstitution with Elk-1 wild type is able to re-establish 
the TPA-dependent repression only at 16 targets. (Left) Pie chart displaying the 
531 TPA repressed TCF-dependent targets. (Right) Relative expression across cell 
lines for the 16 selected targets. Parental lines uninfected and reconstituted cell 
lines are displayed. 
 





Figure 7.5 Elk-1 is sufficient to control the baseline expression of 20% of the 
TCF-dependent genes  
(A) Analysis of the baseline expression in ESN MEF against wild type MEF for 
TCF-dependent genes (n=3745). We selected genes whose baseline was impaired 
in ESN MEF and rescued with Elk-1 (comparison between Elk-1 rescue and control 
line n=586). From this group we excluded genes showing a baseline expression 
still impaired if compared to wild type MEF (n=79). (B) Relative expression across 
cell lines for the 507 selected targets. Parental lines uninfected and reconstituted 
cell lines are displayed. (C) Analysis of the baseline expression in ESN MEF 
against wild type MEF for TCF-repressed genes (n=3627). We selected genes 
whose baseline expression was repressed in wild type MEF compared to ESN 
MEF and where the ectopic expression of Elk-1 was sufficient to establish 
repression in ESN MEF (comparison between Elk-1 rescue and control line n=685). 
From this group we excluded genes showing a baseline expression still higher if 
compared to the parental wild type MEF (n=106). (D) Relative expression across 
cell lines for the 579 selected targets. Parental lines uninfected and reconstituted 
cell lines are displayed. In B and D Friedman test ( **** P<0.0001). 








Figure 7.6 GO analysis of the TCF-dependent Elk-1-dependent targets 
Each group of genes was analysed using DAVID. The top half of the table shows 
genes whose expression is activated either following TPA or where their 
constitutive expression relies on the TCFs. TCF-dep (red, first column on the left) 
are genes whose induced expression following TPA requires the TCF (n=871). The 
Elk-1 suff (orange, second column from the left) are genes induced by TPA, TCF-
dependent were Elk-1 is sufficient to re-establish inducibility in ESN MEF (n=92). 
TCF-ind (yellow, third column from the left) are genes induced by TPA in both wild 
type MEF and ESN MEF (n=2027). Elk-1 suff (pink, second column from the right) 
are genes unaffected by TPA whose expression requires the TCFs and Elk-1 is 
sufficient to re-establish expression (n=507). Elk-1 not suff (blue, first column from 
the right) are genes unaffected by TPA which baseline expression is TCF 
dependent but Elk-1 is not sufficient (n=3159). The bottom half is organised in the 
same way as the active genes but considering functional terms enriched in genes 
whose expression is repressed either following TPA or their constitutive expression 
or repression is affected in the ESN MEF compared to wild type MEF: TCF-dep 
n=531; Elk-1 suff n=16; TCF-ind n=1559; Elk-1 suff n=579; Elk-1 not suff n= 2942. 
Functional classes enriched with a minimum p-value of 10-3 are highlighted in red. 





Figure 7.7 Selected group of Elk-1 dependent TPA induced and sensitive to FW 
and Nona mutations 
(A) Relative expression across cell lines of genes TCF-dependent, Elk-1 sufficient 
and statistically impaired in Elk-1 FW and Nona. (B) Analysis of the distance of 
SRF to constitutive, TCF-dependent and the selected group of genes using the 
SRF loci coordinates defined in Esnault et al. 2014. 
 




Figure 7.8 H3K4me3 and H3K9K14ac ChIP-seq tracks on Egr2 and Egr1. 
Top half of the figure display the ChIP-seq signal across Egr1 and Egr2 only for the 
reconstituted ESN MEF for H3K9K14ac ChIP-seq signal while the bottom half 
shows H3K4me3 ChIP-seq signal. The data displayed shows all reads normalised 
to the depth of sequencing therefore not normalised to total histone occupancy. 




Figure 7.9 H3K4me3 metaprofiles 
(A to D) Density plot of the selected targets centred on the TSS of each gene. The 
data displayed shows all reads normalised to the depth of sequencing therefore not 
normalised to total histone occupancy. 




Figure 7.10 H3K9K14ac metaprofiles 
(A to D) Density plot of the selected targets centred on the TSS of each gene. The 
data displayed shows all reads normalised to the depth of sequencing therefore not 
normalised to total histone occupancy. 
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Chapter 8. Discussion 
8.1 Outline 
This thesis explores mechanisms controlling signal-dependent transcription 
from different angles. Many mechanisms affecting TF-dependent gene activation 
are considered in the context of the SRF transcription network.  
The first three chapters of the results focused on how the SRF co-factor 
MRTF is controlled once in the nucleus and how this in turn controls transcriptional 
activation.  
o Using genomic approaches it was shown that nuclear MRTF activities are 
influenced by nuclear actin. Unbiased selection of genes confirmed that actin-
dependent gene repression is an MRTF specific phenomenon. Direct interference 
with the MRTF-actin complex in the nucleus is sufficient to activate SRF-MRTF 
target genes.  
o Nuclear actin directly inhibits MRTF-DNA binding but not Myocardin. The 
RPEL motifs are the primary regions involved in this mechanism of regulation. 
Differences within the RPEL1-2 unit between MRTF and Myocardin account for 
their diverse regulation. Actin-dependent MRTF-DNA binding inhibition occurs 
dynamically after Rho activation. This is probably due to changes in filament 
assembly. 
o The mechanism of MRTF-dependent gene activation was investigated by 
assessing steps encompassing Pol II recruitment, escape and productive 
elongation. MRTF-DNA binding is sufficient for Pol II recruitment and escape. 
Nevertheless, its disassociation from actin is required for productive transcription to 
occur. Thus, nuclear actin seems to control mRNA synthesis at steps beyond Pol II 
recruitment and escape. 
 
The second part of the thesis exploits the Ras/MAPK signalling pathway and 
the activation of the TCF co-regulators. The immediate-early response in 
combination with cells lacking all three TCFs provides a valuable system to study 
how extracellular signals, which target transcriptional activation domains, initiate 
changes in the chromatin environment.  
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o Using genomic approaches to assess TCF-dependent gene expression it 
was possible to describe the transcriptional signature left by the TCFs in response 
to TPA.  
o TCFs control one third of the transcriptional response elicited by Ras-Erk 
activation. TCFs control genes involved in transcriptional regulation and cell cycle 
progression. Cells lacking all TCFs show a marked defect in proliferation and a cell 
cycle block in the G2/M transition. One of the TCFs, Elk-1, although unable to re-
establish a correct cell proliferation, is sufficient to control one tenth of the TCF-
dependent genes. 
o TCF-dependent gene activation in response to TPA is achieved through the 
establishment of a defined chromatin signature. The signal induced chromatin 
marks described completely relies on the TCFs. Chromatin changes in response to 
cues can occur independently from transcriptional activation and rely uniquely on 
the TCFs’ DNA binding and activation domain. The recruitment of the transcription 
machinery induces a spread of both H3K4me3 and H3K9K14Ac. In addition, the 
analysis of the H3K27me3 mark demonstrated that Elk-1 activation domain is 
required in resting conditions to maintain a permissive chromatin landscape.  
o MLL3, CHD2, AuroraB and SMYD2 are chromatin modifiers required for 
Egr1 and Fos productive transcription. Down-regulation of each of these greatly 
impairs chromatin marks at Egr1 promoter without affecting Pol II recruitment.  
  
8.2 Mechanisms governing MRTF nuclear functions 
8.2.1 Actin in control of MRTF activity 
Nuclear actin impairment of transcription is an MRTF-specific phenomenon 
Actin is a negative regulator of MRTF activity. Previous studies showed that 
actin could also control MRTF-dependent transcriptional activation, but did not 
address the generality and specificity of this phenomenon (Vartiainen et al. 2007). 
Confinement of MRTF into the nucleus using Leptomycin B (LMB) does not cause 
target genes activation. Direct interference with MRTF-actin interaction is required 
in order to induce productive transcription at MRTF-target genes. The diverse 
compounds used to dissect MRTF functions have also been shown to affect other 
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factors. Besides inducing MRTF nuclear accumulation, the Crm1-specific inhibitor 
LMB allows nuclear retention of additional factors including, among others, NFκ-b, 
HDACs and Smad proteins. In addition LMB is known to also affect RNA export 
(Cuevas et al. 2005). Equally, depolymerizing agents such as Latrunculin B (LatB) 
and Cytochalasin D (CD), besides affecting MRTF activity, have been reported to 
affect other transcription networks such as the mechanoresponsive YAP-TAZ 
pathway and NFκ-b (Dupont et al. 2011; Zhong et al. 2013; Kustermans et al. 
2005). For these reasons we considered it necessary to run an unbiased search for 
genes induced by CD regardless of LMB. Genes fulfilling these criteria are spatially 
associated to SRF-MRTF binding and functionally relate to genes involved in 
cytoskeletal dynamics. In addition, LMB showed a negligible effect across the 
genome. Genes constitutively active and linked to SRF showed no changes in 
expression when cells were treated with LMB. Thus, MRTF nuclear accumulation 
using LMB is not sufficient to activate productive transcription of SRF-MRTF target 
genes. The clear implication of these observations is that nuclear actin prevents 
MRTF from engaging in productive transcription. 
As described in Chapter 2, despite the clear impairment of SRF-MRTF 
target expression following LMB treatment, it is possible to observe a mild 
activation especially of highly induced genes. Given that this LMB-dependent 
induction is sensitive to LatB treatment, leads back to MRTF-dependent nuclear 
activities. This suggests that the transcriptional inhibited state is not absolute. The 
dynamic behaviour of the MRTF-actin interaction could cause this partial activation. 
Changes in the relative amounts of MRTF and actin, besides affecting nuclear 
accumulation, might shift this condition from inactive to active.  
Actin may also play a role in regulating nuclear MRTF activity following 
growth factor stimulation. The MRTF-actin interaction recovers rapidly, within 
minutes of serum stimulation (Miralles et al. 2003; Vartiainen et al. 2007), and 
MRTF-DNA binding also decreases even when MRTF remains nuclear (see below). 
Cell-type specific regulation of MRTF nuclear activities 
Actin might also control MRTF nuclear activities in those cell lines where 
MRTF is constitutively nuclear. Cell lines such as the Cancer Associated Fibroblast 
(CAF), MDA-231 (a human breast cancer cell line) and eye fibroblasts, despite 
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presenting constitutively nuclear MRTF, are still responsive to CD treatments 
(Medjkane et al. 2009 and unpublished data by Charles Foster and Cynthia Yu-
Wai-Man). Thus, it is likely that the actin-dependent mechanisms affecting MRTF 
nuclear functions are employed by specific cell types in order to control MRTF 
activity.  
Cell lines such as the CAFs are characterised by pronounced stress fibers 
and more focal adhesion, factors reminiscent of changes in actin filament assembly 
(Calvo et al. 2013). Relative amounts of monomeric and filamentous actin are 
characteristic of each cell type and behaviour and could directly affect MRTF 
activities and subcellular localisation. It is therefore intriguing to consider the MRTF 
localisation and activity as a potential readout for cellular behaviours.  
MRTF activation and mechanosensing 
Within the 441 CD induced genes described, gene targets include 
components of the actin cytoskeleton and factors involved in contraction and cell 
motility. This signature extensively overlaps with the SRF-MRTF specific set 
defined by our lab in a recent publication (Esnault et al. 2014). The SRF-MRTF 
signalling pathway seems to be a crucial component in mechanosensing and 
transduction in response to Rho-signaling activation (Esnault et al. 2014). In 
addition to SRF-MRTF, also YAP and TAZ were reported to translocate into the 
nucleus and activate genes in response to Rho stimulation (Dupont et al. 2011; Yu 
et al. 2012). Indeed several SRF-MRTF targets are thought to also be controlled by 
YAP/TAZ including Ctgf, Cyr61 and Ankrd1 (Calvo et al. 2013). Nevertheless CD 
inhibits YAP activities (Zhong et al. 2013). Therefore the transcriptional signature 
observed in response to CD stimulation is not due to YAP/TAZ activation. 
8.2.2 Actin controls MRTF-DNA binding 
Actin directly and specifically controls MRTF-DNA binding activity 
Under resting conditions, nuclear accumulation of MRTF is sufficient for its 
DNA binding (Vartiainen et al. 2007). However, the data presented in this thesis 
show that high levels of G-actin are sufficient to cause disassociation of MRTF from 
SRF targets. Indeed actin directly impairs MRTF-DNA binding specifically though 
the RPEL motifs (see Chapter 3). MRTF mutants, which are unable to interact with 
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actin, besides being constitutively nuclear, efficiently bind target loci and are 
unaffected by increases in actin concentration. Similarly Myocardin, an MRTF 
relative with low actin binding affinity, does not show DNA binding regulation 
following increases in actin concentration. Analysis of MRTF-Myocardin chimeras 
indicates that RPEL1 and 2 are critical for the MRTF DNA binding regulation, while 
RPEL3 is not sufficient. Therefore, due to the differences in actin binding, 
Myocardin and MRTF DNA binding are controlled in different ways. In addition, 
DNA pull-down assays performed using MRTF recombinant proteins show a 
striking reduction of binding activity when monomeric actin was titrated into the 
assay. This suggests that no further proteins are required for actin to inhibit MRTF-
DNA binding. In addition, it was not possible to observe any recovery of monomeric 
actin on the MRTF-SRF-DNA complex. This indicates that MRTF-actin binding is 
incompatible with MRTF-SRF-DNA complex formation. In order to draw a full 
picture of this mechanism of regulation, MRTF mutants lacking the entire N-
terminal domain or with point mutations at the critical residues for actin binding 
should give insights into the sequences involved in this inhibition.  
Are MRTF-actin and MRTF-DNA interaction mutually exclusive? 
If MRTF-actin binding is incompatible with MRTF-SRF-DNA complex 
formation, how can MRTF nuclear localisation be sufficient for DNA binding?  
MRTF nuclear accumulation following LMB treatments allows the 
association with target loci across the genome. Yet, MRTF target genes are not 
activated unless the MRTF-actin complex is severed. The binding intensity under 
this condition is 50-60% reduced if compared to the transcriptionally competent 
condition CD. Since more than 90% of the cells treated with LMB show nuclear 
MRTF, the reduced ChIP signal cannot be ascribed to heterogeneity of the sample. 
Furthermore reduced ChIP signal was also observed in cells selected to express 
MRTF linked to the NLS signal. This implies that the ability to interact with basal 
level of actin affects the degree of MRTF-DNA binding.  
Given these observations it is possible to suggest two scenarios: either 
MRTF-actin binding is incompatible with MRTF-SRF-DNA complex formation or the 
MRTF-actin complex associates less efficiently with target loci. So far we have 
failed to see any actin binding at SRF-MRTF target loci performing ChIP 
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experiments. In addition, as discussed in the previous section, we were unable to 
observe any recovery of monomeric actin on the MRTF-SRF-DNA complex using 
purified components. Therefore MRTF-actin binding seems incompatible with 
MRTF-SRF-DNA complex formation. Thus the reduced ChIP signal reflects the 
reduced availability of free MRTF.  
Recently it has been shown that ChIP experiments could be modelled using 
known chemical reaction rate theory (Poorey et al. 2013). It is therefore 
conceivable to see the MRTF ChIP-seq signals as an indication of the likelihood 
that MRTF binds the given target (Figure 8.1A). Considering that increases in actin 
concentration (e.g. using LatB) completely abolish MRTF-DNA binding, the binding 
intensity observed in LMB conditions might directly reflect an imbalance between 
MRTF and actin relative concentrations. Changes in nuclear actin filament 
assembly could therefore shift the MRTF-actin complex equilibrium, favouring or 
disfavouring MRTF-DNA binding. I am currently establishing a TIRF-based assay in 
order to assess how actin influences MRTF-DNA binding on-off rate.  
MRTF-DNA binding as negative feedback mechanism in Rho-activation 
MRTF-DNA binding changes after Rho activation. Following an initial peak, 
15 to 20 minutes after serum stimulation, MRTF-DNA binding drops by 50%, in 
parallel with the recovery of the MRTF-Actin FRET as previously reported 
(Vartiainen et al. 2007). Rho-induced actin filament assembly is followed by 
disassembly and by an increase in monomeric actin concentration (Vartiainen et al. 
2007). It is therefore captivating to consider actin as its own negative regulator 
given that MRTF directly controls its transcription. In addition, considering that 
MRTF-DNA binding is the primary cause of Pol II recruitment and escape, 
impairment of MRTF-DNA binding would be the most efficient way to dampen the 
transcriptional response (see following section for discussion). The development of 
assays that are able to directly measure the exact concentration of nuclear 
monomeric actin following different cues or in different cellular contexts will provide 
additional information.  
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A model for MRTF-DNA binding inhibition 
An essential question rising from these observations is how does this work? 
How does actin, through the N-terminal RPEL motifs, directly affect MRTF-DNA 
binding association? In the MRTF N-terminal half, about 100 amino acids 
downstream of the last actin-binding unit (RPEL3) is the B1 region, an element 
required for ternary complex assembly (Zaromytidou et al. 2006). Although we 
have no indications supporting a possible interaction between actin and this region, 
it is intriguing to consider a potential role for monomeric actin in occluding the B1 
motif. As shown in Figure 8.1A, different mechanisms could be proposed. Firstly, 
actin could directly interact with the B1 region independently of the upstream RPEL 
motifs. This mechanism is unlikely given that RPEL1 and 2 are required for the 
actin-dependent DNA binding inhibition. Further models might involve cooperative 
binding between the RPELs-actin complex and the B1 region – either directly, or 
through additional actin recruitment (Figure 8.1A).  
Recent structural studies conducted by the lab have established the spatial 
architecture of the actin-RPEL domain complex (Mouilleron et al. 2011). The 
structure revealed a pentavalent complex where five actins were associated with 
the three RPELs. Structural analysis including longer MRTF N-terminal sequences 
might reveal further actin binding with sequences downstream of the RPEL3. In 
addition, in vitro competition assays between actin and peptides harbouring the B1 
sequence would be highly informative in combination with DNA pull-down assays 
and TIRF-based experiments.  
8.2.3 Nuclear MRTF and transcription activation 
MRTF-DNA binding is not sufficient for productive transcription 
MRTF-DNA binding is sufficient for Pol II recruitment and escape (Figure 
8.1B). Comparison of CD and LMB stimulated cells shows that the amount of Pol II 
recruitment is directly proportional to the MRTF ChIP-seq signal. In addition, 
MRTF-DNA binding, as a consequence of either CD or LMB stimulation, allows 
recruitment of pausing factors NELF and DSIF.  
Despite the apparently normal Pol II profiles, under resting conditions 
MRTF-DNA binding is not sufficient for productive transcription. My results indicate 
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that the inhibited state of Pol II involves reduced CTD Ser2 phosphorylation. 
Disassociation between MRTF and actin is essential in order to establish the 
correct pattern of modification displayed at Pol II CTD (Figure 8.1B). Therefore the 
inhibited state of Pol II somehow precludes productive transcription and mature 
RNA accumulation. 
RNA synthesis is the engine that pushes Pol II forward, and nuclear Run-On 
and R-loop ChIP experiments show that, even following LMB stimulation, travelling 
Pol II synthesises RNA. Therefore co-transcriptional RNA degradation must occur. I 
have attempted to identify and target components of the exosome with the aim of 
assessing whether RNA can accumulate following LMB stimulation. However the 
experiments showed high variability and I could not reproducibly identify any 
potential target. A further investigation, optimising the screen and including 
additional enzymes known to either stabilise or associate with newly synthesised 
RNA, is going to be essential to further elucidate the basis for the observed defect.  
It is widely accepted that in eukaryotes the steps of RNA maturation 
including capping, splicing and 3’ end cleavage and polyadenylation occur co-
transcriptionally ahead of mRNA export (M. J. Moore & Proudfoot 2009). The 
recruitment of RNA processing factors to the Pol II CTD is what is thought to 
control pre-mRNA maturation. Several RNA processing factors have been shown 
to specifically interact with phosphorylated Pol II CTD (see Chapter 1 for a full 
introduction about CTD modifications and their role and Table 1.3 for CTD 
interacting proteins).  
Under the unproductive LMB condition the escaped Pol II is associated with 
Ser5 phosphorylation but lacks all the other modifications analysed such as Ser2-P, 
Ser7-P, Tyr1-P and Thr4-P. The appearance of Ser5-P is consistent with efficient 
PIC formation and escape of Pol II. Ser5 is known to be a target of CDK7 kinase, 
which is part of the TFIIH complex (Shiekhattar et al. 1995; Glover-Cutter et al. 
2009; M. Kim et al. 2009; Akhtar et al. 2009). TFIIH is essential to induce the open 
complex transition that precedes Pol II promoter escape (Pan & Greenblatt 1994; 
Fishburn & Hahn 2012). In addition, MRTF nuclear accumulation allows a correct 
redistribution of SPT5 and NELF eviction suggesting that, even though no RNA is 
being detected, p-TEFb might be correctly recruited. Recently it has been shown 
that p-TEFb preferentially phosphorylates Ser5 and the pausing factors NELF and 
DSIF (Baumli et al. 2008; Czudnochowski et al. 2012). Previously it was thought 
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that subunit CDK9 of p-TEFb was the main Serine 2 kinase in metazoan. Its role in 
Ser2 phosphorylation was proposed because flavopirridol, a potent CDKs inhibitor, 
was clearly impairing Pol II elongation and p-TEFb activity (Rahl et al. 2010). 
However several pieces of evidence have shown that CDK9 mainly phosphorylates 
Pol II CTD at Serine 5 and its activity is not required for elongating Pol II in vitro (for 
an extensive review see Eick & Geyer 2013). More recently CDK12 was proposed 
to be the main Ser2 kinase in metazoan (Bartkowiak et al. 2010; Bösken et al. 
2014). CDK12 preferentially phosphorylates Serine 2 when the Pol II CTD is readily 
phosphorylated on Serine 7 (Bösken et al. 2014). My results are consistent with 
this notion as the loss of Serine 2 phosphorylation is accompanied by diminished 
Serine 7 phosphorylation. I am currently investigating the distribution of CDK12 
across bona fide SRF/MRTF targets using ChIP experiments and different CDK12-
antibodies. 
A similar result was recently described by Brookes and colleagues (Brookes 
et al. 2012). The authors described a set of genes controlled by polycomb and 
associated with a Pol II uniquely phosphorylated on Serine 5. Consistent with my 
study, they did not see any phosphorylation at Serine 7 and Serine 2. Similarly to 
my observations they did not see any accumulation of mature mRNA coming from 
this group of polycomb-controlled genes. In addition, a direct relationship between 
polycomb and Pol II occupancy was observed leading the authors to suggest a 
direct co-dependency between the status of Pol II and the association of polycomb 
to target genes.  
In addition Hargreaves and colluegues, while studying the expression of 
Toll-like receptor (TLR)-inducible genes in macrophages, identified several genes 
preassociated with Ser5 but not Ser2-phosphorylated Pol II (Hargreaves et al. 
2009). Pol II associated to these genes generate full-length unspliced transcripts 
that are quickly degraded. Following activation phosphorylation of Pol II at Ser2 
allows accumulation of mature transcripts. 
We are currently investigating the distribution of Ser7, Tyr1 and Thr4 
phosphorylation across the defined SRF-MRTF targets using genomic approaches. 
Following LMB stimulation these modifications were found impaired across the 
Acta2 gene. The full description of the pattern of modifications displayed at Pol II 
CTD will be crucial in understanding the potential mechanism affecting Pol II 
productive transcription. 
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How does this work? As discussed previously, nuclear actin mainly affects 
MRTF-DNA binding and so far we have failed to see any direct interaction between 
MRTF and actin at target genes. This observation implies that actin must indirectly, 
through MRTF, affect the correct modification of Pol II CTD. Given the direct 
relationship between MRTF-DNA binding and Pol II recruitment, it is tempting to 
speculate that a less persistence DNA association might therefore be insufficient 
for the recruitment of defined transcriptional kinases (Figure 8.1B). Again the 
development of in vitro assays to measure the transcriptional outcome given an 
unstable or persistent MRTF-DNA binding will provide further insights. 
This model also needs to take into account how actin directly affects 
modification of the MRTF polypeptide. Notably, MRTF nuclear accumulation is 
accompanied by extensive phosphorylation (Miralles et al. 2003). Much evidences 
collected in the lab have shown that this modification is directly under the control of 
actin and can affect transcription. Indeed LMB treatment does not induce MRTF 
phosphorylation (unpublished data collected by F. Miralles, R. Pawlowski and 
Richard Panayiotou). In addition it has been shown in the lab that Flavopiridol, a 
potent CDK inhibitor, affects MRTF phosphorylation suggesting a direct 
involvement of transcriptional CDKs in this process (Richard Panayiotou 
unpublished data). It is therefore possible to propose that following LMB stimulation 
actin is able to maintain MRTF in an un-phosphorylated state by continuous 
recycling through target promoters. Little is known about the contribution of the 
MRTF phospho-residues in transcriptional activation. It will be interesting to see 
whether phosphorylated MRTF works as a binding platform for factors involved in 
gene activation.  
MRTF activation does not alter Pol II travelling index 
Besides Pol II initiation, additional steps including open complex formation 
and escape were shown to be under the control of TFs (Rahl et al. 2010; Kouzine 
et al. 2013). The rate of initiation and escape is supposed to determine the activity 
of a given gene. TFs can therefore control initiation, escape or both simultaneously. 
It has been proposed that escape is the rate-limiting step at the majority of the 
human genome (Core & Lis 2008). Considering this model, one might expect to 
see a major difference in escape-rate if comparing constitutively expressed and 
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highly inducible genes following acute stimulation. Constitutive and MRTF-inducible 
genes showed similar Pol II distribution on average, and the activity of MRTF did 
not affect the rate of escape when compared to resting conditions. Indeed the 
probability of escape did not change upon induction with either CD or LMB, 
implying that initiation and escape are directly coupled. Accumulation of Pol II at 
the 5’ region of any gene reflects a rate limiting escape into the body of the gene 
and is none other than an indication of active transcription. Corroborating this 
hypothesis is the observation that in resting conditions genes with a high pausing 
index are also showing a higher baseline of expression. It is not possible to exclude 
the possibility that in defined contexts the rate of escape could be specifically 
affected by defined TFs while others are responsible for maintaining Pol II 
associated to target genes. We recently reported that in response to serum 
stimulation, active nuclear MRTF is required for both Pol II recruitment and 
activation at half of its targets (Esnault et al. 2014). The remaining set of genes was 
shown to only rely on MRTF for a post-recruitment step. Activation of signalling 
pathways using serum shock is therefore required to activate additional TFs with 
the ability to recruit Pol II in the absence of MRTF. Analysis of the interplay 
between multiple TFs in establishing Pol II elongation rate deserves further 
investigation. 
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Figure 8.1 Actin controls MRTF nuclear activities 
 (A) Actin (green) prevents MRTF (purple) DNA binding and association with SRF 
(red) at target genes. The impairment of MRTF-DNA binding is concentration 
dependent and partial MRTF-DNA association might reflect an imbalance between 
MRTF and actin concentrations. As this phenomenon of inhibition requires intact 
RPEL motifs a potential mechanism might involve the occlusion of the B1 motif by 
monomeric actin assembling different repressive complexes. (B) MRTF DNA 
binding is sufficient for Pol II recruitment and escape. In absence of actin 
interaction, the stable MRTF-DNA binding allows a correct phosphorylation of Pol II 
CTD and concomitant accumulation of transcript. On the other hand unstable 
MRTF-DNA interaction, controlled by G-actin, allows Pol II recruitment and escape, 
but the correct phosphorylation of Pol II CTD is affected. Possibly, under these 
conditions, MRTF is unable to recruit defined transcriptional kinases. The produced 
RNA must therefore be co-transcriptionally degraded as Pol II moves along the 
gene body.  
(*) MRTF-Actin interaction also affects modification of the MRTF polypeptide. In 
particular the accumulation of MRTF into the nucleus following LMB is not 
accompanied by its phosphorylation. Unphosphorylated MRTF might be unable to 
recruit specific transcriptional kinases required for Pol II productive transcription. 




8.3 Establishment of chromatin signature in response to Ras-
Erk activation 
8.3.1 The TCF-dependent transcriptional signature 
Ras-dependent gene activation is governed by the TCFs 
Ras activation is a major cause of proliferation, invasion and metastasis. 
More than 20% of human cancers are accompanied by Ras activating mutations 
(for a review see Pylayeva-Gupta et al. 2011). Oncogenic active Ras is known to 
stimulate a plethora of targets promoting cell cycle entry and proliferation, possibly 
using different TFs. In particular, AP-1 activity has been widely associated with 
fibroblast transformation in culture and in the progression of skin tumours driven by 
Ras (Granger-Schnarr et al. 1992; Lloyd et al. 1991; Saez et al. 1995). Activation of 
Ras-Erk is a critical event in melanoma, colorectal and renal carcinoma but the 
degree to which Ras-dependent transformation is dependent on the SRF network 
is widely unexplored. In particular, there has been no systematic characterization of 
the TCF-dependent transcriptional response. The analysis of TCF null fibroblasts 
allowed us to characterise the TCF-dependent gene repertoire, and to assess the 
role of TCF signalling in the Ras-Erk dependent transcriptional response. 
Activation of Ras-Erk results in differential expression of about 5000 genes 
in wild type MEFs, among which about 3000 are upregulated and 2000 
downregulated. The depletion of all TCFs affects about 1000 out of the 3000-
upregulated genes and 500 out of the 2000-downregulated genes. In addition the 
depletion of the TCFs results in differential expression of constitutive expressed 
genes.  Among these, 3745 show reduced expression and 3627 show enhanced 
expression in TCF null fibroblasts when compared to wild type cells. Genes that are 
positively controlled by the TCFs are mainly involved in transcription regulation and 
in the regulation of different aspects of the cell cycle. By contrast genes repressed 
in a TCF-dependent manner are significantly involved in cell differentiation, tissues 
and organ development.  
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Not all TCF-dependent genes need to be direct targets, as they could also 
be indirect. As I am going to discuss in the next section, the block in cell cycle 
progression may also influence gene expression in TCF null fibroblasts. 
TCFs are required for cell cycle progression and proliferation 
Embryonic fibroblasts lacking TCFs show a marked defect in proliferation 
and cell cycle progression, with a slower growth rate and a block in G2/M of the cell 
cycle. This observation is consistent with the de-regulation of genes involved in cell 
cycle regulation. Recently it has been shown that Erk2 and Elk-1 are able to 
integrate extracellular signals to support ESCs proliferation and prevent their 
differentiation (Göke et al. 2013). It is therefore tempting to suggest that the TCFs 
are required for efficient cell cycle progression.  
It is important to consider potential indirect effects on gene expression 
caused by a block in cell cycle. It is widely accepted that several immediate-early 
genes (IEGs) can regulate cellular differentiation, proliferation and lineage 
specificity (Fowler et al. 2011). IEGs include several transcription factors, such as 
c-fos, Egr-1 and AP-1 family members, which could subsequently regulate 
secondary gene cascades enabling the expression of genes involved in 
proliferation and cell cycle progression.  
Ectopic expression of Elk-1 alone, despite being sufficient to control several 
TCF-dependent IEGs (Costello et al. 2010), is insufficient to re-establish correct 
proliferation and cell cycle progression in TCF null cells (data not shown, Cyril 
Esnault personal communication). Consequently, gene expression changes upon 
exogenous Elk-1 expression are not likely to reflect cell cycle changes. As I will 
discuss hereafter, Elk-1 is sufficient to control only a small percentage of the TCF-
regulated genes. This might indicate why we failed to successfully rescue the 
proliferation defect of TCF null fibroblasts.  
Despite the functional redundancy that has been reported between Elk-1 
and SAP-1 in thymocyte positive selection (Costello et al. 2010), it is conceivable 
that TCF activities are gene specific. Sap1, Net or a combination of all three TCFs 
might be required in order to maintain the expression of genes involved in 
proliferation.  In addition Elk-1 and SAP-1 are mostly redundant for those functions, 
such as thymocyte development, where SRF is also required. Only a defined 
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subset of SRF-dependent genes are regulated in response to MAPK activation and 
TCF functions (Esnault et al. 2014). TCFs can act redundantly with other ETS 
proteins independently of SRF (Hollenhorst et al. 2011). It has been shown that 
SRF is required for IEGs expression yet is dispensable for proliferation of 
Embryonic stem cells (Schratt et al. 2001). It is therefore conceivable that the TCFs 
act redundantly only for the control of SRF-dependent targets while having non-
redundant specific functions on other genes. 
Elk-1 dependent gene expression 
In order to investigate the mechanisms involved in the TCF-dependent gene 
regulation we used retroviral transgenesis to re-express Elk-1 variants in TCF null 
fibroblasts. Elk-1-mediated gene activation is dependent on multiple 
phosphoacceptor sites and two hydrophobic residues, both of which are required to 
recruit Mediator. TCF null fibroblasts were reconstituted with retroviruses 
expressing Elk-1 wild type, Elk-1 Nona (a variant in which all phosphoacceptor 
sites have been changed to alanine) or Elk-1 FW (mutant in which the two 
hydrophobic residues have been deleted).  
The ectopic expression of the Elk-1 wild type protein showed that Elk-1 is 
sufficient to control about 10% of the TCF-dependent Erk-activated genes (92 out 
of 871 genes) and about 15% of the TCF-dependent constitutively expressed 
genes (507 out of 3745 genes). Elk-1 FW and Elk-1 Nona were both unable to 
active target genes induced by Erk activation. On the other hand, Elk-1 FW and 
Nona could substitute Elk-1 wild type for the expression of the constitutive genes. 
This observation implies that Elk-1 DNA binding, rather than its ability to be 
phosphorylated and to recruit Mediator, is required for the expression of these 
genes. Potentially Elk-1 DNA binding could favour the recruitment of additional 
activators at these genes cooperating either directly or indirectly with them. We are 
currently planning to analyse TF DNA binding motifs at these specific targets in 
order to see whether there is a specific co-occurrence with Elk-1 binding. 
Only a few TPA-repressed genes appeared to be Elk-1 dependent. Greater 
changes were recorded comparing constitutive expressed genes in wild type and 
TCF null fibroblasts. Elk-1 is sufficient to suppress about 600 genes whose 
expression is enhanced in TCF null compared to wild type fibroblasts. Elk-1 was 
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reported to suppress genes by recruiting co-repressor complexes once de-
phosphorylated or specifically sumoylated (S.-H. Yang et al. 2003). Our results 
show that Elk-1-repressed genes are mostly unaffected by Erk activation. This 
observation suggests that Elk-1 DNA binding is sufficient to suppress the 
expression of defined genes. Similarly to Elk-1 dependent constitutive genes, 
ectopic expression of both Elk-1 FW and Nona showed to be sufficient to establish 
gene suppression. The mechanism of gene suppression does not seem to be 
influenced by Erk activity. A potential mechanism might involve the direct 
competition with other TFs for the same DNA binding site.  
The TCFs are part of the large family of ETS transcription factors (see 
chapter 1.6). ETS members show similar and partially overlapping DNA binding 
specificity (Wei et al. 2010). It would be important to compare the DNA binding 
distribution of Elk-1 with the binding of other ETS member in order to gain further 
insight into this mechanism of gene suppression. 
8.3.2 TCFs as anchoring points for signal-induced chromatin changes 
TCFs are required for signal-induced chromatin changes 
Activation of target TFs, modification of chromatin, and direct recruitment of 
components of the transcriptional machinery are all potentially regulated by 
extracellular signals (see Chapter 1). Using the SRF-TCF network, I investigated 
the relationship between signalling, Elk-1 phosphorylation, chromatin changes and 
transcriptional machinery recruitment occurring at the Egr1 gene.  
Activation of transcription was shown to correlate with defined chromatin 
changes including: H3S10 phosphorylation, H3K4 trimethylation, H3K9K14 and 
H3K27 acetylation and H4K16 acetylation (see chapter 1.4). The rapid and 
transient activation of the Ras-Erk pathway elicits chromatin modifications 
associated with transcription activation. A localised phosphorylation of histone 
H3S10 at the SRF/TCF binding site is the first modification to occur in response to 
TPA, followed by enhanced acetylation of lysine residues 27, 9 and 14 of the 
histone H3 and lysine 16 of histone H4. The appearance of these chromatin marks 
coincides with the recruitment of the Mediator complex, followed by Pol II 
recruitment at the TSS. H3K4me3 was the most stable mark, being detectable at 
the SRF-TCF site in resting conditions, but spreading towards the TSS when Pol II 
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was recruited, as did H3K9K14 acetylation. All the modifications analysed did not 
occur in TCF null fibroblasts, and were restored by the expression of Elk-1. Thus, 
the TCFs are required to both mediate the establishment of chromatin changes and 
recruit the transcriptional machinery at Egr1 in response to Ras-Erk activation.  
Elk-1 DNA binding and phosphorylation induce defined chromatin changes 
Previous studies have shown that transcription activation by activated Elk-1 
involves the specific recruitment of the Mediator complex (Balamotis et al. 2009). 
The TCFs, in particular Elk-1, are equipped with a well-characterised activation 
domain harbouring several phosphorylation sites and two key hydrophobic residues 
(see chapter 1.6), both of which are required for recruitment of the Mediator 
complex. We studied the relationship between Elk-1 phosphorylation and chromatin 
modification by using Elk-1 mutants either lacking all phospho sites (Nona) or the 
hydrophobic residues (FW). These mutants allowed us to uncouple Elk-1 
phosphorylation from active transcription.  
Ectopic expression of Elk-1 FW, despite being unable to recruit the 
transcriptional machinery and activate transcription, was sufficient to enhance 
H3S10 phosphorylation, H3K9K14 acetylation and H4K16 acetylation at the 
SRF/TCF binding site following Erk activation. On the other hand TCF null 
fibroblasts reconstituted with the Elk-1 Nona mutant could not induce H3S10, 
H3K9K14 and H4K16 modifications. Elk-1 FW could only restore, in response to 
signal, modifications in the vicinity of the SRF/TCF binding site, while downstream 
modifications at the Egr1 TSS were left unchanged. Therefore, chromatin 
modification can occur in absence of transcription activation at the TCF/SRF site. In 
summary, it is possible to distinguish two types of signal-induced chromatin 
modifications: one directly enhanced by Elk-1 phosphorylation alone and others 
reflecting the recruitment of the transcription machinery. 
In contrast, both Elk-1 FW and Nona were sufficient in resting and 
stimulated conditions to enhance H3K4me3 at the SRF/TCF binding site at Egr1 
promoter. As mentioned earlier, H3K4me3 is the least changing modification in 
response to signal. Following stimulation, H3K4me3 shows the greatest changes at 
the TSS when Pol II is recruited. Taken together, these observations suggest that 
Elk-1 DNA binding is sufficient to enhance H3K4me3 proximal to its DNA binding 
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site while the transcriptional machinery is required to induce changes at the 
downstream TSS. 
Elk-1 DNA binding and phosphorylation are not sufficient for H3K27 
acetylation in response to Erk activation. This modification occurs exclusively at the 
SRF/TCF binding site and coincides with Mediator recruitment. These observations 
imply that Mediator recruitment is essential to enhance H3K27 acetylation. To date, 
Mediator has been reported to exhibit HAT activity only in yeast (Lorch et al. 2000). 
However, several chromatin-modifying complexes such as SAGA have been 
reported to act in synergy with the Mediator complex in both yeast and mammals 
(X.-F. Chen et al. 2012). The specific role of H3K27 acetylation besides being 
enriched at active genes and enhancers is still unclear. The identification of H3K27 
specific HATs will provide additional insights. 
Mediator and Pol II provide further chromatin modifications 
The chromatin signature described at the SRF-TCF binding site is directly 
mediated by TCF-DNA binding and phosphorylation of their activation domain. 
However the distribution of the chromatin modifications change when transcription 
occurs, suggesting that Mediator and Pol II provide additional functions able to 
extend the chromatin modifications. H3K4me3 and H3K9K14Ac are enhanced at 
Egr1 TSS following TPA and require the recruitment of both Mediator and Pol II. 
Both acetyltransferase and methyltransferase have been reported to be either 
directly or indirectly recruited by the transcribing Pol II (Wittschieben et al. 1999; 
Wood et al. 2003). The direct relationship between H3K4me3 and active promoters 
has been observed in several studies and is commonly used as a mark of active 
promoters (reviewed in Ruthenburg et al. 2007). Recently Roeder and colleagues 
showed that H3K4me3 stimulates Pol II PIC formation by interacting with the TAF3 
subunit of TFIID at active promoters (Lauberth et al. 2013). The spreading of 
H3K4me3 by Pol II might therefore re-enforce its own activity. This mechanism 
preferentially occurs at signal or stress induced genes rather than constitutively 
express genes (Lauberth et al. 2013).  
The differential distribution of H3K4me3 at both enhancers and promoter 
sequences raises the general question of whether this modification is mediated by 
different enzymes or by position-specific activities of a common methyltransferase. 
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Given the data presented, MLL3 and SMYD2 are the two potential 
methyltransferases differentially recruited at the Egr1 gene. Further experiments 
including ChIP of the enzymes involved in Egr1 activation and Co-IP experiments 
between Elk-1 and the chromatin modifiers will provide further insights. 
Functional role of chromatin changes in TCF-dependent gene activation 
How do chromatin changes contribute to TCF-dependent gene activation? 
As described above, it is widely accepted that signal activation induces several 
chromatin modifications correlating with sites of active transcription (J. Ernst et al. 
2011). In particular H3S10 phosphorylation has been implicated in IEGs activation 
(Mahadevan et al. 1991 and for a review see Sawicka & Seiser 2012). Despite the 
strong correlation between signal-induced chromatin changes and transcription 
activation, it is not yet clear which of the steps in the transcriptional cycle these 
changes are promoting. 
It has been reported that the induced de-methylation of the stem cell 
leukemia (SCL) locus using TALE-LSD1 fusion protein affects nearby gene 
expression (Mendenhall et al. 2013). Thus chromatin modifications are required for 
transcription to occur, but in which step are they required for? 
To identify chromatin modifiers involved in Erk-mediated gene expression 
we carried out a medium-throughput siRNA screen (see chapter 6). The siRNA-
mediated knockdown of Aurora-B, MLL3, CHD2, Set7, Tip60, Tip49b and SMYD2 
inhibits both Egr1 and Fos expression, and Aurora-B, MLL3, CHD2 and SMYD2 
depletion also impairs specific marks at the Egr1 promoter. In particular Aurora-B 
knockdown reduces H3S10 phosphorylation while MLL3 and CHD2 reduces both 
H3K4me3 and H3S10 phosphorylation. SMYD2 knockdown reduced the 
appearance of H3K4me3 at Egr1 TSS following TPA stimulation. Therefore 
different chromatin modifiers contribute to Egr1 expression. Notably, the reduction 
in gene expression and chromatin modification is not accompanied by a reduction 
in Pol II recruitment, suggesting that the chromatin changes might influence steps 
beyond Pol II recruitment.  
It has been proposed that H4K16 acetylation is sufficient to recruit BRD4 
and p-TEFb at active promoters (Zippo et al. 2009). Our results show that H4K16 
acetylation is not sufficient to recruit p-TEFb. Indeed TCF null fibroblast 
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reconstituted with Elk-1 FW does not show p-TEFb recruitment in response to Erk 
activation, whereas H4K16 acetylation is induced. Both chromatin modifications 
and Mediator recruitment might be required for p-TEFb recruitment and Pol II 
activation. The analysis of the distribution of components of the p-TEFb complex 
and BRD4 following the down-regulation of Aurora-B, MLL3, CHD2 or SMYD2 will 
provide further insights. 
A model for TCF-dependent gene activation 
We propose that the TCFs work as anchoring points where both chromatin 
modifier enzymes and the Mediator complex are recruited in response to signals 
(Figure 8.2). Chromatin changes and Mediator recruitment appears to represent 
two distinct pathways, both under the control of the TCFs, contributing to 
transcription activation.  
The first pathway requires both phospho acceptor and FW residues of Elk-1 
AD in order to recruit the Mediator complex as reported by the Berk lab (Balamotis 
et al. 2009). In addition our results show that Elk-1 phosphorylation and the FW 
residues are sufficient for Elk-1-Mediator interaction and Pol II recruitment, even 
when chromatin modifications are impaired (Figure 8.2 step a). The second 
pathway is characterised by the establishment of chromatin modifications. 
H3K4me3 at the SRF/TCF binding site requires Elk-1-DNA binding (Figure 8.2 step 
b) while Elk-1 phosphorylation allows H3S10 phosphorylation and acetylation of H3 
and H4 (Figure 8.2 step c). Chromatin changes at the SRF/TCF binding site are 
completely independent of the transcription machinery. This might reflect a direct - 
or indirect - recruitment of chromatin modifiers through the Elk-1 AD. Chromatin 
modifications at the SRF/TCF binding site are per-se insufficient for transcription 
activation and might therefore favour a step beyond Pol II initiation (Figure 8.2 step 
d). Chromatin modifications and Mediator might together favour Pol II release 
through the recruitment of p-TEFb (Figure 8.2 step d). Ultimately the transcribing 
Pol II allows H3K4me3 and H3K9K14Ac to spread (Figure 8.2 step e).  
As described in Figure 8.2 the chromatin modifiers could be placed in 
different steps of the activation mechanism. MLL3 and CHD2 could be recruited in 
resting conditions by the TCFs and methylate H3K4me3 (Figure 8.2 step b). MLL3 
is mainly known to induce H3K4me1 but several studies suggest it is also involved 
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in H3K4me3 deposition (Vicent et al. 2011; Valekunja et al. 2013). Aurora-B might 
be directly or indirectly recruited by phosphorylated Elk-1 allowing H3S10 
phosphorylation at the SRF/TCF binding site (Figure 8.2 step c). H3S10 
phosphorylation is followed by acetylation of histone H3 and H4 at different 
residues. So far we failed to identify potential acetyltransferases and we cannot 
interpret the interdependency between the various chromatin modifications. 
Nevertheless all changes require TCF and appeared to be differentially affected 
following Aurora-B, MLL3 or CHD2 knockdown. Finally SMYD2 might be recruited 
in a Pol II dependent manner at active promoters leading H3K4me3 to spread into 
the transcribed sequences (Figure 8.2 step e). 
Signalling to TCF as a mechanism to maintain active chromatin 
It has been recently reported that Erk2 and Elk-1 genomic distribution in 
human embryonic stem cells defines active and poised genes (Göke et al. 2013). 
Genes occupied by both Erk and Elk-1 are associated with cell cycle progression 
and proliferation, whereas genes associated with Elk-1 alone relate to cell 
differentiation and commitment and are not transcribed. The H3K27me3 mark, 
possibly established by the polycomb group of proteins, characterises this latter 
group. Interestingly, silent Elk-1 genes fall into the same functional categories as 
the one specifically suppressed by the TCF as described by our RNA-seq data. In 
this context the mechanism of repression seems to rely exclusively on the DNA 
binding activity. Indeed the Elk-1 Nona and FW mutants, as the wild type protein, 
can restore their normal transcription pattern. The direct implication is that this 
group of genes is suppressed in a signal-independent way. This group of genes 
opposes to the pro-proliferative targets positively controlled by the TCFs. Therefore, 
it is possible to speculate that the TCFs are required to maintain a stable cell 
identity.  
Although it is not clear how Elk-1 can be differentially targeted by Erk protein 
across the genome, a possible implication is that activation of the TCFs provides 
an antagonistic mechanism to silencing. Intriguingly the Elk-1 Nona mutant, which 
cannot be phosphorylated, allows accumulation of H3K27me3 across the Egr1 
ORF. This observation was recently confirmed performing ChIP-seq experiments 
and we are currently analysing the data. A direct implication is that TCF 
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phosphorylation itself prevents the appearance of H3K27me3. Indeed the Elk-1 FW 
mutant does not enhance H3K27me3. Therefore the potential antagonistic 
mechanism, although requiring Elk-1 phosphorylation, does not require active 
transcription. Recent studies described that Erk activity pulses in growing cells and 
this mechanism controls the proliferation rate (Aoki et al. 2013). Therefore Erk 
activity pulses fired spontaneously or through cell propagation could in theory allow 
TCF activation and chromatin modifications in resting conditions. Indeed 
H3K27me3 was not seen in resting conditions in any cell line analysed. Therefore 
the signal-dependent chromatin signature occurring at the SRF-TCF binding site 
might allow the maintenance of an active chromatin template even in resting 
conditions. Further studies are required in order to draw a comprehensive picture of 
this mechanism. 
The function of H3K27me3 in this particular context is not established and 
the involvement of the polycomb group of protein is yet to be determined. It is 
intriguing to consider recent studies conducted by the Helin lab that described how 
polycomb is not required to induce silencing whereas it is indispensable to maintain 
it (Riising et al. 2014). Therefore persistent inhibition might prevent stochastic 
activations leading to active chromatin modifications. The establishment of 
repressive states could therefore be indirectly brought about rather than specifically 
induced. A better undestanding of how H3K27me3 is established at TCF-target 
genes and the potential role of the polycomb complex in this mechanism is of 
crucial interest and it will be further investigated. 





 Figure 8.2 Establishment of chromatin signature in response to Ras activation 
 (a) Activated TCFs recruit the Mediator via direct contact with defined subunits of 
the complex (Balamotis et al. 2009). (b) TCFs through their DNA binding are able 
to enhance H3K4me3 at Egr1 promoter. This modification occurs in absence of 
signal stimulation and transcriptional activation and relies on MLL3 and CHD2 
activities. (c) Upon stimulation phosphorylation of the TCFs’ activation domain 
enhances H3S10P, H4K16Ac and H3K9K14Ac at the SRF/TCF binding site. (d) 
Chromatin changes and Mediator are both required for p-TEFb recruitment and 
transcription activation. (e) The established signature at the TCF-SRF binding site, 
consisting in H3K4me3, H3S10P, H4K16Ac, H3K9K14Ac and H3K27Ac (the latter 
induced only in the presence of the Mediator complex) is then expanded with the 
spreading of H3K4me3 and H3K9K14Ac towards Egr1 TSS. This re-shaping of the 
chromatin signature is entirely dependent on the recruitment of the transcriptional 
machinery and requires SMYD2 activity.  
The maintenance of the chromatin signature in resting conditions seems 
indispensible to keep a permissive chromatin landscape. 
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Chapter 9. Materials & Methods 
9.1 Chemicals and reagents 
The following list shows the most commonly used reagents and materials. 
Specific reagents used are highlighted in each section. 
 
3MM paper       Whatman  
Ampicillin       Sigma 
Blasticidin       Invitrogen 
Bromophenol Blue      BioRad 
BSA        Sigma 
Comassie brilliant blue     BioRad 
Complete protease inhibitor cocktail tablets  Roche 
Cyrochalasin D      Calbiochem 
Dimethyl sulfoxide (DMSO)     Fisher Scientific 
Dithiothreitol (DTT)      Sigma 
Doxyciclin       Sigma 
Dynabeads® M-280 Streptavidin    Invitrogen 
Dynabeads® Protein G for Immunoprecipitation  Invitrogen 
Dynabeads® Rat Anti-Mouse IgM    Invitrogen 
Ethidium bromide       Sigma 
Fetal Calf serum (FCS)     Invitrogen 
Hepes        Invitrogen 
Kanamycin        Sigma 
Latrunculin B        Calbiochem 
Milk powder        Marvel 
Optimem        Invitrogen 
Orange G        Sigma 
Phenylmethyl-sulfonyl fluoride (PMSF)    Sigma 
Poly(dIdC)•poly(dIdC)     Sigma 
Polybrene       Sigma 
Protein marker SeeBlue Plus2 Prestained   Invitrogen 
Puromycin       Invitrogen 
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Spermidine       Invitrogen 
TPA        Sigma 
Triton X-100       Invitrogen 
Trizma-base       Invitrogen 
Tween® 20       Invitrogen 
Zeocin        Invitrogen 
9.2 Expression vectors 
Protein expression in mammal cells 
MRTF and Myocardin derivatives were cloned into a modified pTRIPZ 
vector purchased from Dharmacon (TRIPZ Inducible Lentiviral shRNA). Each 
mutant and derivative was sub-cloned from existing vectors in the lab. Each cDNA 
was inserted between AgeI and MluI sites using homologous recombination 
(InFusion, Clontech). Bovine growth hormone polyadenylation (bgh-PolyA) signal, 
derived from pcDNA™4/TO (Invitrogen) was introduced into the MluI site 
downstream of the inserted cDNA using homologous recombination (In-Fusion, 
Clontech).  
Elk-1 mutants were introduced into pMYs-IRES-GFP. Each cDNA was 
collected from existing plasmid generated by Thomas Ross in the Lab and 
described previously (Cruzalegui et al. 1999; M. A. Price et al. 1995; Marais et al. 
1993). 
 
MRTF(fl) and SRF(fl) protein expression in Sf9 
MRTF and SRF full-length cDNA were optimised using the Invitrogen 
GeneArt® services. The original sequence was obtained from the one in use in the 
lab and already described (Guettler et al. 2008; Miralles et al. 2003; Vartiainen et 
al. 2007). The optimised sequence included a Histidine tag at the N-terminal part 
fused to a TAP tag (Tandem affinity purification) and followed by a TEV protease 
site (Tobacco Etch Virus nuclear inclusion a endopeptidase, aa sequence 
ENLYFQG). The vector used to express the 6XHis-TAP-TEV-MRTF(fl) and SRF(fl) 
was a modified pBacPAK (Clontech). From the vector I removed the entire region 
from NcoI to KpnI. The cDNA was then cloned, following PCR to include restriction 
sites at the extremity, between KpnI and NotI. 




Additional plasmids were used including vectors expressing the viral VSV-G 
envelop (Clontech) and the SV40 large T (Addgene).  
9.3 Bacterial manipulation 
9.3.1 Bacterial strains 
One Shot Top 10 E. coli chemically competent cells were used for routine 
cloning. One Shot® Stbl3™ Chemically Competent E. coli derived from the HB101 
E. coli strain were used for cloning and expansion of the pTRIPZ and pMYs-IRES-
GFP. These vectors harbours long terminal repeats (LTRs) so are highly prone to 
homologous recombination. The Stbl3 strain is design to minimise recombination of 
retrovirus and lentivirus vectors harbouring LTR sequences. 
9.3.2 Bacterial media 
LB media: 1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract, 1% w/v NaCl) 
LB Agar: 1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract, 1% w/v NaCl, 
1.5% w/v Bacto-agar 
SOC media: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM glucose. 
 
LB liquid media and agar plates were supplemented with antibiotics 
according to the resistance marker harboured by the plasmid: 100µg/ml ampicillin, 
30 µg/ml kanamycin, 25-50 µg/ml Zeocin, 50–100 µg/mL Blasticidin. 
9.3.3 Transformation of competent cells 
50 µl of chemically competent Top 10 or Stbl3 were thawed on ice and 
mixed with the DNA for 10 minutes. The mix was then incubated at 42°C for 30 
seconds and then quickly transferred on ice for 2 minutes. The bacteria were then 
incubated with 250 µl of SOC media without antibiotic for 1 hour before plating on 
agar plate with the desired antibiotic. 
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9.4 Nucleic acid manipulations 
9.4.1 Plasmid DNA purification 
5 ml (for small-scale, miniprep) or 200 ml (for large scale, maxiprep) of LB 
media, including the appropriate antibiotic, were incubated with a single Top10 or 
Stbl3 colony and grown overnight at 37°C and 200 rpm. Miniprep plasmid DNA was 
isolated by the CRUK Equipment Park miniprep service while Quiagen Plamid kits 
were used to purify though anion-exchange column larger quantities of DNA 
(Maxiprep).  
9.4.2 Nucleic acid quantification 
The concentration and purity of double stranded DNA and RNA were 
routinely quantified using a ND-1000 UV/Vis spectrophotometer (NanoDrop 
Technologies). Samples generated for high-throughput sequencing were quantified 
and analysed by the Advanced Sequencing facility using the Agilent 2100 
Bioanalyzer. This device is a microfluidic-based system able to assess size, 
quantity and quality of DNA and RNA. 
9.4.3 Elecrophoresis 
1-2% agarose gels were prepared in 1X TBE (89 mM Tris Base 89 mM boric 
acid 2 mM EDTA) supplemented with 0.5 µg/ml of Ethidum bromide. Samples were 
supplemented with 10X loading buffer (0.01 % w/v Orange G, 30 % glycerol in TE 
pH 8.0). Gels were run using CLP electophoresis tanks at 100-150 V. The 
reference marker used was the 2-Log DNA Ladder 0.1-10.0 kb (New England 
Biolabs).  
9.4.4  Recombinant DNA techniques 
cDNA fragments were generated either by Sequence-specific 
endonucleolytic cleavage of plasmid or PCR products. In addition complex cloning 
involving highly recombinant vectors or for long plasmid backbones the 
homologous recombination-based approach In-Fusion was used (Clontech, 
technology based on (M. Z. Li & Elledge 2007). 
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Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used to amplify DNA for cloning or to 
generate biothynilated oligonucleotides for DNA pull down assays using MyTaq 
Red (Bioline, see later). Specific primers were designed by me and synthesised by 
Sigma. PCR products were routinely produced using KOD Hot start polymerase kit 
(Novagen). For Recombinant based cloning techniques according to the 
manufacturer instruction each primer used was designed to overlap for at least 15 
bases with the target sequence (see Clontech web site). For standard molecular 
cloning techniques primers included restriction sites at the extremities.  
 
Standard PCR reaction: 
10ng DNA 
1µl of each primer forward and reverse (0.2µM final) 
5µl 10x PCR reaction mix 
5µl 25 mM MgSO4 
0.2mM final each dNTP 
1µl KOD Polymerase 
Water to a final volume of 50µl 
 
PCR cycling: 
Denaturation: 95°C for 5 minutes at first, for each cycle allow 30 seconds 
Anneal:  50 to 65°C according to primers and templates, for 30 to 45 seconds 
Elongation:  68-72°C according to the type of amplification, for 30 to 60 seconds 
 
Each cycle comprising Denaturation, anneal and elongation was repeated 
20 - 40 times according to the quantity needs (NB increases in cycle numbers 
increase the probability of errors although the KOD polymerase is a proof reading 
enzyme). 
Insertion of DNA fragments into plasmid DNA 
For standard cloning procedure digestion of both plasmid and insertion 
product was conducted according to the manufacturer’s instruction (New England 
Biolabs). Calf intestinal alkaline phosphatase (New England Biolabs) was added 
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when required to the target vector to avoid self-ligation by removing the 5’ 
phosphate groups. The PCRed and digested DNA fragments were purified with 
agarose gel electrophoresis and/or MiniElute PCR product purification kit (Qiagen). 
Ligation was performed using the T4 DNA ligase (NEB) according to the 
manufacturer’s instructions. 2 µl of the ligation mix were used to transform Top10 
or Stbl3 strains. For the homologues recombinant cloning approach I followed the 
manufacturer’s instruction using the In-Fuction HD kit (Clontech). 
DNA sequencing 
DNA sequencing performed by the CRUK Equipment Park sequencing 
services was used to verify each plasmid generated and used. 
9.4.5 List of Plasmid used 
pTRIPZ_MRTF-HA2NLS: 
Full length MRTF-A (“MRTF-A siRAR”) cDNA generated originally by F. 
Miralles (Miralles et al. 2003; Zaromytidou et al. 2006) and was later modified by R. 
Pawlowski (Pawłowski et al. 2010). The cDNA was corrected for point mutations 
introduced originally during PCR and the primary DNA sequence is modified in 
order to become resistant to siRNA oligos targeting from nt 521 to 532 (sequence 
AGCTGGTGGAGA changed in AACTAGTAGAAA). HA2NLS was sub-cloned from 
plasmids encoding MAL-HA originally generated by S. Guettler (Guettler et al. 
2008) by digesting MAL-HA with BbsI and XbaI. The HA2 NLS was fused to the 
siRAR-MRTF-A and then cloned into the pTRIPZ vector using homologous 
recombination as described above. 
 
pTRIPZ_MRTF-HA2NLSmut: 
This plasmid was generated as the pTRIPZ_MRTF-HA2NLS. The MRTF-A 
siRAR was used as substrate to introduce HA2NLSmut (with point mutations 
destroying the nuclear localisation signal) originally cloned by S. Guettler (Guettler 








The pTRIPZ_MRTF-HA2NLSmut was used as substrate to sub-clone using 
BamHI sites the RPEL motifs at the N-terminus of the MRTF123-1A originally cloned 
by S. Guettler obtaining an MRTF123-1A siRAR. 
 
pTRIPZ_MC-HA2: 
Mouse Myocardin variant A obtained originally by F. Miralles by RT-PCR 
from mouse cardiac RNA and subcloned by S. Guettler in pEF as fusion to 2 C-
terminal HA tags. The cDNA was clones by homologous recombination into 
pTRIPZ vector. The cDNA was described in (Guettler et al. 2008). 
 
pTRIPZ_N12MC-MRTF-HA2: 
cDNA described in (Guettler et al. 2008). AA 2-148 of MRTF-A was 
exchanged for AA 1-94 of MC. The cDNA was cloned by homologous 
recombination into pTRIPZ vector. 
 
pTRIPZ_N123MC-MRTF-HA2: 
cDNA described in (Guettler et al. 2008). AA 2-187 of MRTF-A was 
exchanged for AA 1-133 of MC. The cDNA was cloned by homologous 
recombination into pTRIPZ vector. 
 
pMY_Elk-1 WT 
The cDNA was originally obtained by Thomas Ross in the lab and described 
previously (Cruzalegui et al. 1999; M. A. Price et al. 1995; Marais et al. 1993). The 
original human Elk-1 cDNA was fused at its N-terminus with a Flag tag leaving the 
ATG starting codon of Elk-1. The ATG codon was modified in GTG by PCR during 
the cloning of Elk-1 in the retrovirus expressing vector pMY-IRES GFP between 
XhoI and NotI. 
 
pMY_Elk-1 FW 
The cDNA was originally obtained by Thomas Ross in the lab and described 
previously (Cruzalegui et al. 1999; M. A. Price et al. 1995; Marais et al. 1993). The 
original human Elk-1 FW cDNA was fused at its N-terminus with a Flag tag leaving 
the ATG starting codon of Elk-1. The ATG codon was modified in GTG by PCR 
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during the cloning of Elk-1 in the retrovirus expressing vector pMY-IRES GFP 
between XhoI and NotI. The AA in positions 378 and 379 (corresponding to the FW 
AA) were deleted. 
 
pMY_Elk-1 NONA 
The cDNA was originally obtained by Thomas Ross in the lab and described 
previously (Cruzalegui et al. 1999; M. A. Price et al. 1995; Marais et al. 1993). The 
original human Elk-1 cDNA was fused at its N-terminus with a Flag tag leaving the 
ATG starting codon of Elk-1. The ATG codon was modified in GTG by PCR during 
the cloning of Elk-1 in the retrovirus expressing vector pMY-IRES GFP between 
XhoI and NotI. Amino acids in position 324, 336, 353, 363, 368, 383, 389, 417 and 
422 were mutated to alanine. 
 
pBACpAK_SRF and pBACpAK_MRTF 
The original sequence was obtained from the one in use in the lab and 
already described (Guettler et al. 2008; Miralles et al. 2003; Vartiainen et al. 2007) 
and the cDNA was optimised using the Invitrogen GeneArt® services for sf9 
expression. The cDNA was cloned through homologous recombination into a 
modified pBApAK (see previous sections). Each cDNA is fused at its N-terminus to 
a 6x His tag followed by a TAP tag and a TEV site. 
9.5 Mammalian cell culture 
NIH3T3 and MEF derived cells at 50% confluence were cultured in DMEM 
(Gibco, Invitrogen) supplemented with 10% FCS at 37°C and 10% CO2. Cells 
carrying pTRIPZ vectors were maintained in media supplemented with puromycin 
at 1µg/ml. To split confluent cells, cells were washed with PBS and then treated 
with trypsin/versene until they detached (2-3 minutes). Media containing 10% FCS 
was added and cells were distributed to new dishes. Cells were serum starved in 
0.3% FCS DMEM either over night for NIH3T3 or for 48h for MEF cells. For the 
selection of cell harbouring the desired plasmid, cells were transfected with 
lipofectamin reagents (see following section) and treated with puromycin (1-2 
µg/mL) for 2 to 3 weeks. Cells not transfected were treated in parallel as reference 
for negative selection of cells not expressing the resistance marker. 
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9.5.1 Stimulation conditions: Drugs concentration 
The conditions used in each experiment included a step of serum starvation 
(overnight for NIH 3T3 and 48h for MEFs). Cells were then treated for the indicted 
times using different components: 
Leptomycin B (LMB) was used at 50nM. A mix containing warm DMEM with 
no serum and LMB at 150nM was vortex in glass vials. Following starvation the 
media was removed from cell plates and a third of the final volume of DMEM and 
LMB mix was add to the cells. Two thirds of the final volume of warm DMEM 
without serum was then ad to reach the final concentration of LMB (50nM). This 
step was performed to ensure homogeneity of cells as was observed that LMB is 
prone to precipitate in aqueous solutions. The same steps were followed for the 
0.3% FCS condition using warm DMEM with no LMB and serum to exclude 
possible effects caused by the changes in media. 
Cytochalasin D (CD) was used at a final concentration of 3µM and the steps 
of media vortexing and changes were followed as for the LMB condition. 
Latrunculin B (LatB) was used at a final concentration of 0.5µM and the 
steps of media vortexing and changes were followed as for the LMB and CD 
conditions. 
12-O-Tetradecanoylphorbol-13-acetate (TPA) was used at 50ng/ml. For 
homogeneity warm DMEM with no serum was mixed with TPA and add to the cell 
layer. 
9.5.2 Transient transfection of plasmid and siRNA 
NIH 3T3 were transfected using Lipofectamin 2000 reagent (Invitrogen) 
following the manufacturer’s instruction. This procedure was used to generate 
stable cell lines harbouring pTRIPZ vector. I observed that in order to have efficient 
expression of the target protein 10cm plates needed to be treated with at least 10-
15 µg of plasmid DNA. For plasmid transfection cell were seeded on the day of 
transfection, 5 to 6 hours were allowed for the attachment of the cells in 10 cm 
plates and the media was substituted with 4ml of Optimem. 10-15 µg of plasmid 
DNA was mixed with 0.5 mL of Optimem and 10 µl of Lipofectamine 2000 was 
mixed with an equal amount of Optimem. After 5 minutes incubation the two mix 
were combined and incubated at room temperature for 20 minutes. The DNA 
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lipofectamin mix was then added to the cell layer and left to incubate for 2 hours in 
the incubator. The transfection mixture was then replaced with warm fresh media. 
 
HEK-GP293 (Clontech) were transfected using Fugene (Promega) under 
containment conditions. To transfect a 10cm of growing GP-293 557µl of Optimem 
were mixed to 23µl of Fugene in polypropylene tubes and incubated for 5 minutes 
at room temperature. In a clean polypropylene 7.5µg of retroviral vector together 
with 6 µg of VSV-G expressing vector were combined with the Fugene Optipmem 
mix. After 15-30 minutes of incubation the transfection mix was added drop wise to 
the GP-293. 
 
siRNA oligos were transfected into MEF cells using a reverse protocol to 
maximise performance using the RNAimax (Invitrogen). The siRNA oligos were 
purchased from Dharmacon as ON-TARGET plus pool of 4 or as single ssRNA 
oligos. The dry oligo pellet was dissolved in 1x siRNA buffer from Dharmacon to a 
final concentration of 20µM. The assays were performed in different plates or 
dishes according to the type of experiment.  
For the siRNA screen 24 well plates were used. 62.5µl of Optimem were 
mixed with 0.625µl of siRNA oligo (stock solution 20µM) and 62.5µl of Optimem 
were mixed with 0.75µl of RNAiMax (Invitrogen). The mix were incubated for 5 
minutes at room temperature and then mixed and left to incubate at room 
temperature for 20-30 minutes. During this incubation cells were detached and 
diluted in media to reach a concentration of 20000 cell/ml. The 125µl of siRNA and 
RNaiMax were mixed directly in the well of a 24-well plate with 500 µl of cell 
suspension. The transfection was carried for 72 hours. Cells were then starved for 
two days and treated for 30 minutes with TPA (50ng/ml). 
To perform siRNA ChIP assay the quantities were scaled up: 1.5ml of 
Optimem were mixed with 15 µl of siRNA oligos and 1.5ml of Optimem were mixed 
with 18 µl of RNAiMax. The two mix were incubated for 5 minutes at room 
temperature and then mixed for 20-30 minutes. 12ml of cells in suspension at a 
concentration of 60000 cell/ml were mixed directly in 15cm dishes with the 3ml mix. 
As above the cell were left for 72h then starved for two days and finally treated with 
TPA for 30 minutes. 
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9.5.3 Retrovirus infection and cell sorting 
Retroviruses were prepared using HEK-GP293 and Phoenix cells able to 
produce the virus in big quantity. These cells were cultured as for NIH3T3 and MEF. 
As low adherent no trypsin/versene was used, instead mild re-suspension with 
media was enough to detach the cells from the plate. The two stages infection from 
GP-293 to phoenix and then to target cells was followed to minimise cross infection 
and hazards. GP-293 are HEK-293 cells that stably express Gag and Pol viral 
proteins. In order to allow the production of viral particles transfection of the 
retroviral vector, containing the protein of interest, and the vector harbouring the 
envelop protein VSV-G is required. Phoenix cells on the other hand are helper-free 
cells meaning that they express all the constituents in order to produce a viral 
particle given a retroviral vector equipped with the viral package signal and the 
transcription/processing elements. Phoenix cells were seeded at 2.5X105 in 6-well 
plates on the day before the infection (24h after transfecting the Gp-293). The 
supernatant of GP-293 cells was harvested 48h after transfection and fresh media 
was added to the cells (see previous section). The supernatant was passed 
through a 0.45µm filter and supplemented with Polybrene at a final concentration of 
5ug per ml. 2ml of filtered supernatant was used to infect each well of the 6-well 
plate of phoenix. The plates were centrifuged at 1200 rpm 26°C for 90minutes in a 
centrifuge with swinging buckets. This step was repeated twice with the remaining 
media. The following day the procedure was repeated with the media harvested 
from GP-293 (72h after transfection). The infected Phoenix cells were grown and 
expanded for 2 weeks in containment conditions and freezed.  
To infect target cells, such as ESN MEF, Phoenix cells were expanded and 
grown in 10cm dishes for 48h. The media was harvested and the procedure as 
described above repeated. ESN MEF were grown in 6-well plate and infected twice 
in a day with media harvested at 48h and once with media harvested at 72h. Cells 
were grown and expanded until reaching a 70% confluent 15cm dish.  
As ESN MEFs were derived from knockout mice expressing several 
markers of resistance we used the pMY-IRES-GFP vector to ectopically express 
Elk-1 derivatives. Stable cell lines expressing the desired amount of protein were 
collected according to the GFP expression using Fluorescence Activated Cell 
Sorting (FACS) by the FACS laboratory. Three populations were collected as high, 
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low and medium expressing according to the GFP level. Cells were expanded and 
the protein amount compared performing western blots.  
9.5.4 Mouse embryonic fibroblast preparation and immortalisation 
Robert Nicholas and Victoria Lawson generated ESN MEF from mice Elk-1-/-
SAP-1-/-Net∂/∂. After having sacrificed a pregnant mouse at the desired dpc (day 
post coitum) the uterine horns were dissected and placed into cold PBS. Each 
embryo was separated from the horns and placental and embryonic sac in petri 
dishes. The head and red organs were separated from the main trunk. The 
collected tissue was washed in PBS and placed into a clean 6-well plate. Parts of 
the head or red organs were used later to collect total genomic DNA for 
genotypiong. The tissue was then finely minced and placed into glass vials with 
magnetic stirrer and 2ml of trypsin/versene. Each glass vial was incubated in a 
water bath at 37°C for 15min under agitation. Following these steps 10ml of warm 
media supplemented with 10% FCS was added to the shredded tissue and slowly 
re-suspended up and down several times. Cells were centrifuged at low speed 
(300xg) for 5 minutes, the supernatant was removed and the cell pellet re-
suspended with fresh DMEM 10% FCS media and plated in 10 cm dishes.  
 
MEFs were immortalised using SV40 T antigen. Phoenix cells were grown in 
10cm plates and when 70% confluent were transfected using Fugene with 2µg of 
pBABE-SV40 large T-hygromycin. Supernatant was harvested 48h after 
transfection, filtered with 0.45µM syringe filter and gave to MEF as medium in 10cm 
plates with 8µg/ml of polybrene. MEFs were then allowed to reach confluence. 
After 24h from the infection cells were split and after 6 to 8h hygromycin 
(Invitrogen) was added at a concentration of 50µg/ml. In parallel some MEF were 
grown without infection as a control for negative selection. 
9.5.5 Cell growth analysis 
In the result section we analysed the growth and proliferation of MEF wild 
type and ESN MEF using three approaches: 
Crystal violet staining assay 
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Cells were seeded at equal concentration in 10cm plates (15-20% confluent) 
and allowed to grow for 3 days. Cells were fixed in 3.7% Paraformaldehyde (PFA) 
for 5 minutes and then incubated for 30 minutes with an aqueous solution of 
Crystal Violet 0.05% (Filter at 0.45µm before use). The plates were washed with 
double distilled water several times and dried.  
Cell Enumeration time course: 
Cells were seeded in several plates at 15-20% confluent and harvested with 
trypsin/versene everyday for 4 days. Cells were fixed with cold 70% ethanol and 
counted using Fluorescence Activated Cell Sorting (FACS) by the FACS laboratory. 
BrdU staining 
Cells were treated with 10µM Bromodeoxyuridine (BrdU) for 4h, harvested 
and then fixed with 1ml of ice cold 70% ethanol under agitation and incubate on ice 
for 30 minutes. Cells were then centrifuged and washed twice in PBS. The FACS 
laboratory performed the following steps: Cells were re-suspended in 500µl of 2M 
hydrochloric acid (HCl) and incubated at room temperature for 20-30 minutes. Cells 
were pelleted at 2000rpm for 5 minutes and washed twice in PBS and once in 
PBS-Tween (PBS + 0.1% BSA + 0.2% Tween 20, pH 7.4). Pellet cells were 
incubated for 20 minutes in the dark at room temperature with 100µl of anti-BrdU 
antibody (Sigma cat no. B5002, stock 1mM) diluted 1 in 50 in PBS-Tween. 
Following a wash with PBS-Tween cell pellets were incubated with the secondary 
antibody anti-BrdU antibody (Becton Dickinson, cat no. 347580) diluted 1 in 200 in 
PBS-Tween for 20 minutes in the dark at room temperature. Following a wash in 
PBS-Tween cell pellets were incubated with 50µl of ribonuclease A and 150µl 
propidium iodide (PI) at room temperature, in the dark for at least 30 minutes. 
The distribution of the cell population across the G1, S and G2/M phases 
were analysed using a flow cytometry system and the data was processed using 
FlowJo. Several gates were applied through the analysis to select single cells and 
exclude debrides (see London Research institute technologies web site).  
9.5.6 Immunofluorescence 
The immunofluorescence approach was performed on coverslip either 
obtained from 6-well plates, were cells were grown 60-70% confluent, or from 
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coverslip included in 15cm dishes used to prepare chromatin samples after fixation 
(see the Chromatin immunoprecipitation section). 
Following the desired condition, usually including a step of over night serum 
starvation and 30 to 1 hour stimulation, cell were fixed with 4% paraformaldehyde 
for 10 minutes at room temperature (coverslip obtained from 15cm during the 
preparation of chromatin samples were fixed with 1% final formaldehyde for 10 
minutes at 37°C and then incubated with Glycine 250mM final for 5 minutes). Cells 
were washed 3 times with PBS and then permeabilised with 0.2% Triton-X in PBS 
for 10 minutes. Non-specific binding was then blocked with blocking solution (10% 
FCS, 1% fish skin gelatine in PBS) for 1 hour and room temperature. Following this 
step cells were incubated with the cell side on 50µl drops containing the primary 
antibody diluted in blocking solution for 1.5 hours in a close humidified environment. 
Coverslip were briefly washed by dipping in PBS three times and then incubated 
with the secondary antibody including DAPI and phalloidin. Finally cells were 
washed three times in PBS, once in double distilled water and then mounted on 
microscope slides using Mowiol. Cells were incubated in the dark at room 
temperature to let the Mowiol to dry. The images were taken using a Zeiss Axiovert 
microscope equipped with a camera. As described in the figure legends throughout 
the result section the localisation of MRTF was scored as nuclear, cytoplasmic or 
pancellular in at least 150 cells per slide analysed. The distribution of MRTF was 
assessed considering where it was found predominantly between the two cellular 
compartments.  
9.6 Protein purification 
9.6.1 Expression and purification of recombinant SRF and MRTF 
The Protein Purification Facility (PPF) at Lincoln’s Inn Fields Laboratories 
performed the generation of insect cell culture, the isolation of recombinant 
baculovirus expression vector using the BacPAK system (Clontech) and the 
infection of target insect cells (Sf9, Spodoptera frugiperda). For an extended 
protocol see Laboratories 2013.  
 
Sf9 pellet cells, obtained following infection, were kept at -80°C. On the day 
of protein extraction and purification the pellet was thaw in 10ml of Lysis Buffer 
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(50mM NaPi buffer pH 7, 500mM KCl, 0.005% Brij-35, 1mM DTT, 5mM EDTA, 
1mM EGTA, Protease inhibitions) per gram of cell pellet. The mix was pipetted up 
and down several times and transferred into a glass beaker, pre-cooled on ice, 
together with a stir magnetic bar. The lysate was mixed in a cold room for 15 
minutes to dissolve clamps. Cells were lysed by passing them twice through a pre-
cooled (on ice) “french-press” or dounced 6x20 times on ice. The lysate was then 
centrifuged at 50000 rpm (256630 rcf) for 40 minutes at 4°C in a Ti70 UZ rotor. 
During the centrifugation 0.5ml of IgG Sepharose beads, per 2 liters of culture (GE 
helth care), were equilibrated with the lyse buffer by washing 3 times in 10ml and 
pelleting them at 1500 rpm for 5 minutes. The quantity of beads can vary according 
to the amount of protein expressed by the Sf9. The clarified lysate was mixed with 
the equilibrated beads in batch and let under rotation overnight at 4°C. The day 
after, beads were pelleted at 1500 rmp for 5 minutes at 4°C and combined in a 
50ml falcon (Note: the beads were never let to dry, about 0.5ml of buffer were 
always left at the bottom of the falcon tube). Cells were washed with 50ml of lyse 
buffer 5 times. Lastly the pellet of beads was resuspend in 1.5-2ml of lyse buffer 
and combined with 30µl of AcTEV Protease (Invitrogen) in a 2ml eppendorf tube 
and let over night at 4°C on a rotating wheel. The day after the supernatant was 
collected and separated by the beads using a chromatography empty column 
equipped with a filter at its bottom. The beads were washed with an additional 5ml 
of lysis buffer, to collect supernatant soaked into the sepharose. The collected 
protein was concentrated to reach about 0.5ml volume using an ultrafiltration spin 
column with a cutoff of 30KDa (Vivaspin turbo 15, Sartoriusstedim biotech). The 
concentrated protein was then subjected to gel filtration chromatography on a 
calibrated Superose 6 column (GE Healthcare) using the same lysate buffer. 500µl 
fractions were collected and 10 µl of each were resolved by 4-12% SDS-PAGE 
followed by Coomassie brilliant blue staining. Fractions showing a good quantity of 
the desired protein were combined and concentrated again to reach 0.5ml volume. 
The collected protein was quantified using standard Bradford assay and aliquoted 
in 0.1 ml Individual UTW Tubes (Thermo scientific) and snap froze in liquid nitrogen. 
The aliquots were kept in paper boxes either in liquid nitrogen or at -80°C. 
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9.6.2 Purification of rabbit skeletal muscle actin 
This protocol was performed together with Richard Panayiotou and Jessica 
Diring. 
Acetone Powder preparation 
Rabbit skeletal muscle actin was purified as previously described (Feuer & 
Molnar 1948; Spudich & Watt 1971). All the procedure was carried out at 4°C 
unless stated differently. About 500g of white rabbit leg muscle was minced several 
times with the help of a mean mincer. The minced muscle was mixed for 10 
minutes in 2 litres of 10mM KCl solution, 10 minutes in 2 litres of 50mM KaHCO3 
solution and 10 minutes in 2 litres of 1mM EDTA solution. The homogenate was 
separated in half (each part corresponding to 250gr of starting material) and each 
part was then washed twice for 5 minutes in 3.5 litres of water and then brought to 
room temperature. The homogenate was briefly washed in 3.5 litres of cold 
acetone and then washed three times for 10 minutes each in two volumes of 
acetone at room temperature. These last washes were done using a magnetic 
stirrer to keep the homogenate mixing during the 10 minutes incubation. At this 
stage the homogenate was dried on 3MM Whatman paper in a fume hood and the 
acetone powder was then stored at -80°C. 
Actin extraction 
10gr of acetone powder were hydratated in 200ml of ice cold G-Buffer (5mM 
Tris-HCl pH 8, 0.2mM CaCl2, 0.2mM ATP, 0.5mM DTT, 0.15mM PMSF) for 1 hour 
on ice. The homogenate was then filtered through 4 layers of plain muslin and the 
filtrated collected as the fraction containing actin. This step was repeated once 
more with 100ml G-Buffer and the two filtrated pooled together. The Filtrated were 
cleared from insoluble materials by centrifugation at 27000 xg at 0°C in a Beckman 
JLA- 16.250 rotor in a Beckman Coulter Avanti J-25 centrifuge.  
The filtrated was adjusted to 1 mM ATP, 2 mM MgCl2 and 50 mM KCl and 
incubated under slow stirring for 2 hours in order to polymerise the monomeric 
actin in solution. The actin binding proteins, contaminating the sample, were 
removed by adding solid KCl to 600mM and mixed under vigorous stirring for 1.5 
hours. The polymerized actin was collected by centrifugation at 34,000 rpm for 1.5h 
Chapter 9 Materials and Methods 
 
 268 
in a Beckman Coulter Optima L-100 XP ultracentrifuge with a Beckman Type 50.2 
Ti rotor. The pellet made of F-actin was resuspended in G-Buffer containing 0.5mM 
ATP and 1mM DTT to reach about 30ml. The mix was Dounce homogenized on ice 
between 60 and 100 times. The mix was then dialysed against 2 litres of G-Buffer 
for 3 days.The concentration of ATP during dialysis was reduced on the last day to 
0.2mM. Lastly monomeric actin was separated from filamentous actin and insoluble 
material by centrifugation at 100000 xg for 30 minutes. Finally actin was stored in 
aliquots after snap-freeze at -80°C. 
Preparation of Latrunculin B-actin 
The final actin stock was kept in solution with Ca2+. In order to convert the 
Ca2+-actin into Mg2+-actin was dialysed overnight into Mg2+-G-buffer (2 mM Tris-
HCl pH 8.0, 0.3 mM MgCl2, 0.2 mM EGTA, 0.2 mM ATP, 0.5 mM DTT). A 5-fold 
molar excess of latrunculin B (LatB; Calbiochem), quickly mixed to the dialysed 
actin and incubated overnight at 4°C. To remove uncomplexed actin, a 20x 
initiation buffer (2 M NaCl, 60 mM MgCl2, 10 mM ATP) was added and the mixture 
was incubated for 2 hours at 4°C. Following this step filaments were precipitated by 
centrifuging the sample at 2000000 xg for 15 minutes at 4°C in a Beckman TLA 
120.2 rotor in a in a Beckman TL-100 tabletop ultracentrifuge. The supernatant was 
aliquoted and stored at -80°C. 
9.7 Western-blotting 
Proteins samples were collected by harvesting cells cultured in 6-well plates 
directly by adding 200µl of 2x laemmli buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 
20% glycerol, 5% β-mercaptoethanol, bromophenol blue). Samples were collected 
by scraping the wells with CytoOne Cell Scraper (220 mm, 11 mm Fixed Blade 
from Starlab) and sonicated for 1 minute in 1.5ml eppendorf tubes in a BioRuptor 
water bath sonicator. Proteins were separated according to their size using sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). NuPAGE Novex Bis-Tris 4-12% 
gradient gels (Invitrogen) were used following the instruction provided by the 
manufacturer. 20µl of protein lysate were loaded per lane and the electrophoresis 
was carried out at 150-200 volts in MOPS SDS running buffer (Invitrogen). The 
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SeeBlue Plus2 Prestained Standard (Invitrogen) was used as reference in each 
experiment. 
The primary antibodies used were: SRF (G20 sc-335, Santa Cruz), HA 
(High affinity peroxidase conjugated 3F10, Roche), phospho-p44/42 ERK1/2 (Cell 
Signalling), Flag (F7425, Sigma), MRTF-A (C-19 sc-21558, Santa Cruz), Actb (C4 
sc-47778, Santa Cruz). The secondary antibodies were all purchased from Dako 
and use 1:10000. 
9.8 DNA pull down assay 
Preparation of magnetic DNA affinity beads 
Two Biotynilated DNA fragments, 120 bp long, were generated by PCR 
using as templates the wild-type c-fos promoter plasmid, pF711, containing 711bp 
of the 5’ flanking sequence (Treisman 1985) and the pFosΔSRF plasmid (Hill & 
Treisman 1995a), where the SRE was mutated to create an MCM1 binding site 
were SRF cannot bind anymore. 
The PCR reaction was carried out using MyTaq Red (Bioline) preparing 50 
µl of reaction mix as follows: 
 
50ng Template plasmid 
1x NH4 Buffer 
5 µl MgCl2 
1 µl dNTP mix 
1 µl of Forward Biotynilated primer (Sequence: CGCACTGCACCCTCGGTG) 
1 µl of Reward primer (Sequence: GGTCCCCCCCCCAGAACAACAGGGA) 
1 µl of RedTaq 
and H2O to reach 50µl 
 
PCR cycling: 
Denaturation stage: 95°C for 5 minutes at least as first stage, for each cycle allow 
45 seconds 
Anneal stage: 65°C, for 45 seconds 
Elongation stage: 72°C for 45 seconds 
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Each cycle comprising Denaturation, anneal and elongation was repeated from 30 
times. 
 
The PCR reaction was scaled up to 96 independent reactions to reach a 
total of 4.8ml. The product was phenol-chloroform extracted by mixing the sample 
1:1 with a saturated phenol:chloroform:isoamyl alcohol solution (25:24:1, Sigma). 
The sample was then centrifuge at maximum speed for 5 minutes in a tabletop 
centrifuge. The upper aqueous phase was moved to a clean tube and the 
described steps repeated twice again (phenol:chloroform:isoamyl alcohol mix, spin 
and phase separation). Traces of phenol were removed by mixing 1:1 the samples 
(aqueous phase) with chloroform and centrifuged for 5 minutes. The upper 
aqueous phase was then transferred to a clean tube and subject to ethanol 
precipitation. The sample was mixed with 3M NaOAc ph 5.2 (1/10 of the sample 
volume), and 2.5-3 volumes of 100% ice cold Ethanol. The mix was incubated on 
dry ice for 1 hour and then centrifuged at maximum speed for 30 minutes in an 
Eppendorf 5415 R tabletop centrifuge at 4°C. The pellet of DNA was washed twice 
with 500µl of 70% ethanol solution in water. Finally the pellet was re-suspended in 
500µl of TE solution (TRis-HCl 10mM, EDTA 1mM).  
The biotin-labelled dsDNA was coupled to streptavidin magnetic beads 
(Dynabeads® M-280 Streptavidin, Invitrogen). Beads were washed twice in DW 
Buffer (20 mM Tris-HCl pH 8.0, 2M NaCl, 0.5mM EGTA, 0.03%NP40). The 
biotynilated dsDNA was coupled to the washed beads in 0.5x DW Buffer for 30 
minutes at room temperature on a turning wheel (each mg of dynabeads were 
coupled to 250 pmol of dsDNA, considering the 120bp dsDNA used each mg of 
dynabeads were coupled to 20µg of DNA). The dsDNA coupled to beads were 
washed five times in DW buffer and finally once in TE-NP40 (10mM Tris-HCl, 1mM 
EDTA, 0.02% NP40). Beads were equilibrated in 1x Buffer G (10mM Tris-HCl pH 8, 
20mM HEPES pH 8, 1.5mM MgCl2, 100mM NaCl, 0.2mM EGTA, 10mM Potassium 
glutamated, 0.02% NP40, 10mM DTT) and then used for the assay. 
DNA pull down assay 
The DNA pull down was carried out in G Buffer in the presence of 3mM 
Sperimidine and 20ng/µl of polydI-dC (Sigma). The equilibrated Dynabeads 
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coupled to the dsDNA were mixed with recombinant SRF and incubated under 
agitation for 20 minutes at 30°C. The beads were then washed 5 times with 500µl 
of G Buffer and used as substrate for MRTF. MRTF binding and washes were 
carried out as for SRF. The amount of both SRF and MRTF were estimated by 
performing a titration of both in order to obtain a good signal keeping the negative 
control MCM1 devoid of unspecific interaction. Finally pure actin was mixed in G 
Buffer at increasing concentrations with the washed beads carrying SRF and 
MRTF and incubated for 15 minutes at 30°C. The beads were washed 5 times in G 
Buffer and the bound proteins collected in SDS sample buffer for western Blotting. 
9.9 Gene expression analysis by quantitative Q-PCR 
Cells were grown in 6-well plates and staved either over night (NIH 3T3) or 
for 48 hours (MEF wild type and ESN MEF) and then stimulated as described in 
each experiment. RNA was extracted using GenElute Mammalian Total RNA 
Miniprep Kit following the manufacturer instruction (Sigma). The extracted RNA 
was eluted from columns in 50-70µl of ultra clean double filtered water. 5µl of total 
RNA were treated with 1µl of DNAseI (Ambion, Invitrogen) and 1µl of DNaseI buffer 
(provided with the enzyme). The mix was incubated in PCR strips or PCR plates. 
The PCR strips and plates were incubated in termo-cycler for 15 minutes at 37°C. 
The reaction was stopped by adding 1µl of 25mM EDTA solution and incubation at 
65°C for 10 minutes. The DNaseI treated mix of 8µl (5µl of initial RNA, 1µl of 
DNaseI, 1µl of DNase I buffer and 1µl of EDTA solution) was then used to 
synthesise cDNA using SuperScript III (SSIII) First Strand Synthesis system and 
random hexamer primers (Invitrogen) as follow. 1µl of Ransom hexamer and 1µl of 
dNTP mix were add to the 8µl sample and incubated at 65°C for 5 minutes and 
quickly chilled on ice. 10µl of cDNA synthesis mix (2µl of 10x Buffer solution, 4µl of 
25mM MgCl2, 2µl of 100mM DTT, 1µl of RNaseOUT from Ambion, 0.5µl of SSIII 
and 0.5µl of water) were add to the treated samples and mixed well by pipetting up 
and down. The cDNA synthesis was performed as follows: 10 minutes at 25°C, 50 
minutes at 50°C and 85°C for 5 minutes. The samples were diluted with ultra clean 
water 1:10.  
SYBR-Green based real-time PCR (Invitrogen) was assembled by mixing 
8µl of reaction mix (0.2 µl of FW primer, 0.2 µl of RW primer, 2.6 µl water, 5 µl of 
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SYBR-Green mix) with 2 µl of cDNA. The RT-PCR was conducted in ABI Prism® 
7900HT Sequence Detection System following an initial denaturation step at 95°C 
for 5 minutes and then a fast cycle: 10 seconds 95°C, 60°C for 20 seconds 
repeated 40 times. The relative abundance of template cDNAs were normalised to 
GAPDH. 
9.9.1 List of primers used 
Gadph FW   TCTTGTGCAGTGCCAGCCT  
Gadph RW   CAATATGGCCAAATCCGTTCA  
Ctgf Intron FW  GCTCCTCGCTCTCTGCAC 
Ctgf Intron RW  TGTGATCGCAGCTCACTCTG 
Ctgf Exon FW  GGAGGAAAACATTAAGAAGGGCAA 
Ctgf Exon RW  AACTTGACAGGCTTGGCGAT 
Vcl Intron FW   CGTCACTTGCGTTGAGTACC 
Vcl Intron RW   GAAACCACCCACAGGTTGGA 
Vcl Exon FW   ACGGCTCTAGGGGAATCCTT 
Vcl Exon RW   TTACGAACCTCAGCCTCATCG 
Srf Intron FW   TCAAGGCAGCAGCAGTTTCT 
Srf Intron RW   CAGGCAGGGTTAGGAACCAG 
Srf Exon FW   TGAAGAAGGCCTATGAGCTGTC 
Srf Exon RW   ACACATGGCCTGTCTCACTG 
Acta2 Intron FW  CCAGAAGCAATGCGTCCACT 
Acta2 Intron RW  TGAGGTAGTTGCCTGCTCTC 
Acta2 Exon FW  CTGTCAGGAACCCTGAGACGC 
Acta2 Exon RW  GGCTGTGCTGTCTTCCTCTT 
Dusp5 Intron FW  GAGCACGTTAGGCTGTGTCT 
Dusp5 Intron RW  GCCAGGGTCAAAAAGGCAAG 
Dusp5 Exon FW  ACTGCTGACATTAGCTCCCAC 
Dusp5 Exon RW  TTCTTCCCTGACACAGTCAATAAAA 
Pdlim5 Intron FW  GCTTAGTTAGGATGGCCGCT 
Pdlim5 Intron RW  CCTTGTGTCGACAGAGTGCT 
Pdlim5 Exon FW  GCAAAATGGGAAAATTCCACCTA 
Pdlim5 Exon RW  TGCGCTCCACAATGTGTTTT
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Cyr61 Intron FW  CGTAAACTGCCCTGAGCCTA 
Cyr61 Intron RW  GACGCGATCGAGACACTTCT 
Cyr61 Exon FW  ATCGCAATTGGAAAAGGCAGC 
Cyr61 Exon RW  GGTGCCAAAGACAGGAAGCCT 
Serpine1 Intron FW  GTTGGAAGTGCGGTTTGACC 
Serpine1 Intron RW  GCCTTTAGTCCACCCTAGCC 
Serpine1 Exon FW  CATGTTTAGTGCAACCCTGGC 
Serpine1 Exon RW  CTGCTCTTGGTCGGAAAGACT 
Tpm1 Intron FW  AGGTGGGCCAGGATTCAAAC 
Tpm1 Intron RW  CTGATCCGTGCCTGGCTAAC 
Tpm1 Exon FW  GCCCGTAAGCTGGTCATCAT 
Tpm1 Exon RW  CGGCACATTTGCCTTCTGAG 
Thbs1 Intron FW  CTCCTTTATCCTGCCCCGTC 
Thbs1 Intron RW  GTGAACCCGAAGGCTGAAGA 
Thbs1 Exon FW  GAACAACGAGGAGTGGACTGT 
Thbs1 Exon RW  TAACCGAGTTCTGGCAGTGAC 
Palld Intron FW  CACAGCGCCATTGTCTTAGC 
Palld Intron RW  GTTGCCGCAGAATGCCTTAG 
Palld Exon FW  ACGTTCAGATCCACTGCGAG 
Palld Exon RW  CGACCTGTGTCGTCCTCAAA 
Bok Intron FW  GAACCTATCGCCACTTCCCT 
Bok Intron RW  TAAATCTCGCAGATCCCAGCG 
Bok Exon FW   CTTCTCAGCAGGTATCACATGG 
Bok Exon RW  CCACGGAATACAGGGACACT 
Ankrd1 Intron FW  CCACTCAACCCACTCAACCA 
Ankrd1 Intron RW  GGAATAATGTGGGGTTGGCG 
Ankrd1 Exon FW  GCCAGTTCCAGGGGTTCATC 
Ankrd1 Exon RW  TTTTGCCTGTTACCAGCTCCT 
Wdr1 Intron FW  CTGAGCACGGGAGAGACAAG 
Wdr1 Intron RW  AATGAGTCAGTCTGCTGGGC 
Wdr1 Exon FW  TGAGTACCAGCCTTTCGCTG 
Wdr1 Exon RW  GCTCCAAACTTCTCCCTTCCT 
D4Bwg0951e Intron FW CTCGCCCTTGATGTGCTTGT 
D4Bwg0951e Intron RW GGGTAGGAGGCAGTCATTAGC 
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D4Bwg0951e Exon FW AGGGAGCTACCTGGACACTT 
D4Bwg0951e Exon RW TCTGAAGGGGTCTGATGACCT 
Pdlim7 Intron FW  TAGGGGCTCGGGATATGAGG 
Pdlim7 Intron RW  AAAATGGCTAGGACCCGCTC 
Pdlim7 Exon FW  TGTGGATCCTGCATTTGCTGA 
Pdlim7 Exon RW  CACTGTGCTGGTTTTGTCTGG 
Dstn Intron FW  ATAGCAACTGGCTTGCAGGT 
Dstn Intron RW  ACAGCTAAGCATGGTCCGTT 
Dstn Exon FW  CGAACATGGCCTCAGGAGTT 
Dstn Exon RW  GGTGTGGAACATTTCCGAACTT 
Vgll3 Intron FW  AGGTAGCAGAGGGTACCTGAG 
Vgll3 Intron RW  CATCCGACCAGTGTTCCACC 
Vgll3 Exon FW  GCCAGCAGAAGTTAGCGGTAT 
Vgll3 Exon RW  TTTGCTGGGAAGCGTGACTT 
Slc2a1 Intron FW  CCGGATTTACGGAACCCCTC 
Slc2a1 Intron RW  GCAAAGGCGGGACAAGAAAG 
Slc2a1 Exon FW  ATCTTCGAGAAGGCAGGTGTG 
Slc2a1 Exon RW  CAACAAACAGCGACACCACAG 
Klf6 Intron FW  TTGCGGAACGCAGTAGTTCT 
Klf6 Intron RW  AACAAGGCAGGCATACGTGA 
Klf6 Exon FW   ACGAAACGGGCTACTTCTCG 
Klf6 Exon RW  CAGGCAGGTCTGTTGCCAAT 
Rheb Intron FW  GAGAACGCAGAATGAACCGC 
Rheb Intron RW  GGCAGTAGAACACCTTCCCC 
Rheb Exon FW  GCTACCGGTCTGTGGGAAAG 
Rheb Exon RW  TGGTGAACGTGTTCTCTATGGTT 
Tpm4 Intron FW  AGTAGTAGGGCGGTGTTTGC 
Tpm4 Intron RW  ACTACGGCTTCAGGAGACCT 
Tpm4 Exon FW  CAAGTATGAGGAGGTTGCTCGT 
Tpm4 Exon RW  TCAGATACCTCCGCCCTCTC 
Klf7 Intron FW  CACTGGCTCCCTATACCGTG 
Klf7 Intron RW  GATCCAAAGCAGGGTTTGCC 
Klf7 Exon FW   CTCACACAGGTGAGAAGCCTTA 
Klf7 Exon RW  CTTGTGAGCTCATCGCTCCG 
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Zyx Intron FW  CAACCTGGCTCGTTCTCACT 
Zyx Intron RW  GACCATAACGAGGGGCTCAG 
Zyx Exon FW   GCTACACCGACACTTTGGAGA 
Zyx Exon RW   GTGAAGCACTGTGGGTGGTA 
Pdcl3 Intron FW  GGCGGTCACTTCTCAAGGAA 
Pdcl3 Intron RW  TGCTGCTGTCGACTGCTTAT 
Pdcl3 Exon FW  AAGTTACGAAAGCCGGCGA 
Pdcl3 Exon RW  AGAGGGGAATCCCTTGTTTGT 
Actb Intron FW  CGTAGCGTCTGGTTCCCAAT 
Actb Intron RW  GTGTGGGCATTTGATGAGCC 
Actb Exon FW  CGCCACCAGTTCGCCAT 
Actb Exon RW  CTTTGCACATGCCGGAGC 
Egr1 Intron FW  TGATGTCTCCGCTGCAGATC 
Egr1 Intron RW  GGTGGGTGAGTGAGGAAAGG 
Egr1 Exon FW  ATTGATGTCTCCGCTGCAGATC  
Egr1 Exon RW  TCAGCAGCATCATCTCCTCCA  
Fos Intron FW  GCATGGGCTCTCCTGTCAA 
Fos Intron RW  GACCTGGCGGCTACACAAA 
Fos Exon FW   TTCCTACTACCATTCCCCAGCC  
Fos Exon RW   GATCTGCGCAAAAGTCCTGTG  
Egr2 FW   GAGCAAATGATGACCGCCAA  
Egr2 RW   TGTCAGGCAGCTGGTGCATAA  
Ier2 FW   CCTGCGGTTCCTTTGTCCTTA  
Ier2 RW   TCACTTTGGTTTCCGACATGC  
Nr4a1 FW   CTTCTGTCACCCATGTGCCTTT 
Nr4a1 RW   TCAGTCTTAGCTCAAAACCAGGCT 
9.10 RNA-seq library preparation and data collection 
RNA-seq libraries were prepared by the Advanced Sequencing facility using 
directional mRNA-Seq Library Prep v1.0 Protocol from Illumina with minor 
adjustments. The samples were collected using GenElute Mammalian Total RNA 
Miniprep Kit and DNA contaminants were removed by treating the samples with 
DNaseI (see section above). To reduce the ribosomal rRNA in the libraries, 
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samples were processed using the Ribo-zero rRNA removal kit (Epicentre; 
separate CD-stimulation experiment). The Kapa HiFi HotStart ready mix, which 
reduced the overall volume of the PCR, was substituted to the Illumina kit Phusion 
enzyme and the ratio for the Agencourt AMPure XP beads was adjusted 
accordingly. The standard PCR cycle suggested by the Illumina protocol was 
changed to match the quantity of the total RNA measured initially with the 
Bioanalyser. The libraries were subject to cluster formation and then 72 single end 
sequencing using a Hiseq analyser.  
The Bioinformatics and Biostatistics group performed the annotation and 
collection of RNA-seq reads. The RNA-seq data collected were all aligned to the 
NCBI37/mm9 with the BWA (version 0.5.6) using default settings. The reads were 
aligned to the canonical gene features annotated in RefSeq. All Reads and reads 
with sequences included in intronic features, were annotated using coverage Bed 
(bedtools version 2.14.3) using the bam file obtained by bwa as input. The data 
was then normalised as in (Esnault et al. 2014) using the same set of 6664 genes 
not changing across conditions. As described in the result section the differential 
gene expression analysis was performed using DESeq (Anders & Huber 2010) at 
p<0.2 for genes induced by Cyrochalasin D while genes induced by TPA in MEFs 
were considered at p<0.05.  
The data were annotated in text files then analysed using Microsoft Excel 
and GraphPad Prism (GraphPad Software, Inc.). 
9.11 Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed as previously described (Miralles et al. 2003) 
with few modifications. Each replica point was obtained by growing 3 15cm dishes 
of cells 60-80% confluent. Cells were fixed for 10 minutes at 37°C by 
supplementing the culturing media with a 4% formaldehyde solution in PBS to 
reach a final concentration of 1% formaldehyde in solution. The reaction was then 
stopped by adding glycine directly to the plates to reach a concentration of 250mM 
in solution. Each dish of cell was washed twice with 20ml of cold PBS. Cells were 
kept on ice using metallic plates and ice buckets. Cells were collected by scraping 
the dishes with a rubber policeman with 3ml of cold PBS supplemented with 
Protease inhibitors. At this stage the three plates were combined into a 15ml falcon 
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tube and pelleted at 3000rpm at 4°C for 5 minutes using a Beckman GS-6KR 
centrifuge. The pellet of cells was washed once in 5ml of Buffer A (Hepes pH8.0 
5mM, KCl 85mM, 0.5% Triton-X-100, Protease Inhibitor cocktail, PMSF 1mM) and 
once with in 5ml of Buffer A’ (Hepes pH8.0 5mM, KCl 85mM, Protease Inhibitor 
cocktail, PMSF 1mM). Finally the crude nuclei were resuspended in 1ml of Buffer B 
(Tris-HCl pH8 50mM, 1% SDS, 10 Mm EDTA, Protease Inhibitor cocktail, PMSF 
1mM) and snap frozen on dry ice. At this stage cells could be kept at -80°C or thaw 
on ice to proceed with the sonication stage. DNA was sheared to reach an average 
of 300-500bp fragments using a Bioruptor® Plus (Diagenod) in 15ml Polystyrene 
tubes (blue cap) with automatic water bath cooling system. Before sonicating I 
checked that all the SDS contained in the sample was homogenously dissolved as 
this can cause changes in the fragment sizes. Four cycles of 30 s low intensity 
sonication followed by 30 s of pause were performed to reach the desired fragment 
size. Samples were sonicated three by three using aluminium rings to fit the falcon 
in the sonicator wheel The supernatant was collected by centrifugation and diluted 
1 in 10 in FA/SDS like buffer (Hepes KOH pH 7.5 50mM, NaCl 150mM, Triton-X-
100 1%, Na deoxycholate 0.1%, Protease Inhibitor cocktail, PMSF 1mM). 0.1ml of 
the diluted sample were kept as input sample, reverse-crosslinked overnight and 
purified using the QIAquick PCR Purification Kit. 
Each IP was performed with 1ml of the diluted sample (with 3 dishes we 
performed up to 10 IP with different antibodies). 0.5mg of magnetic Dynabeads 
(either IgG or IgM according to the type of antibody used) was used for each IP. 
The beads were washed three times with 1ml of PBS-BSA solution (PBS, 0.1% 
BSA w/v) and incubated with the desired antibody at 4°C under agitation for 1 hour. 
In parallel 0.25mg of beads were also washed three times in PBS-BSA and mixed 
with the 1ml sample to pre-clear unspecific bindings for 1 hour in the cold under 
agitation. The beads coupled to the antibody were then washed in clean tubes 5 
times with PBS-BSA. The washed beads coupled to the antibody were combined 
with the pre-cleared sample and left over night at 4°C under agitation. The day 
after the samples were collected, transferred to clean tubes and washed three 
times with 1ml of FA/SDS solution (Hepes KOH pH 7.5 50mM, NaCl 150mM, 
Triton-X-100 1%, Na deoxycholate 0.1%, EDTA 1mM, SDS 0.1%, Protease 
Inhibitor cocktail, PMSF 1mM). At the last wash the samples were incubated for 10 
minutes at 4°C under agitation. Finally the samples were washed with 1ml of WB 
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Buffer (Tris-HCl pH 8 10mM, LiCl 0.25M, EDTA 1mM, NP40 0.5%, Na 
deoxycholate 0.5%) and with 1ml of TE Buffer (Tris-HCl pH 8 10mM, EDTA 1mM). 
The Immune complexes were then eluted with 125µl of Elution Buffer (Tris-HCl pH 
7.5 25mM, EDTA 5mM, SDS 0.5%) at 65°C for 25 minutes using and Eppendorf 
thermocycler under agitation. The samples were then reverse cross linked over 
night with 10µl of Proteinase K at 65°C. The samples were then collected and 
purified using the QIAquick PCR Purification Kit. 
The samples were analysed using RT-PCR as described in the previous 
sections. The same samples were used to prepare ChIP-seq libraries. 
9.11.1 List of antibodies used 
Antibodies used were: H3K4me3 (AB1012, Abcam); H3K9ACS10P 
(AB12181X510/AC, Abcam); H4K16ac (AB61240, Abcam); Histone H3 (AB1791, 
Abcam); H3K27ac (AB4729, Abcam); H3K27me3 (AB6002, Abcam); Thr4P Pol II 
(6D7, ActiveMotif); Ser7P PolII (4E12, ActiveMotif); MED1 (A300793A, Bethnyl 
Lab); Ser5P PolII (H14, Covance); Ser2P PolII (H5, Covance); Tyr1P PolII (3D12, 
kindly provided by Kindly provided by Dirk Eick,Helmholtz-Zentrum Muenchen); 
H3K9K14ac (06-599, Millipore); H3S10P (04-817, Millipore), H3S0P 
(C15410116/pAb-116-050, Diagenode); SRF (sc-335, S. Cruz); PolII N20(sc-899, S. 
Cruz); MRTF-A (sc-21558, S. Cruz); NELF-A (sc-23599, S. Cruz); SPT5 (sc-28678, 
S. Cruz); CDK9 (sc-484, S. Cruz); Pol II 8WG16 (sc-56767, S. Cruz); HA (1867431, 
Roche). 
The Elk-1 antibody was obtained from an in-house affinity-purified anti-
mouse Elk-1 aa309–429 (Costello et al. 2010; Buchwalter et al. 2005). The 
antibody was re-purified against a peptide derived from the human Elk-1 NONA 
proteins (aa309-429).  
9.11.2 List of primers used for ChIP RT-PCR 
ACTA2 UP f    CCTGCAAGCCAAGGTTCTGA 
ACTA2 UP r    GCACTCCCAGAATCCATCCA 
ATCA2 SRE(-0.3Kb) FW  GAGGCCTGGGTCTCTTCCA 
ATCA2 SRE(-0.3Kb) RW  GCTGAGCTGCCTCCTGTTTC 
ACTA2 TSS(0Kb) FW  CATTCAGATTCCCACAGACAATG 
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ACTA2 TSS(0Kb) RW  TCGAGTTTTCCCAGGCTCTTT 
ACTA2 (2.8Kb) FW   CCCACGATGGATGGGAAA 
ACTA2 (2.8Kb) RW   CGGCTTCGCTGGTGATG 
ACTA2 (6.6Kb) FW   AGAGGAGCGTGGTAATCTGTTCTT 
ACTA2 (6.6Kb) FW   GAACATCCCTGTCCCTTTCCA 
ACTA2 (12.3Kb) FW   ACTGGACCCCTGAGTTTCACA 
ACTA2 (12.3Kb) RW   GGCAAGCCTCAATTCTCCAA 
ACTA2 (14.1Kb) FW   ATACGCAAGGCTTGATGCAA 
ACTA2 (14.1Kb) RW   AAGCATACACACGTGCATGGA 
ACTA2 (16.3Kb) FW   CCGTATTTGAATCTGCAACATTCT 
ACTA2 (16.3Kb) RW   TATAACACAAGAGCAAATGGCTGAA 
Actb FW TSS 0kb   AGGAGCTGCAAAGAAGCTGT 
Actb RW TSS 0Kb   CCGCTGTGGCGTCCTATAAA 
Actb FW 1Kb    GGCTTTGCACATGCCGGA 
Actb RW 1Kb    CTTTTGTGTCTTGATAGTTCGCCA 
Actb FW 2Kb    CGGAGTCCATCACAATGCCT 
Actb RW 2Kb    GCCATGTACGTAGCCATCCA 
Actb FW TES 3.1Kb   GCCTTCACCGTTCCAGTTTT 
Actb RW TES 3.1Kb   TGAGCTGCGTTTTACACCCT 
Actb FW 4.1Kb out   GTCCAAGGATCACGACTGACA 
Actb RW 4.1Kb out   CATCCTGGAAATCAGCCCCT 
Zfp37 FW    CCAGCAATGTGTGACTTGGATC 
Zfp37 RW    TATTTCGAGCGCTGTGGCA 
SRF FW    ATACCGAACTCGCTGCTGTCAT 
SRF RW    AACTGGTTCGGCTCCACTGTT 
Cyr61 FW    ATGCCTTGTGGTTGGATAACAGAGG 
Cyr61 RW    CCAGATGGTGAATCAGACACCAGAC 
Klf7 FW    GGAGGAGGGCGTCCATTAG 
Klf7 RW    CATGAGCCCCCTGTTTACCTT 
Col1a1 FW    CCAGGAGGGCATATGGAAGA 
Col1a1 RW    GTCCTCAGCCCCTTATTTGGT 
Actg1 FW    AACGCGGTGCACGAGAAG 
Actg1 RW    TCACACTGCCCAGTTGCAA 
Myh9 FW    CCTGGTGCTACCATAAAAGGAAA 
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Myh9 RW    GGACAGCCCTGGGAAACAGT 
Mir145-143 FW   CCTTGCCCGTGGCTCTCT 
Mir145-143 RW   AGGCTCGTTTCTTCAGCTCATATAA 
Actb FW    GCCGCCGGGTTTTATAGG 
Actb RW    CGTTCCGAAAGTTGCCTTTTA 
FilaminA FW    TGAGCTCAGCGCTCTGTGAA 
FilaminA RW    GCTCTGGAGGTGAGCCCTACT 
EGR1-1 F    TGGAAACAAGAGCCTCCCATT 
EGR1-1 R    GAAGCCCTATCTCCGAAGCA 
EGR1-2 F    GCCATATAAGGAGCAGGAAGGA 
EGR1-2 R    AAGGCGCTGCCCAAATAAG 
EGR1-3 F    TGATGTCTCCGCTGCAGATC 
EGR1-3 R    GGTGGGTGAGTGAGGAAAGG 
EGR1-4 F    AAGCCTTTTGCCTGTGACATTT 
EGR1-4 R    ATGCCTCTTGCGTTCATCACT 
9.12 ChIP-seq library preparation and data collection 
ChIP-seq libraries were prepared by the Advanced Sequencing facility. The 
DNA samples were end repaired, poly-A tailed and the Illumina signle end adapters 
were ligated following the protocol provided by Illumina. Agencourt AMPure XP 
beads were used to remove the adaptors. As for the RNA-seq library the Kapa HiFi 
HotStart ready mix was substituted to the Illumina kit Phusion enzyme and the ratio 
for the Agencourt AMPure XP beads was adjusted accordingly. 15 cycle of PCR 
were performed to amplify the library and the library was size selected performing 
agarose gel electrophoresis (2% Agarose gel, NB E-gels were avoided as we 
estimated a consistent loss of material during the process of extraction). Libraries 
with sizes between 200bp and 1Kb were cut from the gel and extracted using the 
MinElute Gel Extraction Kit  (Qiagen). As described previously the purified library 
was then quality controlled on the DNA 1000 BioAnalyser 2100 chip. Clusters were 
assembled and subsequent 36-50bp single end sequencing on a Hi-seq 2000/1000. 
The ChIP-seq reads were aligned using Eland (version pipeline 1.4) to the 
to the NCBI37/mm9 mouse genome using the default settings. The frequency 
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distribution of the reads was analysed to assess homogenous distribution and 
discharge samples affected by over-amplification.  
9.12.1 ChIP-seq SRF and MRTF peak calling 
MACS version 1.4.2 was used to identify regions enriched over background 
(IP using beads only as negative control). MACS threshold of p<10-5 were used. 
The ChIP-seq mapped reads were normalised to 30 milions total reads and the 
read density per base was calculated for each enriched region. As described in the 
result section SRF and MRTF peaks were crossed with the set of SRF peaks 
already described (Esnault et al. 2014). Peaks were considered as equal if the 
coordinates per peak defined by MACS were overlapping for at least 1 bp. Given 
the size of the genome, while 1bp overlap maybe arbitrary, if 2 peaks overlap then 
we can say that is a true overlap, as the search space is large. We considered 
defining the standard deviation of each bell shape peak and define the overlap 
between peaks as fraction of this number but the shape of the peaks is not 
normally distributed and as a result it would have been less statistically valid. 
9.12.2 RNA Pol II analysis and normalisation 
Pol II, Ser5P and Ser2P ChIP-seq data were aligned to the mouse genome, 
version NCBI37/mm9 using Eland (version 1.4). The mapped reads were 
normalised to 30 millions comparing the distribution of reads mapped in gene 
feature of constitutively expressed genes (invariant genes as assessed by RNA-
seq and analysed by DeSeq showing at least 5 reads in intronic features). A 
scaling factor was obtained by generating Bland-Altman plots comparing each 
condition to the 0.3% FCS for the invariant set of genes. As constitutively 
expressed genes should show equal amount of Pol II signal within their gene 
features, the distribution of the differences across conditions should assume a 
Gaussian distribution. The mean difference between the distributions obtained 
reflects the systematic error across the sample under analysis. Therefore each Pol 
II plot was scaled to the reference set of invariant constitutively expressed genes.  
For all UCSC mm9 annotated gene we quantified the signal counting the 
reads in 250bp windows from -2Kb from the TSS to the annotated polyA site. 
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These values were used to generate scatter and box plots to compare the amount 
of Pol II signal per groups of genes. 
9.12.3 Density plots for SRF, MRTF and Pol II  
The nucleotide average read density was used to generate density plots for 
SRF, MRTF-A and Pol II. In the case of SRF and MRTF-A, the average read 
density was calculated by centring on the SRF or MRTF-A ChIP-seq binding loci 
(±2 kb around the SRF or MRTF-A ChIP-seq signal summit).  
For the Pol II data sets the density profiles were calculated across the gene 
loci ±5 kb. The density plots were then scaled according to the invariant set as 
described in the previous section. 
9.13 Go analysis 
As described in the result section Gene Ontology analysis were performed 
using DAVID (Huang et al. 2009). Functional terms were collected per group of 
genes using the Functional annotation clustering, obtained with David, which group 
similar annotations together to reduce the redundancy of the annotations. One term 
per cluster, with lowest p-value and higher number of gene included, was selected 
per functional cluster. The same term was then search into the Functional 
annotation chart, which identify enriched annotation terms associated to the list 
examined, in order to identify the enrichment p-value associated to the functional 
term compared to the list of genes analysed. The Functional annotation chart is 
based on an enrichment analysis therefore is highly redundant. The selection of 
unique terms using the DAVID functional clustering avoids the selection of 
redundant categories. The p-value displayed for each term was collected from the 
functional chart in order to express the enrichment of that category within the list of 
gene provided. Therefore is not possible to compare the enrichment of functional 
categories across different gene groups. However the data displayed provides 
information regarding how well one group is enriched compared to another within 
the same gene list. 
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9.14 Nuclear Run-On assay 
The nuclear Run-On protocol was performed as previously described by 
others (Preker et al. 2008; Kwak et al. 2013; Hah et al. 2011). Each replicate 
derived from one 15cm dish (6X106 cells 80% confluent) treated as described in the 
result section. Each dish of cell was washed 3 times with cold PBS and placed on 
ice over metallic plates. 10ml of Swelling Buffer (10mM TRis pH 7.5, 2mM MgCl2, 
3mM CaCl2) were added to the cell layer directly in the dish and let to incubate on 
ice for 5 minutes. The cells were then scraped with rubber policeman, transferred 
to a 15ml falcon tube and centrifuged in a Beckman GS-GR tabletop centrifuge at 
1200rpm for 5 minutes at 4°C. After removing the supernatant 1ml of Lysis Buffer 
(10mM TRis pH 7.5, 2mM MgCl2, 3mM CaCl2, 0.5% NP40, 10%glycerol, 2Units/mL 
SuperaseIn from Ambion) was add to the pellet resuspended seveal times using a 
p1000 pipet and let to incubate on ice for 10 minutes. The lysate was diluted 10 
times using the Lysis Buffer and pelleted at 2000 rpm in Beckman GS-GR tabletop 
centrifuge. The pellet was washed again in 10ml of Lysis Buffer and pelleted again 
at 2000 rpm in Beckman GS-GR tabletop centrifuge. The Nucleai pellet was then 
washed once in 1ml of Freez buffer (50mM Hepes pH 8.2, 40%Glycerol, 5mM 
MgCl2, 0.1mMEDTA), centrifuged at 1000 xg and resuspended in 0.1ml and snap 
frozen in dry ice and kept at -80°C. 
100µl of nuclei were thaw on ice and mixed with 100µl of Reaction Buffer 
(10 mM Tris–HCl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCl, 20 U of RNase 
inhibitor, 1% sarkosyl, 0.5 mM of BrUTP, ATP, and GTP, and 5 mM CTP) was add 
to carry out the Run-on assay for 5 minutes at 30°C ina thermo shaker. The 
reaction was stop by adding 0.5ml of Trizol (Sigma) to the mix and the RNA 
extracted according to the manufacturer’s protocol. The RNA was extracted and 
precipitated using isopropanol and the pellet resuspended in 20µl of DEPC water. 
The Run-on reaction could also be stop by adding 50 U DNase I and Proteinase K 
at 37°C for 1h. The RNA was subject to base hydrolysis by adding 5µl of 1M NaOH 
solution and incubating on ice for 40 minutes. The hydrolysis reaction was stop by 
adding 25µl of 1M Tris-HCl pH 6.8. The RNA was then extracted using GenElute 
Mammalian Total RNA Miniprep Kit following the manufacturer instruction (Sigma) 
and eluted in 70µl. The sample was treated with 10µl of RQ1 DNaseI (Promega) 
and incubated for 10 minutes at 37°C with 6.7µl of RQ1 DNaseI buffer. The RNA 
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was then re-extracted as above using GenElute Mammalian Total RNA Miniprep 
Kit. 100µl of anti-BrdU agarose beads (Santa Cruz Biotech) were blocked in 
Blocking solution (0.5SSPE, 1mMEDTA, 0.05% Tween, 0.1%PolyVinylPirrolidone 
1mg/ml BSA) for 1h at 4°C under rotation. 85µl of the treated RNA were mixed with 
the beads in 500µl of binding buffer (0.5XSSPE, 1mM EDTA, 0.05%Tween) and 
incubated under rotation for 1h at 4°C. The beads were then washed once in 
LowSalt Buffer (0.2X SSPE, 1mM EDTA, 0.05%Tween), twice in HighSalt Buffer 
(0.5%SSPE, 1mM EDTA, 0.05% Tween) and twice in TETBuffer (TE Ph 7.4, 0.05% 
Tween). The RNA was then eluted with 125µl of Buffer E (20mM DTT, 300mM KCl, 
5mM Tris-HCl ph7.5, 1mM EDTA, 0.1% SDS), phenol-chloroform extracted and 
ethanol precipitated overnight. The collected RNA was then used to perform 
reverse transcription and RT-PCR as described above. 
9.15 DIP/DRIP assay 
The DNA-R-loop IP (DRIP) was performed using an antibody recognizing 
RNA/DNA hybrids purified from S9.6 hybridoma cell lines (Boguslawski et al. 1986) 
and kindly provided by Nicholas J Proudfoot. The protocol follows overall the step 
described in the ChIP protocol. Cells were not crosslinked. After Nuclear lysis the 
DNA was treated with 30mg of proteinase K (Roche) at 55°C for 3 hours. The DNA 
was then extracted by Ethanol precipitations, resuspendent in 1ml Buffer B (see 
ChIP protocol) and sonicated as in the ChIP protocol. The samples were diluted 10 
times in Buffer FA/SDS like (see ChIP protocol) and the DIP analysis carried out 
using the S9.6 antibody. Each 0.5mg of dynabeads were mixed with 10µl of the 
purified S9.6 antibody and used with 1ml of the diluted DNA. The IP, supernatant 
and the input (collected as for the ChIP protocol, 100µl of the diluted DNA) were 
purified using the QIAquick PCR Purification Kit and used in Q-PCR. The same IP 
was performed using 1ml samples previously treated with 10 U of RNase H (NEB) 
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